

EXHIBIT 11

Page 1

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

IN RE JOHNSON & JOHNSON §
TALCUM POWDER PRODUCTS § MDL NO.:
MARKETING, SALES §
PRACTICES, AND PRODUCTS § 16-2738(MAS)(RLS)
LIABILITY LITIGATION §

REMOTE VIDEOCONFERENCED DEPOSITION OF
WILLIAM SAGE, M.D.

APRIL 1, 2024

Job No. 6485334

Page 2	Page 4
<p>1 REMOTE VIDEOCONFERENCED DEPOSITION OF WILLIAM</p> <p>2 SAGE, M.D., produced as a witness at the instance</p> <p>3 of the Defendants, and remotely duly sworn by</p> <p>4 agreement of all counsel, was taken in the</p> <p>5 above-styled and numbered cause on April 1, 2024,</p> <p>6 from 9:25 a.m. to 12:27 p.m., before Karen L. D.</p> <p>7 Schoeve, RDR, CRR, RSA, reported remotely by</p> <p>8 computerized machine shorthand, pursuant to the</p> <p>9 Federal Rules of Civil Procedure and the provisions</p> <p>10 stated on the record or attached hereto.</p> <p>11</p> <p>12</p> <p>13 REPORTER'S NOTE: Please note that due to the</p> <p>14 quality of a Zoom videoconference and transmission</p> <p>15 of data, overspeaking can cause audio distortion</p> <p>16 which disrupts the process of preparing a</p> <p>17 videoconference transcript.</p> <p>18</p> <p>19 Quotation marks are used for clarity and do</p> <p>20 not necessarily reflect a direct quote.</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p>1 I N D E X</p> <p>2 PAGE</p> <p>3 Appearances 3</p> <p>4</p> <p>5</p> <p>6 WILLIAM SAGE, M.D., J.D.</p> <p>7 Examination By Mr. Ewald 8</p> <p>8 Examination By Dr. Thompson 128</p> <p>9</p> <p>10</p> <p>11 Changes and Signature 131</p> <p>12</p> <p>13 Certified Stenographic</p> <p>14 Court Reporter's Certificate 133</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>
Page 3	Page 5
<p>1 A P P E A R A N C E S</p> <p>2 *****</p> <p>3 ALL PARTIES APPEARED REMOTELY VIA ZOOM</p> <p>4 *****</p> <p>5 FOR THE MDL PLAINTIFFS:</p> <p>6 MARGARET M. THOMPSON, ESQUIRE</p> <p>7 BEASLEY ALLEN, P.C.</p> <p>8 218 Commerce Street</p> <p>9 Montgomery, Alabama 36104</p> <p>10 T: 800.898.2034</p> <p>11 F: 888.212.9702</p> <p>12 m.thompsonmd@gmail.com</p> <p>13 FOR THE PLAINTIFF STEERING COMMITTEE:</p> <p>14 MICHELLE A. PARFITT, ESQUIRE</p> <p>15 ASHCRAFT & GEREL</p> <p>16 701 East Bay Street, Suite 411</p> <p>17 Charleston, South Carolina 29403</p> <p>18 T: 843.699.8280</p> <p>19 F: 850.435.7000</p> <p>20 mparfitt@ashcraftlaw.com</p> <p>21 FOR PLAINTIFF NEW JERSEY STATE COURT:</p> <p>22 RICHARD GOLOMB, ESQUIRE</p> <p>23 GOLOMB LEGAL</p> <p>24 130 North 18th Street, 16th Floor</p> <p>25 Philadelphia, Pennsylvania 19103</p> <p>T: 215.278.4449</p> <p>FOR DEFENDANTS JOHNSON & JOHNSON:</p> <p>JOHN EWALD, ESQUIRE</p> <p>KING & SPALDING LLP</p> <p>1185 Avenue of the Americas, 34th Floor</p> <p>New York, New York 10036</p> <p>D: 212.790.5341</p> <p>T: 212.556.2100</p> <p>jewald@kslaw.com</p> <p>CERTIFIED STENOGRAPHIC COURT REPORTER:</p> <p>Karen L. D. Schoeve, CRR, RDR, RSA</p>	<p>1 EXHIBIT INDEX</p> <p>2</p> <p>3 NO. DESCRIPTION PAGE</p> <p>4 Exhibit 1 9</p> <p>5 Curriculum Vitae of William M. Sage,</p> <p>6 MD, JD</p> <p>7 (28 pages)</p> <p>8 Exhibit 2 15</p> <p>9 Invoice, dated 10/01/21</p> <p>10 (1 page)</p> <p>11 Exhibit 3 16</p> <p>12 Invoice, dated 01/15/24</p> <p>13 (1 page)</p> <p>14 Exhibit 4 19</p> <p>15 Amended Rule 26 Expert Report of</p> <p>16 William Sage, MD, JD, dated 11/15/23</p> <p>17 (99 pages)</p> <p>18 Exhibit 5 31</p> <p>19 Amended Rule 26 Expert Report of</p> <p>20 William Sage, MD, JD Amended Exhibit B</p> <p>21 - Materials Considered List, dated</p> <p>22 03/27/24</p> <p>23 (24 pages)</p> <p>24 Exhibit 6 31</p> <p>25 Amended Rule 26 Expert Report of</p> <p>William Sage, MD, JD Second Amended</p> <p>Exhibit B - Materials Considered List,</p> <p>dated 03/27/24</p> <p>(24 pages)</p> <p>Exhibit 7 32</p> <p>Amended Rule 26 Expert Report of</p> <p>William Sage, MD, JD Third Amended</p> <p>Exhibit B - Materials Considered List,</p> <p>dated 03/31/24</p> <p>(24 pages)</p>

<p>1 Exhibit 8 32 United States Government 2 Accountability Office Report to Congressional Requesters, titled 3 "Cosmetic Safety - Better Planning Would Enhance FDA Efforts to Implement 4 New Law" (77 pages) 5 6 Exhibit 9 35 Congressional Research Service document, titled "FDA Regulation of 7 Cosmetics and Personal Care Products Under the Modernization of Cosmetics 8 Regulation Act of 2022 (MoCRA)" (25 pages) 9 10 Exhibit 10 36 Expert Report of George E. Newman, Ph.D., dated 11/15/23 11 (83 pages) 12 Exhibit 11 45 White paper titled "IWGACP Scientific 13 Opinions on Testing Methods for Asbestos in Cosmetic Products 14 Containing Talc" (31 pages) 15 16 Exhibit 12 53 MAS report titled "Analysis of Non-Historical J&J's Talcum Powder 17 Consumer Product Containers and J&J Chinese Historical Talc Retain 18 Samples," dated 11/17/23 (20 pages) 19 20 Exhibit 13 84 FDA Public Meeting transcript, dated 02/04/20 21 (382 pages) 22 Exhibit 14 104 Johnson & Johnson letter to Windsor 23 Minerals, Inc, dated 02/23/1978 Bates stamped JNIMX68 000003591 - 3592 24 Protected Document - Subject to Protective Order 25</p>	<p>Page 6</p> <p>1 PROCEEDINGS 2 THE COURT REPORTER: If the 3 attorneys could please introduce 4 themselves for the record, then I will 5 swear in the witness. 6 DR. THOMPSON: Hi. This is 7 Margaret Thompson, with Beasley Allen, for 8 MDL plaintiffs. 9 MS. PARFITT: Michelle Parfitt for 10 the plaintiff steering committee. 11 MR. EWALD: And John Ewald for J&J. 12 DR. THOMPSON: And while Richard 13 Golomb is not currently -- he will be 14 joining -- Sir Richard Golomb, 15 representing New Jersey State litigation. 16 THE COURT REPORTER: Okay. Thank 17 you, everyone. 18 WILLIAM SAGE M.D., 19 having been first duly sworn to tell the truth, the 20 whole truth, and nothing but the truth, so help him 21 God, testified as follows: 22 EXAMINATION 23 BY MR. EWALD: 24 Q. Good morning, Doctor. Where are you 25 located today?</p> <p>Page 8</p>
<p>1 Exhibit 15 120 Article in Press, titled 2 "Characterization of elongate mineral particles including talc, amphiboles, 3 and biopyriboles..." (17 pages) 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25</p>	<p>Page 7</p> <p>1 A. Good morning. I am in a hotel room in 2 downtown Fort Worth, Texas. 3 Q. And we've discussed this off the record 4 collectively, but who was in the room with you 5 currently? 6 A. Currently, Margaret Thompson. 7 Q. Okay. Let's go ahead and start with your 8 CV. We'll mark that as Exhibit 1. First, let me 9 just pull it up, and you can let me know if it is 10 the current version. 11 (Exhibit 1 marked.) 12 BY MR. EWALD: 13 Q. Okay. Doctor, do you see that? 14 A. (Examined exhibit.) I do. 15 Q. And this is what we were provided by 16 plaintiffs' counsel. I'm not sure if there's a 17 date on it anywhere, but is -- does this appear to 18 be the current version of your CV? 19 A. If you don't mind scrolling down to page 20 5, that's an easy check for me. 21 Q. Okay. (Scrolling.) 22 A. So far so good. 23 Q. (Scrolling.) 24 A. Stop. 25 Q. (Scrolling.)</p> <p>Page 9</p>

<p style="text-align: right;">Page 10</p> <p>1 A. Stop.</p> <p>2 Q. (Complied.)</p> <p>3 A. That one. Yep. That --</p> <p>4 Q. Okay.</p> <p>5 A. -- that looks like my current CV.</p> <p>6 Q. All right. And while we're here it talks</p> <p>7 about -- where you said "Stop" -- "Book Chapters,"</p> <p>8 you're an author on "Private Law as Health Law:</p> <p>9 What It Means, Why It Matters, in Health Law As</p> <p>10 Private Law." It's forthcoming later this year;</p> <p>11 is that correct?</p> <p>12 A. Yes.</p> <p>13 Q. And can you just, very briefly, just</p> <p>14 describe what the nature is of that book chapter?</p> <p>15 A. This was an invited academic book,</p> <p>16 looking at the ways in which U.S. health law is</p> <p>17 driven by private parties. Very little, if any,</p> <p>18 of my book chapter has to do with product</p> <p>19 liability or tort law. Almost all of it has to do</p> <p>20 with system issues in terms of how budgetary</p> <p>21 allocations are made, what is done by direct</p> <p>22 government, and what is done indirectly through</p> <p>23 private parties. And it's much more focused on</p> <p>24 the private parties who comprise the healthcare</p> <p>25 system, such as hospitals and physicians, than on</p>	<p style="text-align: right;">Page 12</p> <p>1 social service professionals, usually to help</p> <p>2 patients from vulnerable communities to deal with</p> <p>3 what we call "health-harming legal needs." And</p> <p>4 these fall in sort of income and insurance,</p> <p>5 education, employment, housing, legal status,</p> <p>6 whether it's immigration, veteran status or the</p> <p>7 like. And then personal matters which are usually</p> <p>8 matters of family and personal -- and familial</p> <p>9 safety. Again, nothing in this has anything to do</p> <p>10 with tort liability or product liability.</p> <p>11 Q. Fair enough. Let's go back to the top of</p> <p>12 your CV.</p> <p>13 A. (Complied.)</p> <p>14 Q. And do you recall -- maybe not a specific</p> <p>15 date -- but do you recall that you were deposed in</p> <p>16 this case, for the first time, back in around</p> <p>17 September 2021? Does that sound right?</p> <p>18 A. Absolutely.</p> <p>19 Q. All right.</p> <p>20 A. I think it -- I think it was -- yeah, it</p> <p>21 was, like, the last week of September.</p> <p>22 Q. And not -- wasn't going to be my next</p> <p>23 question, but when I -- have you reviewed your</p> <p>24 deposition transcript in preparation for today's</p> <p>25 deposition?</p>
<p style="text-align: right;">Page 11</p> <p>1 other private parties.</p> <p>2 Q. To the extent that that chapter covers</p> <p>3 product liability litigation, can you give me a</p> <p>4 sense of what is discussed?</p> <p>5 A. I suspect almost nothing. I didn't go</p> <p>6 back to look at the most recent draft. But that</p> <p>7 wasn't the import. This is an overview</p> <p>8 introductory chapter I was invited to contribute</p> <p>9 to a book that's on many topics. I don't think</p> <p>10 any of the chapters, that I recall, are focused on</p> <p>11 product liability or tort liability.</p> <p>12 Q. Thank you. And so now we've moved down</p> <p>13 to page 7 of the CV under "Articles," and there's</p> <p>14 another submitted for publication where you are a</p> <p>15 coauthor, and it's titled, "Public Investment in</p> <p>16 MLP: Why It's Time to be Explicit that Legal Care</p> <p>17 is Health Care."</p> <p>18 Can you just describe again, very</p> <p>19 generally, what that article's about?</p> <p>20 A. Certainly. This was invited by the AMA's</p> <p>21 journal of ethics. It's now gone through most</p> <p>22 stages of editing, and it is provisionally and</p> <p>23 almost finally accepted in the usual course of</p> <p>24 things. Medicolegal partnership is a</p> <p>25 collaboration between medical, legal, and other</p>	<p style="text-align: right;">Page 13</p> <p>1 A. I have barely skimmed it. It was not a</p> <p>2 focus of the preparation for today.</p> <p>3 Q. All right. Since you were deposed, it</p> <p>4 appears that you have made a change in your work,</p> <p>5 correct?</p> <p>6 A. Yes.</p> <p>7 Q. All right. Can you describe what</p> <p>8 prompted the move from the University of Texas to</p> <p>9 Texas A&M?</p> <p>10 A. I was offered the opportunity to have</p> <p>11 multiple-component academic appointment at A&M and</p> <p>12 to have chancellor's funding to launch a health</p> <p>13 policy institute which we call the Institute For</p> <p>14 Healthcare Access. I remain an academic in terms</p> <p>15 of teaching and research, but -- so it's not a</p> <p>16 major career change, but it is a change of</p> <p>17 University and a great opportunity.</p> <p>18 Q. And it does sound like a good</p> <p>19 opportunity, and as a undergraduate and law school</p> <p>20 graduate of the University of Texas, I won't hold</p> <p>21 it against you for going to A&M.</p> <p>22 A. I could make a hook 'em for you</p> <p>23 (demonstrating).</p> <p>24 Q. Let the record reflect, he just did the</p> <p>25 hook 'em sign. My wife was born in College</p>

<p style="text-align: right;">Page 14</p> <p>1 Station, so it's about even.</p> <p>2 But I'm sorry. I don't want to delve</p> <p>3 too much into it, but if we're talking about the</p> <p>4 teaching component in Texas A&M, how does that</p> <p>5 differ, if at all, from what you were teaching in</p> <p>6 2021 at the time of your first deposition?</p> <p>7 A. It doesn't differ much from what I was</p> <p>8 teaching in 2021 because I was a visiting</p> <p>9 professor at George Washington University that</p> <p>10 fall, and that's why the deposition was taken in</p> <p>11 Washington, D.C.</p> <p>12 I am delighted that with A&M, I get</p> <p>13 to teach half of 1L class, their required</p> <p>14 legislation and regulation course, which is the</p> <p>15 course I developed and taught for over a decade at</p> <p>16 Columbia Law School, and it's the one that grounds</p> <p>17 my expertise in regulatory theory and in aspects</p> <p>18 of the regulatory state that are central to my</p> <p>19 report.</p> <p>20 Q. All right. During your first deposition,</p> <p>21 you were asked some questions about the approval</p> <p>22 requirements at University of Texas School of Law</p> <p>23 for you to do consulting work. You generally --</p> <p>24 you don't need to remember the specific questions,</p> <p>25 but do you recall being questioned on that?</p>	<p style="text-align: right;">Page 16</p> <p>1 Q. And the (as read) "For" is "Further</p> <p>2 research in connection with deposition testimony,</p> <p>3 deposition preparation, and deposition from</p> <p>4 July 27th through September 30th, 2021?"</p> <p>5 Did I read that correctly?</p> <p>6 A. Yes.</p> <p>7 Q. And for this time period between</p> <p>8 July 27th to September 30th, 2021, you have billed</p> <p>9 a total of 74 hours at your past rate of \$800 an</p> <p>10 hour for a total of 59,200, correct?</p> <p>11 A. Correct.</p> <p>12 Q. And have you been paid by counsel for</p> <p>13 this invoice?</p> <p>14 A. For that one, yes.</p> <p>15 Q. Okay. And this reflects preparation for</p> <p>16 deposition, 46 hours, correct?</p> <p>17 A. That's what it says on the invoice, yes.</p> <p>18 Q. And -- all right.</p> <p>19 We'll mark as Exhibit 3 another</p> <p>20 invoice.</p> <p>21 (Exhibit 3 marked.)</p> <p>22 A. (Examined exhibit.)</p> <p>23 BY MR. EWALD:</p> <p>24 Q. And this invoice is dated January 15th,</p> <p>25 2024, and it covers preparation of amended expert</p>
<p style="text-align: right;">Page 15</p> <p>1 A. Yes.</p> <p>2 Q. Okay. How, if at all, does the</p> <p>3 guidelines at Texas A&M on consulting work done by</p> <p>4 you differ from the time that you were at</p> <p>5 University of Texas?</p> <p>6 A. I wouldn't be able to make that</p> <p>7 comparison for you casually. But I will say that</p> <p>8 before I did any work on this case, I went -- I</p> <p>9 reviewed and went through the requirements for</p> <p>10 Texas A&M University and received all the required</p> <p>11 approvals.</p> <p>12 Q. And do all of the fees that you receive</p> <p>13 in connection with this consulting work still go</p> <p>14 directly to you?</p> <p>15 A. Yes.</p> <p>16 Q. And am I correct that your current hourly</p> <p>17 rate is \$900 per hour?</p> <p>18 A. Yes.</p> <p>19 Q. All right. Okay. Doctor, I want to show</p> <p>20 you a couple of invoices that we've received from</p> <p>21 plaintiffs' counsel. We'll mark as Exhibit 2 this</p> <p>22 invoice dated October 1st, 2021.</p> <p>23 (Exhibit 2 marked.)</p> <p>24 A. (Examined exhibit.)</p> <p>25 BY MR. EWALD:</p>	<p style="text-align: right;">Page 17</p> <p>1 report from October 1st through November 15th,</p> <p>2 2023, correct?</p> <p>3 A. Yes.</p> <p>4 Q. And so I want to talk about, before</p> <p>5 getting into the time that is reflected on this</p> <p>6 invoice and how you spent it, what, if anything,</p> <p>7 did you do in connection with your work on this</p> <p>8 case, from the date of your deposition on</p> <p>9 September 2021, at some point in time, through the</p> <p>10 initial meetings that are reflected here on</p> <p>11 October 1st, 2023?</p> <p>12 A. Oh, I did not do paid work on the case.</p> <p>13 As I recall, your client had several visits to the</p> <p>14 bankruptcy court during that period. I'm a law</p> <p>15 professor and health policy academic. I got</p> <p>16 interested in this topic intensively in</p> <p>17 preparation for the first deposition and that</p> <p>18 work. So obviously, I've -- I followed the case</p> <p>19 and asked occasional questions and seeing what's</p> <p>20 been in the news and looked at, you know,</p> <p>21 whatever -- whatever was happening in the</p> <p>22 regulatory world, largely, as I was preparing</p> <p>23 academic material for teaching, occasionally, for</p> <p>24 writing.</p> <p>25 Q. All right. So then we have this time</p>

<p style="text-align: right;">Page 18</p> <p>1 period of October 1st through November 15th with</p> <p>2 two hours in initial meetings and case review.</p> <p>3 What did you understand what your task was for</p> <p>4 this amended report?</p> <p>5 A. Well, I'd love to look at what's stated</p> <p>6 in the report so that I'm consistent with what's</p> <p>7 stated in the report in terms of the questions I</p> <p>8 was -- (overtalk distorted audio).</p> <p>9 Q. Sure. Happy -- I'm going to pick that up</p> <p>10 and should have asked, do you have any documents</p> <p>11 in front of you?</p> <p>12 A. I have -- I have in front of me a binder</p> <p>13 containing, I believe, all the documents that were</p> <p>14 sent to you as well, but I don't do this often,</p> <p>15 and I was a corporate lawyer, not a litigator in</p> <p>16 practice. So the rhythms of Zoom teaching are</p> <p>17 great. The rhythms of Zoom litigation are not.</p> <p>18 So tell me what you need.</p> <p>19 Q. No, and that's just a matter of, as we go</p> <p>20 through this, and supplement generally what have</p> <p>21 in front of you, of course, we'll work through any</p> <p>22 kind of pickups on any side.</p> <p>23 But do you have a copy of your</p> <p>24 report -- I'm going to put it up on the screen,</p> <p>25 but I think it'll be helpful if you have it in</p>	<p style="text-align: right;">Page 20</p> <p>1 THE COURT REPORTER: Yes, ma'am.</p> <p>2 MR. EWALD: All right.</p> <p>3 THE COURT REPORTER: Okay. Sorry</p> <p>4 guys. I couldn't do everything at once</p> <p>5 there.</p> <p>6 MR. EWALD: No, you do everything</p> <p>7 so well, so it's hard to do any more.</p> <p>8 THE COURT REPORTER: All right.</p> <p>9 They're admitted, so sorry to interrupt.</p> <p>10 Doctor, you may answer.</p> <p>11 THE WITNESS: Thanks.</p> <p>12 A. So under "B. Methodology" in paragraph</p> <p>13 11, this, I believe, is unchanged from the first</p> <p>14 report. The questions I was asked to address in</p> <p>15 the original and the revised report, "What are the</p> <p>16 regulatory practices and standards under which</p> <p>17 manufacturers of cosmetics operate? and Did</p> <p>18 Johnson & Johnson comply with these standards in</p> <p>19 its general development, manufacture, marketing,</p> <p>20 and sale of talcum powder products?"</p> <p>21 And it says, "I was not asked to give</p> <p>22 an opinion as to whether talcum product -- powder</p> <p>23 products cause cancer."</p> <p>24 MR. EWALD: Y'all are having</p> <p>25 feedback issues.</p>
<p style="text-align: right;">Page 19</p> <p>1 front of you have, too?</p> <p>2 A. So I do -- I do have it in front of me.</p> <p>3 If you want to put it up on the screen, that's</p> <p>4 great.</p> <p>5 Q. Okay. Okay. So we'll go ahead and mark</p> <p>6 Exhibit 4, the amended expert report of Dr. Sage,</p> <p>7 which is dated November 15th, 2023.</p> <p>8 (Exhibit 4 marked.)</p> <p>9 A. (Examined exhibit.)</p> <p>10 BY MR. EWALD:</p> <p>11 Q. Okay. Doctor, I'd asked you before</p> <p>12 bringing this up, essentially, what did you</p> <p>13 understand your task to be with respect to this</p> <p>14 amended report?</p> <p>15 A. So on page 2 --</p> <p>16 THE COURT REPORTER: Excuse --</p> <p>17 gentlemen, excuse me. I've got people in</p> <p>18 the waiting room I need to let in, and I</p> <p>19 can't get to that screen. If you could</p> <p>20 please put your document down for me.</p> <p>21 MR. EWALD: Oh. Oh, yeah. Sure.</p> <p>22 DR. THOMPSON: That's Richard. And</p> <p>23 I also left to fix my microphone issue,</p> <p>24 and I'm back on as well so you may have</p> <p>25 both of us.</p>	<p style="text-align: right;">Page 21</p> <p>1 THE WITNESS: Yes. I --</p> <p>2 DR. THOMPSON: That was Richard.</p> <p>3 He's fixing it.</p> <p>4 MR. EWALD: Okay. Cool. No</p> <p>5 worries.</p> <p>6 BY MR. EWALD:</p> <p>7 Q. All right. And so --</p> <p>8 A. So that --</p> <p>9 Q. -- go ahead.</p> <p>10 A. I -- I was -- so the amended report,</p> <p>11 after the delay and the progression of these</p> <p>12 cases, was to make sure that my answer remained</p> <p>13 the same, given developments in information and</p> <p>14 particularly given developments in applicable</p> <p>15 federal law.</p> <p>16 THE COURT REPORTER: Okay. Sorry</p> <p>17 to interrupt again, but I need you to put</p> <p>18 the document down for me.</p> <p>19 MR. EWALD: Sure.</p> <p>20 THE COURT REPORTER: Okay. One</p> <p>21 more time.</p> <p>22 Okay. There you go.</p> <p>23 BY MR. EWALD:</p> <p>24 Q. All right. So understanding you</p> <p>25 correctly, Doctor, the questions that you were</p>

<p style="text-align: right;">Page 22</p> <p>1 asked to answer were basically the same from the 2 first report to the second report, fair? 3 A. That is correct. 4 Q. All right. And tell me then about your 5 process in determining what needed to be updated 6 from your prior report. 7 A. My process is the same I would engage in 8 in all of my academic work and associated writing, 9 which meant reading carefully what I had written 10 before and asking whether there were documents 11 that plaintiffs' counsel thought I should review. 12 And most important for this, doing a careful 13 personal review of publicly available sources, 14 notably, the modernization of cosmetics before MAC 15 and associated regulation to the extent that 16 exists. 17 Q. All right. And so let's take those 18 separately. 19 The aspect of asking plaintiffs' 20 counsel whether there are any documents that you 21 should review. What, if any, documents were 22 provided to you in connection with you preparing 23 the amended report? 24 A. The two documents that come to mind were 25 the update of the, I guess, Longo report on</p>	<p style="text-align: right;">Page 24</p> <p>1 right? 2 A. I don't know what you received from 3 counsel. 4 Q. All right. Did you play any role in 5 putting together a reference list for your report? 6 A. The role -- yes. The role I played was I 7 was asked to provide to counsel, to be provided to 8 you, documents that I had found on my own that 9 were relative to my report, and I used it as 10 preparation. I sent a -- an e-mail attaching a 11 couple of those, and then I reviewed the list 12 yesterday and noticed something that seemed not to 13 be on the list that I had put in the original 14 e-mail, so I pointed that out, and I hope and 15 believe you were provided that. 16 Q. I was. Thank you. 17 On the Longo -- updated Longo report, 18 is that something that you received back in this 19 September 2023 time frame when you were preparing 20 your amended report? 21 A. This -- I can't recall, actually. I 22 don't remember the -- I don't remember the date. 23 So I don't remember whether it was before the 24 amended report submission or after. 25 Q. And I'll -- well, we'll go through it</p>
<p style="text-align: right;">Page 23</p> <p>1 testing of talcum for presence of asbestos which 2 was an update of a report I had seen before. I 3 also asked regarding marketing practices and the 4 like because that had been an area of relevance of 5 my report the first time and also an area defined 6 of great academic interest. And I was given a 7 report by a Professor Newman that had to do with 8 Johnson & Johnson's marketing. 9 Q. Okay. And the -- sorry? 10 A. I was also -- I was -- I mean, I guess 11 those were things I asked for, which was your 12 question. 13 Q. Yes. Yes. And before we get to that 14 second bucket of what you found on your own, when, 15 approximately, did you receive the updated Longo 16 report? 17 A. I don't recall. I would have to go back 18 and find the day. 19 Q. We'll get to it, but maybe this will ring 20 a bell. I received an amended -- well, let me 21 withdraw the question. 22 I'll represent to you that I've 23 received from counsel three different amended 24 reliance lists -- or reference lists in connection 25 with your amended report. Does that sound about</p>	<p style="text-align: right;">Page 25</p> <p>1 more in a little bit, but I want to circle back to 2 some basics. 3 The research you did on your own in 4 connection with your amended report, can you walk 5 me through generally what that was? 6 A. Um-hum. There's a leading text on food 7 and drug regulation by Hutt and Grossman and maybe 8 another author I can't recall. I looked to see if 9 they had a section on the modernization's act that 10 was relevant and found what they had which was 11 minor, so I didn't specify that and there was not 12 a lot of development in it. I did the basic 13 research for public documents. I went to the FDA 14 website, read everything they had on what they had 15 done, subsequent to my 2021 involvement in this 16 litigation. So that was all, just the FDA website 17 and any FDA website links that were provided 18 there. 19 Then I looked for other government 20 documents. Found a couple of congressional 21 research service reports. Looked at the 2023 one 22 which, as I was looking through it, said that it 23 was built on the 2022 one, so I did not look 24 separately at the 2022 one. I found this 25 government accountability office report. I read</p>

<p style="text-align: right;">Page 26</p> <p>1 that.</p> <p>2 And I think that's -- that's in</p> <p>3 ess- -- oh, and, of course, you know, pulled the</p> <p>4 text of the act. Spent some time trying to figure</p> <p>5 out whether there were constituent bills that had</p> <p>6 gone into the act, but like most federal</p> <p>7 legislation these days, it was done as a</p> <p>8 consolidation app- -- consolidated appropriations</p> <p>9 act, and it was passed at the very end of the year</p> <p>10 in 2022 in the way that these things often are.</p> <p>11 And I wasn't able to trace the origin of statutory</p> <p>12 language, so I just worked directly from what the</p> <p>13 final language was.</p> <p>14 Q. Have you reviewed any Johnson & Johnson</p> <p>15 internal corporate documents since your deposition</p> <p>16 in September 2021?</p> <p>17 A. There were documents referenced in the</p> <p>18 Newman report, but I can't recall having reviewed</p> <p>19 any internal documents.</p> <p>20 Q. And fair to say, as you sit here today,</p> <p>21 you don't recall requesting or receiving any</p> <p>22 internal Johnson & Johnson corporate documents</p> <p>23 since your deposition that were not reflected on</p> <p>24 your earlier reliance list?</p> <p>25 A. I don't recall that, no.</p>	<p style="text-align: right;">Page 28</p> <p>1 testing method for asbestos and talc.</p> <p>2 There were -- the FDA, in my</p> <p>3 experience, is pretty good on its website at</p> <p>4 directing you to their processes and their</p> <p>5 documents and their guidances of this or that</p> <p>6 sort, so there were a number of things to look at.</p> <p>7 Q. And what is your understanding of,</p> <p>8 currently, the status of the FDA's development of</p> <p>9 a standardized testing method for presence of</p> <p>10 asbestos and talc?</p> <p>11 A. My understanding, absent any attempt to</p> <p>12 find out beyond what is publicly available, is</p> <p>13 that the interagency working group from a few</p> <p>14 years ago raised this issue. The Modernization</p> <p>15 Act captured it in regulatory language, attached a</p> <p>16 deadline at the end of 2023 for publication of</p> <p>17 some type of proposal. I can't remember the exact</p> <p>18 administrative law form of that proposal of a</p> <p>19 standardized testing method for public comment.</p> <p>20 And when I have done searches and looked at the</p> <p>21 FDA website, I do not find any information about</p> <p>22 such a proposal or preliminary standard having</p> <p>23 been yet released.</p> <p>24 Q. Okay. And when you say "released," do</p> <p>25 you have any understanding as to whether or not</p>
<p style="text-align: right;">Page 27</p> <p>1 Q. Did anyone assist you, apart from</p> <p>2 plaintiffs' counsel, in connection with the</p> <p>3 preparation of your amended report?</p> <p>4 A. No.</p> <p>5 Q. You talked about one of the things that</p> <p>6 you did on your own was to research what the FDA</p> <p>7 had done in this area -- cosmetic regulation --</p> <p>8 since your deposition in September 2021, correct?</p> <p>9 A. Correct.</p> <p>10 Q. And you have to -- tell me what you</p> <p>11 found. What would you say?</p> <p>12 A. I found that --</p> <p>13 DR. THOMPSON: Object to form.</p> <p>14 You may answer.</p> <p>15 THE WITNESS: That means I go</p> <p>16 ahead?</p> <p>17 BY MR. EWALD:</p> <p>18 Q. Yes.</p> <p>19 A. Sorry. This is not intuitive.</p> <p>20 Q. No, that's okay.</p> <p>21 A. What I found is the FDA had done quite a</p> <p>22 lot. They were doing quite a lot before the</p> <p>23 Modernization Act was finalized, and then the</p> <p>24 passage of the Modernization Act gave them</p> <p>25 specific tasks, notably, developing a standardized</p>	<p style="text-align: right;">Page 29</p> <p>1 FDA has sent a proposed standardized testing</p> <p>2 regulation for presence of asbestos and talc to</p> <p>3 the proper governmental entities for review?</p> <p>4 A. I have no knowledge of that.</p> <p>5 Q. In preparing your amended expert report</p> <p>6 in this case, was there anything that you were</p> <p>7 asked at the first deposition, that caused you to</p> <p>8 say to yourself, "I want to look into that</p> <p>9 further"?</p> <p>10 DR. THOMPSON: Objection; form.</p> <p>11 A. I was disturbed in the first deposition</p> <p>12 by how long the uncertainties and the scientific</p> <p>13 knowledge about the risks associated with talcum</p> <p>14 powder products had percolated in the regulatory</p> <p>15 debate. So I was attentive to what was happening</p> <p>16 with the reform act, and I had told myself at the</p> <p>17 time that regardless of whether I had litigation</p> <p>18 involvement in this matter subsequently, I would</p> <p>19 pay attention. And as I thought proper for an</p> <p>20 academic, I would incorporate it into my teaching</p> <p>21 and work.</p> <p>22 BY MR. EWALD:</p> <p>23 Q. And my question was broad to answer it</p> <p>24 just right. I'll ask a slightly more narrow</p> <p>25 question, which is: Is there anything that was</p>

<p style="text-align: right;">Page 30</p> <p>1 discussed at your first deposition in this case, 2 that caused you to conduct further investigation 3 in preparation for your opinions in your amended 4 report? 5 DR. THOMPSON: Same objection. 6 A. As I said in response to your earlier 7 question, I barely skimmed my deposition 8 transcript, so I have very little direct recall. 9 There was certainly nothing at the time that made 10 me feel in the least uncomfortable with any of the 11 opinions I expressed in the preliminary report. 12 And, yes, I was seriously interested in this 13 matter since. And, you know, I am a health policy 14 academic, and my work is broad, and my teaching 15 involves the fundamentals of legislation and 16 regulation, so of course, I was interested. 17 BY MR. EWALD: 18 Q. Am I correct that you have not provided 19 any deposition or trial testimony in any other 20 litigation matter since you provided deposition in 21 September of 2021? 22 A. That's correct. 23 Q. Have -- since September of 2021, have you 24 been retained as an expert in any other matter? 25 A. No.</p>	<p style="text-align: right;">Page 32</p> <p>1 (Exhibit 7 marked.) 2 A. (Examined exhibit.) 3 BY MR. EWALD: 4 Q. Okay. Doctor, I'll scroll down to the 5 last page of Exhibit 7, the third amended 6 Materials Considered list. There are a couple of 7 documents that were highlighted by counsel as new 8 materials that you reviewed. First one I'll ask 9 you about is this "United States Government 10 Accountability Office, Report to Congressional 11 Requesters: Cosmetic Safety: Better Planning Would 12 Enhance Update Efforts to Implement New Law," 13 December of 2023. And I guess we'll go ahead and 14 mark that as Exhibit 8. 15 (Exhibit 8 marked.) 16 A. (Examined exhibit.) 17 BY MR. EWALD: 18 Q. Doctor, can you tell me what, if 19 anything, you are relying on this GA report -- GAO 20 report for in connection with the opinions in this 21 case? 22 DR. THOMPSON: Can we put that on 23 the screen or in Chat? 24 MR. EWALD: Sure. Sure. 25 DR. THOMPSON: Okay. We don't have</p>
<p style="text-align: right;">Page 31</p> <p>1 Q. All right. 2 THE WITNESS: I'm going to grab a 3 sip of water, so I'm going to leave my 4 screen. 5 MR. EWALD: Go for it. 6 BY MR. EWALD: 7 Q. Okay. So I'm just gonna go ahead and 8 mark the three different Materials Considered 9 lists that I have received from counsel in 10 connection with your amended report. I will mark 11 as Exhibit 5 the material -- "Amended Exhibit B - 12 Materials Considered List" that's dated 13 March 27th, 2024. 14 (Exhibit 5 marked.) 15 A. (Examined exhibit.) 16 BY MR. EWALD: 17 Q. Then I have here as Exhibit 6 the "Second 18 Amended Exhibit B - Materials Considered List" 19 which has a date of also March 27th, 2024. 20 (Exhibit 6 marked.) 21 A. (Examined exhibit.) 22 BY MR. EWALD: 23 Q. Then the "Third Amended Exhibit B - 24 Materials Considered List," which I received 25 yesterday, March 31st, 2024.</p>	<p style="text-align: right;">Page 33</p> <p>1 a copy of that. 2 THE WITNESS: We do. 3 DR. THOMPSON: Do we? 4 THE WITNESS: Yep. That one there. 5 DR. THOMPSON: Oh, yes, we do. 6 Okay. 7 THE WITNESS: That one we do. The 8 other one we don't. 9 BY MR. EWALD: 10 Q. All right. Well, it's on the screen 11 regardless, so -- 12 DR. THOMPSON: Thank you. 13 MR. EWALD: Of course. 14 BY MR. EWALD: 15 Q. So, Doctor, I'll reask the question. 16 Basically, what, if anything, do you 17 rely on this GAO report, that we've marked as 18 Exhibit 7, for your opinions in this case? 19 A. I was very interested in this report when 20 I did my search for government documents because 21 it was a December '23 date, and that was, you 22 know, among other things, the original 23 congressional deadline for issuing a preliminary 24 standard. 25 I've read this document. GAO is now</p>

<p style="text-align: right;">Page 34</p> <p>1 called the Government Accountability Office. It's 2 what most of us knew was the general accounting 3 office, and so kind of opportunities for 4 congressional and occasionally other requesters to 5 get information about pretty much anything, so I 6 was interested in what it contained. 7 I discovered that what it contained 8 was largely the assessor's opinions of how FDA's 9 process complied with whatever the standards they 10 would apply to kind of good government development 11 in terms of staffing, leadership, transparency, 12 and things like that. That was interesting to me, 13 but I didn't rely heavily on it for anything 14 specific to my report. It was more an impression 15 I had of the implementation efforts, but I was 16 grateful that it existed. If I'm -- I'm pretty 17 sure, from being able to read it. 18 Q. All right. I'll probably get back to 19 that. But let's talk about the other document on 20 that page, the one we received last night. 21 First, let's go back to the third 22 amended. The last document that shows up on that 23 screen is a Nora Wells "FDA Regulation of 24 Cosmetics and Personal Care Products Under the 25 Modernization of Cosmetics Regulation Act of 2022.</p>	<p style="text-align: right;">Page 36</p> <p>1 had done in these areas subsequent to my last 2 deposition. That's the short answer. 3 Q. Is there anything you can recall from the 4 Nora Wells article that provided you with new 5 information that you previously weren't aware of, 6 that you are relying on in this case? 7 A. This was an extremely well done, in my 8 view, review of the law and the changes that had 9 been made from the premodernization version of 10 cosmetics regulation. It wasn't something that 11 drew heavily from outside empirical work or 12 scholarly work or any other source that I would 13 have relied on. So I used it, as I said, as 14 another way of feeling fully confident that my 15 statements in my report were an accurate 16 reflection of the legal change. 17 Q. All right. Marking as Exhibit 10 the 18 expert report of George Newman, Ph.D., dated 19 November 15th, 2023. 20 (Exhibit 10 marked.) 21 A. (Examined exhibit.) 22 BY MR. EWALD: 23 Q. And this is something that you reviewed, 24 Doctor, in connection with the preparation of your 25 amended report?</p>
<p style="text-align: right;">Page 35</p> <p>1 (MoCRA)." 2 (Exhibit 9 marked.) 3 A. (Examined exhibit.) 4 BY MR. EWALD: 5 Q. Is that something that you reviewed in 6 connection with your opinions in this case, 7 Doctor? 8 A. Yes. 9 DR. THOMPSON: And if we could have 10 that up as well. 11 MR. EWALD: Sure. 12 DR. THOMPSON: Are these being 13 marked as exhibits or -- 14 MR. EWALD: They are. The GAO is 15 Exhibit 8. 16 DR. THOMPSON: And this is 17 Exhibit 9? Thank you. 18 MR. EWALD: Of course. 19 BY MR. EWALD: 20 Q. What, if anything, did you rely on 21 Ms. Wells' article we've marked as Exhibit 9 for 22 your opinions in this case? 23 A. I relied on it as a verification of my 24 own insights from reading the text of the new law 25 and from reviewing the FDA's website on what they</p>	<p style="text-align: right;">Page 37</p> <p>1 A. This is something I received subsequent 2 to the submission of the revised report but prior 3 to today. 4 Q. Okay. And when did -- (overtalk 5 distorted audio). 6 A. And I did review it. 7 Q. All right. You said you did review it? 8 A. Yes. 9 Q. Great. And when, approximately, did you 10 receive a copy of this expert report from 11 Dr. Newman? 12 A. In the last two weeks or so. I don't 13 know more specifically than that. 14 Q. Okay. And how, if at all, does the 15 report of Dr. Newman inform the opinions that 16 you're offering in this case? 17 A. Many of the opinions I offer have to do 18 with the informational environment that Johnson & 19 Johnson has created and maintained around its 20 talcum powder products and its marketing 21 activities. Both the history of those marketing 22 activities and more recent versions of those 23 marketing activities are directly relevant. 24 Q. All right. And so because this came in 25 after your drafting of the amended expert report</p>

<p style="text-align: right;">Page 38</p> <p>1 that you've submitted in this case, I'm trying to 2 get a sense of -- of how, if at all, you were 3 going to rely on Dr. Newman's report for any of 4 the specific opinions that you are including in 5 your report. 6 A. My litigation experience doesn't allow -- 7 isn't sufficient to answer that question. My 8 understanding was that my -- this deposition 9 reflects my opinions about my report up to the 10 date of the deposition. I don't know beyond that 11 what -- who's supposed to do what, but ... 12 Q. And that's fine. And here's what I'm 13 trying to understand is -- if we go back to your 14 amended report -- your amended report in this 15 case. 16 Let me know when you have it in front 17 of you. 18 THE WITNESS: Where'd my report go? 19 It needs to produce -- here we go. Thank 20 you. No. That's the old one. Thanks. 21 A. Yes, I have it in front of me. 22 BY MR. EWALD: 23 Q. For which sections in your expert report 24 are you relying on the opinions contained in 25 Dr. Newman's report?</p>	<p style="text-align: right;">Page 40</p> <p>1 rely on, but I'm trying to get a sense from you. 2 You have the expert report -- amended expert 3 report we've marked as Exhibit 4. If you had to 4 say, "This section is primarily what I'm also 5 relying on Dr. Newman's report to support." That 6 is what I'm asking. 7 DR. THOMPSON: Object to form. 8 A. Absolutely. The -- this report is 9 relevant to many of the sections that have to do 10 with Johnson & Johnson's informational obligations 11 which go to the term of art labeling but also go, 12 in general, to their corporate reputation, their 13 stated corporate intent. Representations they've 14 made to -- specifically to consumers and to the 15 broader public about their level of transparency 16 and their understanding of risks and uncertainties 17 around their talcum powder products at the time. 18 And so, therefore, you know, it goes 19 to almost all of the material that has to do with 20 misbranding. It goes to the sections that have to 21 do with Johnson & Johnson's communications as it 22 learned various types of scientific information. 23 And it goes to the section that begins on 24 paragraph 109 where Johnson & Johnson claims it 25 has a robust ethics and compliance program that</p>
<p style="text-align: right;">Page 39</p> <p>1 A. Again, your question reflects the report 2 as it reflects my opinions as I sit here. 3 Obviously, I can't rely on a written document 4 dated previously to today on something I've 5 received subsequently to that date. 6 Q. I understand. And maybe it was just a 7 bad question on my part. What I'm trying to 8 figure out is -- you have a -- 9 A. So with that -- with that -- 10 Q. Yeah. I'm sorry -- 11 (Speaking simultaneously.) 12 A. With that understanding, I'm happy to 13 answer the question. 14 Q. Yeah. And before you answer, let me just 15 try to make it a little clearer. I may fail. 16 But, you know, you have a, you know, 32-page 17 report, and the first question is: I assume that 18 you are not relying on Dr. Newman's report to 19 further support every single opinion contained 20 over these 33 pages, correct? 21 DR. THOMPSON: Object to form. 22 A. Correct. 23 BY MR. EWALD: 24 Q. And so I'm not asking you to identify 25 every single paragraph that the report that they</p>	<p style="text-align: right;">Page 41</p> <p>1 goes above and beyond legal requirements. It goes 2 to the next section about resistance to testing, 3 though less so to that one. And it goes heavily 4 to the sections that have to do with 5 misrepresentations and the like that Johnson & 6 Johnson has, in my opinion, made in its marketing 7 material. 8 I'm also very happy to talk about 9 specific insights gained from the Newman report, 10 if you'd like. 11 BY MR. EWALD: 12 Q. Yes. So first of all, thank you. That 13 was an extremely helpful overview. And please -- 14 if you have certain specific insights in mind from 15 Newman, what are they? 16 DR. THOMPSON: Object to form. 17 A. Well, you know, in this case, I have to 18 say, you know, this protracted resistance by 19 Johnson & Johnson to honoring its legal and 20 corporate ethical obligations to be forthcoming 21 with the public about the risks of talcum powder 22 and the uncertainties in assessing those risks 23 was, you know, confirmed and made worse for me by 24 what I read in the Newman report. In particular, 25 the Newman report talks about Johnson & Johnson's</p>

<p style="text-align: right;">Page 42</p> <p>1 belief as a corporate matter that perfect trust in 2 the maternal child bond transferred to Johnson & 3 Johnson as a corporate entity was essential to how 4 the corporation thought about itself and its 5 long-term business product -- prospects. Excuse 6 me. And I have to say, I found a deep and 7 disturbing irony in the fact that Johnson & 8 Johnson's communications, conduct that was 9 intended to preserve that relationship of trust 10 was accomplished by completely violating that 11 relationship of trust. I was very -- I mean, 12 there were things in the Newman report that I 13 found incredibly disturbing. 14 BY MR. EWALD: 15 Q. After reading the Newman report -- well, 16 not "after." Have you spoken with Dr. Newman at 17 any point in time? 18 A. No. 19 Q. After reviewing Dr. Newman's report, did 20 you ask plaintiffs' counsel to review any 21 additional documents? 22 A. To review any additional documents? 23 Could you give me an example of what you mean by 24 that? 25 Q. Sure. What I'm trying to get at is you</p>	<p style="text-align: right;">Page 44</p> <p>1 For example -- we'll get to it -- but 2 you were given testing from Dr. Longo's updated 3 report, correct? 4 A. Correct. 5 Q. Did you ask plaintiffs' counsel for 6 anything that they're aware of, that gives any 7 critiques of Dr. Longo's testing that's reflected 8 in that report? 9 A. In connection with the preparation of my 10 amended report, no. 11 Q. No? 12 A. The original report included review of 13 many documents that had both similar and less 14 similar findings on many levels. 15 Q. Okay. But with respect to the amended 16 report and the testing given to you by Dr. Longo, 17 did you not ask from plaintiffs' counsel any 18 information that is responding to and/or 19 critiquing the opinions in the report that you 20 received, correct? 21 A. Correct. 22 Q. All right. You also mentioned earlier 23 the interagency working group and their efforts 24 over the past couple of years, right? 25 A. Yes.</p>
<p style="text-align: right;">Page 43</p> <p>1 talked about some things that you read in 2 Dr. Newman's report that concerned you, Fair? 3 A. Fair. 4 Q. Did -- at any point in time after 5 reviewing Dr. Newman's report, did you ask 6 plaintiffs' counsel for more information about a 7 particular topic that was raised in Dr. Newman's 8 report? 9 A. No. 10 Q. Have you reviewed a report from a 11 Dr. David Kessler in this case? 12 A. No. 13 Q. In preparing your amended report in this 14 case, did you ask plaintiffs' counsel for any 15 information about the defendant's, Johnson & 16 Johnson, position on any particular matter? 17 DR. THOMPSON: Object to form. 18 A. I'm not exactly sure how to answer that. 19 Could you break that down into categories? I 20 mean, for example, I haven't read any Johnson & 21 Johnson legal motions if you're asking about. 22 BY MR. EWALD: 23 Q. That's a fair question. And I -- you 24 know, I would leave aside the sort of legal 25 motions.</p>	<p style="text-align: right;">Page 45</p> <p>1 Q. Okay. And amongst other things in your 2 amended report, you cite to the white paper that 3 was released in 2021, correct? 4 A. Correct. 5 Q. We will mark as Exhibit 11 the white 6 paper "IWGACP Scientific Opinions On Testing 7 Methods For Asbestos in Cosmetic Products 8 Containing Talc. Interagency Working Group On 9 Asbestos In Consumer Products," dated 10 December 2021. 11 (Exhibit 11 marked.) 12 BY MR. EWALD: 13 Q. Is this the white paper you're aware of, 14 sir? 15 A. (Examined exhibit.) As best I can tell, 16 yes. I don't know if I have a copy in front of 17 me. 18 Q. Okay. And do you recall citing to this 19 document in your amended report? 20 A. Yes. 21 Q. Let's look at what you said there. I 22 believe it is on -- yeah, page 20, paragraph 123. 23 Let me know when you're there. 24 A. (Complied.) Yes. 25 Q. Okay. And specifically in paragraph 123,</p>

<p style="text-align: right;">Page 46</p> <p>1 you discuss the J4-1 method and then go on and</p> <p>2 state, (as read) "The peculiarity of retaining</p> <p>3 without reconsideration for nearly half a century</p> <p>4 the testing method clearly at odds with current</p> <p>5 science is repeatedly noted in the White Paper</p> <p>6 issued in late 2021 by the federal government's</p> <p>7 Interagency Working Group on Asbestos in Consumer</p> <p>8 Products."</p> <p>9 Did I read that correctly?</p> <p>10 A. You did.</p> <p>11 Q. All right. And so what are you -- what</p> <p>12 are you getting at with that sentence there in</p> <p>13 connection with the J4-1 method?</p> <p>14 A. In all my work, I take note of time</p> <p>15 frames associated with regulatory change,</p> <p>16 particularly scientific regulatory change, and I</p> <p>17 always take note of areas where, undoubtedly,</p> <p>18 science and technology have advanced but</p> <p>19 regulatory and self-regulatory standards have not,</p> <p>20 and that seem to be a very strong example for</p> <p>21 that.</p> <p>22 Q. Okay.</p> <p>23 DR. THOMPSON: And, Doctor, you</p> <p>24 need to review that document. If there</p> <p>25 are going to be more questions, you can do</p>	<p style="text-align: right;">Page 48</p> <p>1 in preparing the amended report this year and, I</p> <p>2 guess, late last year -- that there had been</p> <p>3 legislation. The legislation had included a</p> <p>4 direct instruction to the FDA to develop a</p> <p>5 standardized method, and this was part of that</p> <p>6 regulatory story.</p> <p>7 BY MR. EWALD:</p> <p>8 Q. Do you have any criticisms of the FDA</p> <p>9 white paper?</p> <p>10 A. I didn't read it with criticisms in mind.</p> <p>11 I read it for context and direction and reform.</p> <p>12 Q. And beyond the context that you just</p> <p>13 discussed, do -- does the FDA white paper inform</p> <p>14 any of your other opinions that you're offering in</p> <p>15 this case?</p> <p>16 DR. THOMPSON: Object to form.</p> <p>17 A. Certainly. I mean, it informs opinions</p> <p>18 on levels of scientific risk, of scientific</p> <p>19 uncertainty regarding the risk, on insufficiency</p> <p>20 of the industry-developed standards to reflect the</p> <p>21 underlying risks and materials. And it supported</p> <p>22 various inferences about Johnson & Johnson's lack</p> <p>23 of interest in finding out current scientific fact</p> <p>24 about its products over this long period of time.</p> <p>25 So it goes quite directly to many of the opinions</p>
<p style="text-align: right;">Page 47</p> <p>1 that.</p> <p>2 A. If there --</p> <p>3 BY MR. EWALD:</p> <p>4 Q. Certainly.</p> <p>5 A. -- if you were planning to ask me, you</p> <p>6 know, to find the specific quotes in a document</p> <p>7 that I read first a while back and then reread in</p> <p>8 direct preparation for the report, I, you know,</p> <p>9 would have to take time to do that.</p> <p>10 Q. Sure. And I may ask more questions about</p> <p>11 it a little bit later. What I'm trying to figure</p> <p>12 out right now is just kind of the basics. And so</p> <p>13 I understand what you just said.</p> <p>14 With respect to the white paper, do</p> <p>15 you have any opinions as to the testing methods</p> <p>16 that were recommended by the interagency working</p> <p>17 group in the December 2021 white paper?</p> <p>18 DR. THOMPSON: Object to form.</p> <p>19 A. My view of the interagency working group</p> <p>20 white paper was that it was a clear indication</p> <p>21 that improvements were necessary in testing</p> <p>22 methods for asbestos and similar substances that</p> <p>23 could be harm-producing in cosmetic talc. I don't</p> <p>24 have specific opinions on what they said. I did</p> <p>25 have the additional knowledge that -- especially</p>	<p style="text-align: right;">Page 49</p> <p>1 in the report.</p> <p>2 BY MR. EWALD:</p> <p>3 Q. And the -- that last point you made,</p> <p>4 the -- going to the Johnson & Johnson's</p> <p>5 inferences -- I'm sorry. I don't want to put</p> <p>6 words in your mouth.</p> <p>7 The last part you talked about with</p> <p>8 Johnson & Johnson and how it impacted inferences</p> <p>9 that -- about Johnson & Johnson's testing</p> <p>10 approach. Can you describe what you were -- are</p> <p>11 referring to?</p> <p>12 A. Again, this is, you know, qualitative,</p> <p>13 not quantitative. But my core expertise in</p> <p>14 legislation regulation and its development and</p> <p>15 change in the associated obligations, it matters</p> <p>16 to me when I see a -- an agency that is newly</p> <p>17 invigorated, whether it's by an FDA finding of</p> <p>18 asbestos in a Johnson & Johnson talcum powder</p> <p>19 sample by congressional hearings, recognizing that</p> <p>20 the self-regulatory models of cosmetic regulation</p> <p>21 were not sufficiently enforced in order for the</p> <p>22 modern risks of the globalized, industrialized</p> <p>23 cosmetic sector to be properly safe. Yes, all of</p> <p>24 this goes to that, but it goes in a qualitative</p> <p>25 fashion.</p>

<p style="text-align: right;">Page 50</p> <p>1 Q. And then, specifically, you were talking</p> <p>2 about Johnson & Johnson's, I guess, lack of, in</p> <p>3 your mind, of dedication to current testing</p> <p>4 technologies. Is that a fair understanding of</p> <p>5 what you're saying?</p> <p>6 DR. THOMPSON: Object to form.</p> <p>7 A. Not exactly.</p> <p>8 BY MR. EWALD:</p> <p>9 Q. Okay.</p> <p>10 A. What I'm concerned with in my expert</p> <p>11 report is whether Johnson & Johnson has complied</p> <p>12 with its self-regulatory obligations under federal</p> <p>13 cosmetics law which I believe it has not. And,</p> <p>14 particularly, its obligations regarding</p> <p>15 information, labeling, warning, and other</p> <p>16 communications, and many of those communications</p> <p>17 have to do with its assertions of having</p> <p>18 asbestos-free talcum powder products to which this</p> <p>19 report goes directly.</p> <p>20 Q. And about to take a break because we've</p> <p>21 been going about an hour. But I just want to</p> <p>22 finish off this line of questioning.</p> <p>23 When you say that this white paper</p> <p>24 goes directly to the asbestos-free talcum powder</p> <p>25 representations by Johnson & Johnson, what do you</p>	<p style="text-align: right;">Page 52</p> <p>1 longer than that. Okay.</p> <p>2 MR. GOLOMB: Can we -- just before</p> <p>3 we go off the record. This is Richard</p> <p>4 Golomb. I'm here for the State court</p> <p>5 plaintiffs. I apologize for entering</p> <p>6 late. But I just want to make sure the</p> <p>7 record's clear. I'm here now. And I</p> <p>8 reserve the right to make objections based</p> <p>9 on the coordination order.</p> <p>10 Can we agree that any objections</p> <p>11 that Ms. Thompson makes applies to the</p> <p>12 State court as well so my objections will</p> <p>13 be minimal?</p> <p>14 MR. EWALD: Sure.</p> <p>15 MR. GOLOMB: Thank you.</p> <p>16 MR. EWALD: So I -- and,</p> <p>17 Dr. Thompson, I didn't hear you. Do you</p> <p>18 want five or ten?</p> <p>19 DR. THOMPSON: I -- we could</p> <p>20 probably do five. We'll just come back as</p> <p>21 soon as we're ready. We'll --</p> <p>22 MR. EWALD: Right. It's -- I think</p> <p>23 my general experience is that when people</p> <p>24 say "five," they don't get back --</p> <p>25 (Speaking simultaneously.)</p>
<p style="text-align: right;">Page 51</p> <p>1 mean?</p> <p>2 DR. THOMPSON: Objection; form.</p> <p>3 A. I mean, that this is a federal</p> <p>4 interagency working group doing, as far as I can</p> <p>5 tell, the most systematic and thoughtful review of</p> <p>6 the current state of science, in combination with</p> <p>7 congressional investigations, that led to a</p> <p>8 regulatory modernization and reform law. And when</p> <p>9 you put it all together in that way, it's pretty</p> <p>10 clear to me that Johnson & Johnson took comfort</p> <p>11 that was not justified in stand- -- testing</p> <p>12 practices for asbestos that were questionable when</p> <p>13 adopted but had been in place for so long that</p> <p>14 they did not keep up with science.</p> <p>15 MR. EWALD: All right. Like I</p> <p>16 said, we've been going about an hour. I</p> <p>17 was thinking we'd take, like, a five-</p> <p>18 minute break. We can take a little bit</p> <p>19 longer if folks need to grab coffee or</p> <p>20 anything like that. Just let me know.</p> <p>21 THE COURT REPORTER: Yeah. Just</p> <p>22 a --</p> <p>23 THE WITNESS: Whatever you like.</p> <p>24 Whatever you need.</p> <p>25 THE COURT REPORTER: Just a touch</p>	<p style="text-align: right;">Page 53</p> <p>1 DR. THOMPSON: Yeah. Let's say --</p> <p>2 let's say no more than ten.</p> <p>3 MR. EWALD: Let's shoot for five</p> <p>4 but no more than ten. Correct. Thanks.</p> <p>5 DR. THOMPSON: All right. That</p> <p>6 sounds good.</p> <p>7 THE COURT REPORTER: We're off the</p> <p>8 record at 10:29.</p> <p>9 (A recess was taken from 10:29 a.m. to</p> <p>10 10:36 a.m.)</p> <p>11 THE COURT REPORTER: And we are</p> <p>12 back on the record at 10:36.</p> <p>13 BY MR. EWALD:</p> <p>14 Q. All right. I want to mark as Exhibit 12</p> <p>15 the new report of -- well, the newest report from</p> <p>16 Dr. Longo. Let me just identify it so that we're</p> <p>17 all on the same page.</p> <p>18 (Exhibit 12 marked.)</p> <p>19 BY MR. EWALD:</p> <p>20 Q. All right. So I've shared my screen. I</p> <p>21 have what's identified as the "3rd Supplemental</p> <p>22 MDL Report. Analysis of Non-Historical J&J's</p> <p>23 Talcum Powder Consumer Product Containers and J&J</p> <p>24 Chinese Historical Talc Retain Samples,"</p> <p>25 November 17th 2023. It's marked as Exhibit 12.</p>

<p style="text-align: right;">Page 54</p> <p>1 Is this, Doctor, the Longo report</p> <p>2 that you were referring to that you received?</p> <p>3 A. (Examined exhibit.) Yes. This is --</p> <p>4 this is the report that I have looked at most</p> <p>5 recently.</p> <p>6 Q. All right. And I understand that you</p> <p>7 previously had received a -- an earlier version of</p> <p>8 an MDL report from Dr. Longo, and you include that</p> <p>9 in your amended expert report, correct?</p> <p>10 A. Yes.</p> <p>11 Q. And am I correct that you do not cite to</p> <p>12 this November 17th, 2023, test results in your</p> <p>13 amended expert report, correct?</p> <p>14 A. I just looked at my amended report, and</p> <p>15 it's dated November, 15th and this is dated</p> <p>16 November 17th. This doesn't necessarily mean that</p> <p>17 it's the days we saw things. But, you know, let's</p> <p>18 say that -- well, I'm gonna agree with -- I'm</p> <p>19 gonna agree with you for now, absent</p> <p>20 more information.</p> <p>21 Q. I wasn't sure if they, you know,</p> <p>22 successfully created time travel back down at A&M.</p> <p>23 A. (Laughing.)</p> <p>24 Q. All right. So what I'm trying to figure</p> <p>25 out is -- I asked this a little bit earlier, but</p>	<p style="text-align: right;">Page 56</p> <p>1 going to be able to pinpoint a specific day in</p> <p>2 which you received it, I'm trying to get a sense</p> <p>3 -- is -- you get the Dr. Longo November 2023</p> <p>4 report around the same time you got the Newman</p> <p>5 report, or is this something that happened a</p> <p>6 number of months ago?</p> <p>7 A. I believe it was shortly after I got the</p> <p>8 Newman report.</p> <p>9 Q. All right. And so we're talking roughly</p> <p>10 a couple weeks ago approximately?</p> <p>11 A. I don't know.</p> <p>12 Q. All right.</p> <p>13 A. What I can -- what I can say is that the</p> <p>14 Newman and the Longo reports were interesting and</p> <p>15 relevant for me in preparing for today.</p> <p>16 Q. All right. So then let's talk a little</p> <p>17 bit about the report from Dr. Longo that we've</p> <p>18 marked as Exhibit 12. And this is something, I</p> <p>19 believe you testified earlier today, that</p> <p>20 plaintiffs' counsel provided to you, correct?</p> <p>21 A. Correct.</p> <p>22 DR. THOMPSON: And, again, could</p> <p>23 you put that in Chat or -- he's gonna need</p> <p>24 to review it if you're gonna ask specific</p> <p>25 questions -- or if you would like to</p>
<p style="text-align: right;">Page 55</p> <p>1 approximately when you did receive it -- so let me</p> <p>2 show you just show you something. The -- if I go</p> <p>3 back to what we've marked as Exhibit 5, which is</p> <p>4 the Amended Exhibit B dated March 27th, 2024, and</p> <p>5 I show on the screen here, word searching, I get</p> <p>6 one hit which is to the 2019 report.</p> <p>7 Do you see that?</p> <p>8 A. Yes.</p> <p>9 Q. Okay. And then I look at --</p> <p>10 MR. EWALD: I'm starting to get a</p> <p>11 little feedback somewhere. Maybe Richard?</p> <p>12 MR. GOLOMB: I don't think it's</p> <p>13 feedback as much as it is skipping, it</p> <p>14 sounds like.</p> <p>15 MR. EWALD: All right. I think</p> <p>16 it's feedback. All right. We'll</p> <p>17 continue.</p> <p>18 BY MR. EWALD:</p> <p>19 Q. Then if we look at the second amended,</p> <p>20 which we've marked as Exhibit 6, also dated</p> <p>21 March 27, 2024, we then see that it has both the</p> <p>22 2019 version of the report and the November 2023.</p> <p>23 Do you see that?</p> <p>24 A. Yes.</p> <p>25 Q. Okay. And so understanding you're not</p>	<p style="text-align: right;">Page 57</p> <p>1 review it.</p> <p>2 THE WITNESS: Sure.</p> <p>3 DR. THOMPSON: You could have it in</p> <p>4 front of you. I'm just saying.</p> <p>5 THE WITNESS: Yes.</p> <p>6 MR. EWALD: Okay. It should be in</p> <p>7 the Chat. While people are pulling that</p> <p>8 up, I will also put it on the screen.</p> <p>9 THE WITNESS: Thank you. I'm a</p> <p>10 Windows user, and the computer in front of</p> <p>11 me is a Mac, so I have very few buttons I</p> <p>12 can push without worrying.</p> <p>13 (Speaking simultaneously.)</p> <p>14 THE WITNESS: He'll put it on the</p> <p>15 screen.</p> <p>16 DR. THOMPSON: Yeah, but if you</p> <p>17 want to look at the whole thing, you'll</p> <p>18 need it in Chat rather than...</p> <p>19 BY MR. EWALD:</p> <p>20 Q. Yeah. At any point in time, Doctor,</p> <p>21 yeah, you want to look at something else, you can</p> <p>22 either direct me -- I will be your page scroller</p> <p>23 -- or if you want to look on your own with</p> <p>24 counsel, that's also fine.</p> <p>25 Okay. So have you heard anything</p>

<p style="text-align: right;">Page 58</p> <p>1 about the November 2023 Longo report before 2 receiving it from counsel? 3 A. "Heard anything" is a little vague in the 4 sense that I think I'm not supposed to tell you 5 about conversations. But the easy answer to the 6 question is I heard there was one and nothing 7 more. 8 Q. All right. Okay. So you received the 9 report that we've marked as Exhibit 12. How, if 10 at all, does this report from Dr. Longo inform the 11 opinions that you're offering in this case? 12 A. It's confirmatory regarding the presence 13 of asbestos in talcum powder samples and 14 containers. My understanding was that this was 15 Dr. Longo's testing of samples that came from 16 Chinese mines rather than domestic U.S. mines. 17 And my understanding, if I recall correctly, is 18 that Johnson & Johnson started sourcing its 19 talcum -- its talc for talcum powder products from 20 China in -- somewhere in the early 2000s, I 21 believe, which makes it overall relevant to the 22 issues of adulteration and violation of legal 23 obligation. 24 Q. What is your understanding of the method 25 of testing that Dr. Longo is using in this report?</p>	<p style="text-align: right;">Page 60</p> <p>1 not only Dr. Longo's report, but you would have to 2 go search the list, possibly a deposition or 3 something else and some statement of expertise at 4 the time. Again, you know, what is relevant here 5 is that this is a -- a scientific assessment, and 6 I have no reason to question Dr. Longo's 7 expertise. 8 BY MR. EWALD: 9 Q. Well, you said that you -- it's not like 10 you said -- well, you indicated relying is not 11 accepting without thought, so what thought did you 12 apply to this, Exhibit 12, in reviewing in 13 connection with your opinions in this case? 14 DR. THOMPSON: Object to form; 15 asked and answered. 16 A. At this point in my involvement with the 17 subject matter, I have read a number of reports 18 that have to do with different testing methods, 19 assay methods, microscopy, crystallography, 20 various other things. I find them all interesting 21 to read. This seemed to be a sophisticated method 22 brought very recently to bear on a relevant topic, 23 and I rely on it as any expert would rely on other 24 peoples' expertise. 25 BY MR. EWALD:</p>
<p style="text-align: right;">Page 59</p> <p>1 DR. THOMPSON: Object to form. 2 A. I rely on the methods in the report as 3 stated. I don't have detailed recollection of 4 them, and I wouldn't have a way to endorse or 5 critique them. 6 BY MR. EWALD: 7 Q. So if you don't have a way to endorse or 8 critique the testing methods by Dr. Longo, on what 9 basis are you relying on them for your opinions in 10 this case? 11 DR. THOMPSON: Object to form. 12 A. I rely on them as reflecting the 13 scientific expertise Dr. Longo brings to this 14 tasks. The same way I would, you know, rely on 15 statements of science in a lot of context from a 16 lot of sources. "Relying" of course does not mean 17 accepting without thought. "Relying" means I 18 found them relevant and scientifically grounded to 19 the extent that I understood them. 20 BY MR. EWALD: 21 Q. Okay. And so what did you know about 22 Dr. Longo's scientific expertise? 23 DR. THOMPSON: Object to form. 24 A. I cannot recall in that -- in preparation 25 for the original report, I believe I had copies of</p>	<p style="text-align: right;">Page 61</p> <p>1 Q. Are you aware of any lab -- testing lab 2 outside of MAS that has confirmed the PLM 3 chrysotile findings reflected in this report? 4 DR. THOMPSON: And can you give a 5 time frame on that? 6 MR. EWALD: Doesn't matter. It 7 does not. 8 BY MR. EWALD: 9 Q. But go ahead. How would you -- 10 (Speaking simultaneously.) 11 DR. THOMPSON: Yeah. Are you 12 talking about since November of 2023 when 13 the -- or September of 2023 when the 14 report was submitted? 15 MR. EWALD: Well, as Dr. Longo 16 reflects here, this testing that's 17 contained here was produced in various 18 litigations at various points in time 19 before November of 2023. But I will 20 ask -- so I'm not limiting it to time. 21 BY MR. EWALD: 22 Q. I'm asking, Doctor, are you aware of any 23 testing lab -- outside of MAS -- that has ever 24 validated the PLM chrysotile findings of Dr. Longo 25 in this report?</p>

<p style="text-align: right;">Page 62</p> <p>1 DR. THOMPSON: Object to form. And</p> <p>2 that would encompass old ground that could</p> <p>3 have been questioned. That was questioned</p> <p>4 previously.</p> <p>5 BY MR. EWALD:</p> <p>6 Q. Well, I'll go ahead and respond to that</p> <p>7 before you answer, Doctor.</p> <p>8 MR. EWALD: Previous to this,</p> <p>9 Dr. Sage had not been relying on any PLM</p> <p>10 chrysotile testing of Dr. Longo. He'd</p> <p>11 only been relying on the report as</p> <p>12 reflected on his prior reliance list which</p> <p>13 only led to amphibole testing.</p> <p>14 DR. THOMPSON: Your question as --</p> <p>15 BY MR. EWALD:</p> <p>16 Q. So from that side now, Doctor --</p> <p>17 MR. EWALD: Excuse me?</p> <p>18 DR. THOMPSON: Excuse me. Go</p> <p>19 ahead, finish.</p> <p>20 MR. EWALD: What?</p> <p>21 THE WITNESS: It's a "Go ahead.</p> <p>22 Please finish."</p> <p>23 DR. THOMPSON: Yeah. Go ahead and</p> <p>24 finish. I didn't mean to interrupt you.</p> <p>25 MR. EWALD: Oh, I thought I was</p>	<p style="text-align: right;">Page 64</p> <p>1 DR. THOMPSON: Object to form.</p> <p>2 A. This is the only report, in preparation</p> <p>3 for revising my report in this deposition on this</p> <p>4 particular testing, that I have read.</p> <p>5 I have also read various FDA</p> <p>6 statements and other reports on all of their</p> <p>7 testing from the 2019 finding of asbestos to the</p> <p>8 present. I have not focused, other than in this</p> <p>9 report, on amphibole asbestos versus chrysotile</p> <p>10 asbestos.</p> <p>11 I also have noted the EPA's recent --</p> <p>12 I don't remember if it was a guidance or a</p> <p>13 regulation -- proposing the complete prohibition</p> <p>14 of chrysotile asbestos in consumer products and</p> <p>15 occupational exposure. But I -- again, there</p> <p>16 would be no reason for me, in preparation for my</p> <p>17 report, to survey every testing lab. As I said in</p> <p>18 my first deposition, now that I recall, if you'd</p> <p>19 like to provide me with something that is contrary</p> <p>20 to something I state and you would like me to</p> <p>21 consider that, I would be happy to do so.</p> <p>22 BY MR. EWALD:</p> <p>23 Q. Well, do you -- on that front, do you</p> <p>24 perceive -- well, let me put it back to your</p> <p>25 academic career in context.</p>
<p style="text-align: right;">Page 63</p> <p>1 done. I'm done that -- are you referring</p> <p>2 to -- was that something that was on his</p> <p>3 list?</p> <p>4 DR. THOMPSON: So I think it's --</p> <p>5 the question of whether Dr. Longo's</p> <p>6 findings of chrysotile have been confirmed</p> <p>7 implies that that would only be since</p> <p>8 Dr. Longo's chrysotile findings have been</p> <p>9 available. So the question would be:</p> <p>10 Have there been findings of chrysotile</p> <p>11 from other sources prior to this? And I</p> <p>12 think that would be off-limits.</p> <p>13 MR. EWALD: Okay. But that's not</p> <p>14 what I'm asking, and the record will</p> <p>15 reflect when the first Dr. Longo testing</p> <p>16 results for chrysotile PLM were made</p> <p>17 available in litigation which is around</p> <p>18 2020. But, again, my question is not</p> <p>19 limited to time. So you shouldn't have a</p> <p>20 problem with it.</p> <p>21 BY MR. EWALD:</p> <p>22 Q. My question is: Dr. Sage, are you aware</p> <p>23 of any laboratory -- outside of MAS -- that has</p> <p>24 ever validated Dr. Longo's PLM findings of</p> <p>25 chrysotile that are reflected in this report?</p>	<p style="text-align: right;">Page 65</p> <p>1 When you are drafting up an article</p> <p>2 for peer-reviewed publication, is it your position</p> <p>3 that you don't need to worry about any potential</p> <p>4 criticisms unless somebody writes a letter to the</p> <p>5 editor?</p> <p>6 DR. THOMPSON: Object to form.</p> <p>7 A. I actually spend a lot of time</p> <p>8 interpreting my own work and anticipating and</p> <p>9 responding to criticisms of that work. In this</p> <p>10 instance, the court questioned regarding testing</p> <p>11 has to do with the presence of asbestos and</p> <p>12 asbestiform fibers in talc and talcum powder</p> <p>13 products and whether Johnson & Johnson has</p> <p>14 complied with its legal and ethical corporate</p> <p>15 obligations, which I conclude that it has not. I</p> <p>16 believe that my review of this material, absent</p> <p>17 something else you would like to show me, is</p> <p>18 completely consistent with how I would approach</p> <p>19 this as an academic matter.</p> <p>20 BY MR. EWALD:</p> <p>21 Q. All right. And just to be clear -- and</p> <p>22 we'll get there. But just to be clear: At no</p> <p>23 point in time after receiving and reading this</p> <p>24 report from Dr. Longo from 2023 did you ask</p> <p>25 plaintiffs' counsel, "Can you give me anything</p>

<p style="text-align: right;">Page 66</p> <p>1 that may be out there that criticizes the testing 2 method of Dr. Longo that is reflected in this 3 report?"</p> <p>4 A. It's import- --</p> <p>5 DR. THOMPSON: Object to form.</p> <p>6 A. -- it's important to remember here that 7 Johnson & Johnson's legal obligations do not 8 require a certainty of anything. They require 9 information that is suggestive of risk, and 10 certainly, the presence of asbestos and any sample 11 at any time is suggestive of risk. The 12 uncertainty surrounding that risk is also the 13 subjective legal obligation of disclosure by 14 Johnson & Johnson. So I stand by my statement. 15 Everything I read here was sufficient to ground my 16 opinions. I'm happy to look at contrary 17 information, should you like to provide it.</p> <p>18 BY MR. EWALD:</p> <p>19 Q. And we'll get there. But --</p> <p>20 DR. THOMPSON: And, John, the 2019 21 FDA findings and Longo's first report were 22 covered in the previous 2021 report in 23 deposition, so I don't think we can really 24 go into anything that's ever happened in 25 the whole history of asbestos testing</p>	<p style="text-align: right;">Page 68</p> <p>1 DR. THOMPSON: Wait. Okay. 2 There's no question on -- there's no 3 question up. 4 MR. EWALD: I agree with you, 5 Dr. Thompson, and I think the only 6 disagreement we have on that is whether 7 the PLM chrysotile testing that is 8 reflected in this report, which is a 9 compilation of a number of expert reports 10 from Dr. Longo, had previously been 11 available before the date of this report, 12 November 2023. And I am confident that 13 that is the case. I understand that you 14 may not be so confident. And so that's 15 why my question does not have a particular 16 date. 17 But, yes, you are correct. I'm 18 asking about any validation by any testing 19 lab in the world of the findings of 20 chrysotile by using its PLM testing in 21 Dr. Longo -- in this report. That's what 22 I'm asking. 23 DR. THOMPSON: And Dr. Sage has 24 already testified that he is not offering 25 any -- any critique or opinions as to</p>
<p style="text-align: right;">Page 67</p> <p>1 today. 2 MR. EWALD: I don't believe I 3 mentioned anything about Longo's 2019 4 report or the FDA findings. That's what 5 you're talking about. 6 I'm talking about specifically the 7 PLM chrysotile findings that are reflected 8 in the report that Dr. Sage is relying on 9 for the very first time. I'm asking 10 questions about that, and I'm going to 11 continue asking questions about that.</p> <p>12 BY MR. EWALD:</p> <p>13 Q. Okay. So, Doctor --</p> <p>14 DR. THOMPSON: But so -- but wait a 15 minute. You're saying the validation of a 16 chrysotile finding by Dr. Longo. If 17 you're talking about a validation of 18 Dr. Longo's findings, it would just be 19 since those findings. If you're talking 20 about others finding chrysotile, then that 21 has been covered previously in 2021 in 22 Dr. Sage's deposition report.</p> <p>23 MR. EWALD: I agree with you.</p> <p>24 THE WITNESS: Could I ask, John, if 25 it's --</p>	<p style="text-align: right;">Page 69</p> <p>1 Dr. Longo's methods of testing. 2 MR. EWALD: Oh, I know, but he has 3 also said -- 4 DR. THOMPSON: But you -- 5 (Speaking simultaneously.) 6 MR. EWALD: And, really, as far as 7 the speaking objections and because we 8 are -- you know, if you'd like to proceed 9 with my examination, there's been a lot of 10 colloquy with counsel and a lot of 11 speaking objections on your end. And I 12 appreciate you may not understand the 13 intricacies and details of this, but I 14 would like to ask the questions of 15 Dr. Sage and not of Dr. Thompson, okay? 16 DR. THOMPSON: Okay. Well, if 17 you're talking about the methods, it's one 18 thing. If you're talking about the 19 findings of chrysotile, it's another 20 thing, and -- and so we'll see what the 21 question is and -- 22 MR. EWALD: Yes, we will. 23 DR. THOMPSON: -- and what his 24 answer is. 25 MR. EWALD: Okay.</p>

<p style="text-align: right;">Page 70</p> <p>1 BY MR. EWALD:</p> <p>2 Q. So, Doctor, before all that, we were</p> <p>3 talking about -- well, actually, that's always a</p> <p>4 problem with all the wordy colloquies. I lose my</p> <p>5 train of thought. Just give me one moment.</p> <p>6 A. Sure.</p> <p>7 Q. Oh, all right. You were talking about</p> <p>8 self-regulatory obligations, and I sense that you</p> <p>9 were suggesting that there is some reporting</p> <p>10 obligation from Johnson & Johnson on the findings</p> <p>11 from Dr. Longo here, regardless of whether or not</p> <p>12 they are reliable, scientific findings. Is that</p> <p>13 your testimony?</p> <p>14 DR. THOMPSON: Object to form.</p> <p>15 A. That is not my testimony.</p> <p>16 BY MR. EWALD:</p> <p>17 Q. What is your testimony?</p> <p>18 A. What is my testimony on what point? I'd</p> <p>19 be happy to tell you, if it's helpful, what I,</p> <p>20 with respect to my report, thought I got out of</p> <p>21 the Longo report. But the things that I don't</p> <p>22 talk about are just -- don't have any particular</p> <p>23 negative conclusion to them. They're simply</p> <p>24 things that did not strike me as important to my</p> <p>25 report from this material.</p>	<p style="text-align: right;">Page 72</p> <p>1 Q. Okay. So tell me what you want to say</p> <p>2 about that.</p> <p>3 A. As I said when we first mentioned this</p> <p>4 Longo report, my understanding was that this</p> <p>5 report was Chinese-sourced talc as opposed to, I</p> <p>6 believe, Vermont-sourced talc that it preceded in</p> <p>7 Johnson & Johnson's business practices.</p> <p>8 Q. (Scrolling.)</p> <p>9 A. All right. Thank you.</p> <p>10 I see Vermont and Chinese on the --</p> <p>11 on the screen. And given that there now is a</p> <p>12 roughly 20 year history of Chinese-sourced talc,</p> <p>13 it seemed relevant to me to know what an expert</p> <p>14 laboratory detected in terms of asbestos. My</p> <p>15 understanding is that the Vermont-sourced talc had</p> <p>16 not been tested -- at least by this lab -- for</p> <p>17 chrysotile serpentine asbestos. And so, yes, that</p> <p>18 is, you know, an interesting finding for me. It</p> <p>19 is not a dispositive finding in some way, which a</p> <p>20 lot of your questions seem to be kind of centered</p> <p>21 around. That was interesting to me.</p> <p>22 More interesting to me was that the</p> <p>23 overall prevalence, in terms of percentage of</p> <p>24 samples that had some form of detectable asbestos,</p> <p>25 was at least as high in the Chinese sourced talc</p>
<p style="text-align: right;">Page 71</p> <p>1 Q. Okay. I'm going to get to that.</p> <p>2 But I'm trying to get a sense of you</p> <p>3 talked about, in the prior answer, things like</p> <p>4 suggestion of risk and a lack of certainty doesn't</p> <p>5 really mean -- a lack of ambiguity does not free</p> <p>6 the cosmetic company from reporting the adverse</p> <p>7 event, fair?</p> <p>8 DR. THOMPSON: Object to form.</p> <p>9 A. As a general matter, fair.</p> <p>10 BY MR. EWALD:</p> <p>11 Q. Okay. And so I'm trying to get -- from</p> <p>12 your perspective, you see this expert report from</p> <p>13 Dr. Longo, and it reports chrysotile findings</p> <p>14 using PLM. And is this something that need to, in</p> <p>15 your mind, be reported out immediately as a</p> <p>16 finding of asbestos in Johnson & Johnson talc?</p> <p>17 DR. THOMPSON: Object to form.</p> <p>18 A. I don't know what the basis would be for</p> <p>19 the reporting out. I don't -- I'm really not sure</p> <p>20 what the question is. Again, I'm happy to tell</p> <p>21 you in what way this report informs my testimony</p> <p>22 today, and what it does is give me continued and</p> <p>23 greater confidence in the adulteration of talcum</p> <p>24 powder products with asbestos.</p> <p>25 BY MR. EWALD:</p>	<p style="text-align: right;">Page 73</p> <p>1 as it was in the Vermont sourced talc, and it</p> <p>2 seemed actually to be significantly higher. I</p> <p>3 believe the Vermont source talc had something like</p> <p>4 68 percent of samples tested, and this one had</p> <p>5 90 percent of samples tested.</p> <p>6 And I also drew the inference that</p> <p>7 asbestiform fibrous talc, not mineral asbestos,</p> <p>8 was prevalent in all of the samples and, you know,</p> <p>9 was ubiquitous and, therefore, didn't even bear</p> <p>10 reporting. And those were the things that were</p> <p>11 relevant to me, and It really had to do with the</p> <p>12 shift in Johnson & Johnson's business practices</p> <p>13 from Vermont to China sourcing and whether that</p> <p>14 would influence the risk and uncertainty around</p> <p>15 adulteration of talcum powder products. That's</p> <p>16 it.</p> <p>17 Q. Okay. And you mentioned the difference</p> <p>18 in percentage of positives from 68 percent, which</p> <p>19 I believe that's when you -- that's what you</p> <p>20 include in your report for Italy and Vermont,</p> <p>21 right?</p> <p>22 A. It's what's in my re- -- it's what's in</p> <p>23 my report, and it was -- you know, again, no</p> <p>24 number above zero would be reassuring here. So</p> <p>25 these are sort of significant findings that don't</p>

<p style="text-align: right;">Page 74</p> <p>1 seem to me to be sample-dependent.</p> <p>2 Q. And --</p> <p>3 A. And I just wanted to make sure that this</p> <p>4 later report with Chinese-sourced talc was also</p> <p>5 insignificant nonsample dependent sort of ballpark</p> <p>6 for my purposes.</p> <p>7 Q. And when you see -- for Chinese talc,</p> <p>8 according to this MAS PLM chrysotile analysis,</p> <p>9 93 percent are positive. Does the delta between</p> <p>10 the 93 percent and the 68 percent of the prior</p> <p>11 findings have any impact whatsoever on your</p> <p>12 assessment of the reliability of Dr. Longo's PLM</p> <p>13 chrysotile analysis?</p> <p>14 DR. THOMPSON: Object to form.</p> <p>15 A. I don't think you're accurately reading</p> <p>16 the statement here, at least here as you have it</p> <p>17 on the screen. 40 of the 43 talcum powder samples</p> <p>18 from -- with Chinese-sourced talc were positive</p> <p>19 for either amphibole or chrysotile. It doesn't</p> <p>20 say "for chrysotile" which is what your question</p> <p>21 said.</p> <p>22 With that modification to your</p> <p>23 question, 68 and 93 are both concerning numbers,</p> <p>24 and the difference between them does not affect my</p> <p>25 opinion.</p>	<p style="text-align: right;">Page 76</p> <p>1 A. This -- this is --</p> <p>2 MR. EWALD: Thank you for the</p> <p>3 speaking. We are still in federal court.</p> <p>4 BY MR. EWALD:</p> <p>5 Q. Dr. Sage, what's your answer?</p> <p>6 A. This is the statement Dr. Longo puts in</p> <p>7 the report. I have, you know, the scientific</p> <p>8 background to understand something that is, I</p> <p>9 believe, referring to polarized light microscopy</p> <p>10 and something -- and I'm not -- I can't right now</p> <p>11 remember what HLS stands for. But, you know,</p> <p>12 there are liquid sampling analyses and things like</p> <p>13 that I don't remember.</p> <p>14 What I do from this paragraph, when I</p> <p>15 read it and I do recall reading it, was an</p> <p>16 impression that it was saying that this was a</p> <p>17 newly developed method by an academic reputable</p> <p>18 institution that, to my knowledge, is not</p> <p>19 connected to this litigation. That is what I drew</p> <p>20 from this paragraph.</p> <p>21 BY MR. EWALD:</p> <p>22 Q. Okay. Do you have an understanding as to</p> <p>23 whether or not the Colorado School of Mines method</p> <p>24 has ever been published, peer-reviewed?</p> <p>25 DR. THOMPSON: Object to form.</p>
<p style="text-align: right;">Page 75</p> <p>1 BY MR. EWALD:</p> <p>2 Q. Oh, yeah.</p> <p>3 All right. So scrolling up a little</p> <p>4 bit on the report from Dr. Longo, here we have --</p> <p>5 on page 2, you see the second full paragraph.</p> <p>6 "Also, when the last MDL report was issued, MAS</p> <p>7 was not analyzing cosmetic talc samples for</p> <p>8 chrysotile using the heavy liquid separation</p> <p>9 sample preparation method. After reviewing the</p> <p>10 Colorado School of Mines (CSM) protocol for the</p> <p>11 analysis of chrysotile using a HLS sample</p> <p>12 preparation method with PLM analysis, MAS worked</p> <p>13 on developing a more efficient protocol for the</p> <p>14 detection of chrysotile in cosmetic talc samples.</p> <p>15 The Colorado School of Mines developed this</p> <p>16 method."</p> <p>17 Did I read that correctly?</p> <p>18 A. Yes.</p> <p>19 Q. And is that your understanding of the</p> <p>20 test method that Dr. Longo was using in this</p> <p>21 report?</p> <p>22 DR. THOMPSON: Objection. He's</p> <p>23 already testified that he does not have</p> <p>24 opinions as to Dr. Longo's testing</p> <p>25 methodology.</p>	<p style="text-align: right;">Page 77</p> <p>1 A. I have no knowledge one way or the other.</p> <p>2 BY MR. EWALD:</p> <p>3 Q. Okay. Does that matter to your</p> <p>4 assessment as to whether or not it is a reliable</p> <p>5 method?</p> <p>6 DR. THOMPSON: Object to form.</p> <p>7 A. I'm sorry. If you tell me that the</p> <p>8 Colorado School of Mines has developed a testing</p> <p>9 method in its core sweet spot of geological</p> <p>10 science, I am inclined to believe it. I can't say</p> <p>11 more than that.</p> <p>12 BY MR. EWALD:</p> <p>13 Q. Okay. Well, if we go down a little</p> <p>14 further in the report, it talks about the Colorado</p> <p>15 School of Mines with HLS, heavy liquid separation,</p> <p>16 sample preparation of cosmetic talc. And</p> <p>17 specifically talks about documents from the 1970s.</p> <p>18 Here you see, "The sample preparation</p> <p>19 part of the MAS chrysotile analysis is based on</p> <p>20 the work done by the CSMP in the early 1970's for</p> <p>21 the detection specifically for possible chrysotile</p> <p>22 and amphibole asbestos in J&J sourced Vermont</p> <p>23 talcum powder."</p> <p>24 Do you see that?</p> <p>25 A. I do.</p>

<p style="text-align: right;">Page 78</p> <p>1 DR. THOMPSON: And, you know, I'm</p> <p>2 going to object to this being way beyond</p> <p>3 the scope of a amended report submitted in</p> <p>4 September of 2023.</p> <p>5 MR. EWALD: Excuse me? This is</p> <p>6 a -- this is a testing report that you</p> <p>7 guys showed him a couple weeks ago, that's</p> <p>8 not even a report -- let me finish my</p> <p>9 answer, please.</p> <p>10 (Speaking simultaneously.)</p> <p>11 MR. EWALD: Do not interrupt me.</p> <p>12 I'll let you give as long a speech as you</p> <p>13 want to. I'm not done.</p> <p>14 This is reflecting a report that</p> <p>15 was in November 2023, that you provided</p> <p>16 your expert, Mr. Sage -- Dr. Sage.</p> <p>17 Apologies.</p> <p>18 THE WITNESS: That's okay.</p> <p>19 MR. EWALD: Two weeks ago --</p> <p>20 (Speaking simultaneously.)</p> <p>21 THE WITNESS: When I taught -- when</p> <p>22 I taught at Colombia Law School, "Mr." was</p> <p>23 the honorific that was this lack of</p> <p>24 respect.</p> <p>25 MR. EWALD: Right.</p>	<p style="text-align: right;">Page 80</p> <p>1 Just let him answer the question.</p> <p>2 MR. EWALD: No. I will not let him</p> <p>3 answer the question when his -- when your</p> <p>4 counsel -- your co-counsel keeps on</p> <p>5 interrupting me. So I'm more than happy</p> <p>6 to proceed, but I want to make clear about</p> <p>7 what plaintiffs' position is in this</p> <p>8 matter.</p> <p>9 Is it plaintiffs' position that</p> <p>10 Mr. Hegarty, who took Day 1 of Dr. Sayta's</p> <p>11 deposition in 2021, should have questioned</p> <p>12 Dr. Sage about Dr. Longo's chrysotile</p> <p>13 opinions which were not included in the</p> <p>14 only report that Dr. -- that Dr. Longo and</p> <p>15 Dr. Sage received? Is that plaintiffs'</p> <p>16 position?</p> <p>17 MR. GOLOMB: We're not here to</p> <p>18 answer questions. Dr. Sage is here to</p> <p>19 answer questions. Ask your question, and</p> <p>20 we'll make an objection when appropriate,</p> <p>21 and he can answer.</p> <p>22 MR. EWALD: Okay. I will be more</p> <p>23 than happy to proceed when you guys -- if</p> <p>24 you guys want to just make your objections</p> <p>25 to "form" or "asked and answered" and not</p>
<p style="text-align: right;">Page 79</p> <p>1 THE WITNESS: I didn't know what to</p> <p>2 make with even "professor."</p> <p>3 MR. EWALD: Nonetheless, something</p> <p>4 that is not reflected in his report and</p> <p>5 I'm asking him questions about, so how</p> <p>6 could it possibly be something that is</p> <p>7 beyond the scope of a report that's</p> <p>8 reflected in September 2023?</p> <p>9 DR. THOMPSON: Because this</p> <p>10 information was in previous Longo reports</p> <p>11 and available at Dr. Sage's previous</p> <p>12 deposition and could have been asked about</p> <p>13 then.</p> <p>14 MR. EWALD: All right.</p> <p>15 DR. THOMPSON: To -- with that</p> <p>16 caveat and his statement that he's not</p> <p>17 commenting at all on any methodology or</p> <p>18 giving opinions, we can proceed, I</p> <p>19 suppose.</p> <p>20 MR. EWALD: Okay. And I just want</p> <p>21 to be clear. Is it your position that</p> <p>22 I --</p> <p>23 (Speaking simultaneously.)</p> <p>24 MR. GOLOMB: Wait. Wait. Is there</p> <p>25 a question on the table? Let him answer.</p>	<p style="text-align: right;">Page 81</p> <p>1 always give these long speaking</p> <p>2 objections. If you're going to continue</p> <p>3 with speaking objections, I'm going to</p> <p>4 continue to say why your speaking</p> <p>5 objections do not have any merit. So if</p> <p>6 we have an agreement, no speaking</p> <p>7 objections, I'll agree not to explain why</p> <p>8 they're wrong.</p> <p>9 MR. GOLOMB: Just ask your next</p> <p>10 question.</p> <p>11 DR. THOMPSON: Just ask the</p> <p>12 question. But if we're talking about a</p> <p>13 1973 document, and I -- we can certainly</p> <p>14 go back and pull that document and see</p> <p>15 whether it was covered in all sorts of --</p> <p>16 whether it's Hopkins or other J&J expert</p> <p>17 or 30(b)(6) witnesses, et cetera. I don't</p> <p>18 think it's worth taking the time to do</p> <p>19 that. So he can answer, but I do -- would</p> <p>20 still take the position that -- that a</p> <p>21 1973 document about asbestos is in the</p> <p>22 scope of what this deposition should be</p> <p>23 about today.</p> <p>24 MR. EWALD: Okay. So -- and I</p> <p>25 genuinely do not remember, Madam Court</p>

<p style="text-align: right;">Page 82</p> <p>1 Reporter, what the pending question was, 2 if there was one. Would you mind trying 3 to find it after all those pages of 4 colloquy?</p> <p>5 THE COURT REPORTER: Yes, sir. It 6 will take me a minute.</p> <p>7 MR. EWALD: No problem.</p> <p>8 THE COURT REPORTER: The last 9 pending question I have has to do with 10 reading the section in the Colorado School 11 of Mines with the HSL, heavy liquid 12 separation. You read that paragraph. And 13 then you said, "Do you see that?" And he 14 said, "I do." And then the objections 15 started. Do you want me to --</p> <p>16 MR. EWALD: Well, thanks.</p> <p>17 THE COURT REPORTER: Okay. Thank 18 you.</p> <p>19 BY MR. EWALD:</p> <p>20 Q. So my only follow-up question on that, 21 Doctor, is you had mentioned that you thought it 22 was a recent Colorado School of Mines method. 23 This, at least, is -- saying 1970s. Do you have 24 an understanding, one way or another, which is 25 right?</p>	<p style="text-align: right;">Page 84</p> <p>1 Q. Is that something you looked at in 2 connection with your amended report?</p> <p>3 A. No.</p> <p>4 Q. Okay. Do you recall whether or not 5 Dr. Longo presented any of his PLM chrysotile 6 heavy liquid separation findings at that 7 February 4th, 2020, meeting?</p> <p>8 DR. THOMPSON: Object to form.</p> <p>9 A. I don't recall.</p> <p>10 BY MR. EWALD:</p> <p>11 Q. Okay.</p> <p>12 A. I do remember going through that public 13 meeting material at the time, but I don't remember 14 any of the --</p> <p>15 Q. Sure. All right. And we'll mark as 16 Exhibit 13.</p> <p>17 (Exhibit 13 marked.)</p> <p>18 BY MR. EWALD:</p> <p>19 Q. Here we have the February 4th, 2020, 20 transcript of the meeting we were just referring 21 to, and I just have a couple of questions on this 22 one, Doctor.</p> <p>23 First of all --</p> <p>24 DR. THOMPSON: If you can put that 25 in Chat also --</p>
<p style="text-align: right;">Page 83</p> <p>1 A. All right. That's what I thought you 2 were -- you're getting at with the question.</p> <p>3 So if the thing is my prior answer is 4 that I read the introduction to suggest that this 5 was a recent method, you've now shown me a part of 6 the report that says at least part of it is not a 7 recent method. But the difference between is not 8 something that I considered earlier, and I cannot 9 imagine that it would change the way in which this 10 report bears on my opinion. Painful as that was.</p> <p>11 Q. Okay. So you, in your report, mention 12 the -- let's pull up here -- okay. I'm going back 13 to your Materials Considered list, Doctor. This 14 would be, again, the third amended, Exhibit 7.</p> <p>15 And amongst the materials that you see here, you 16 have the "U.S. Food and Drug Administration Public 17 Meeting: Testing Methods for Asbestos in Talc and 18 Cosmetic Products Containing Talc," February 4th 19 of 2020.</p> <p>20 Do you see that, Doctor?</p> <p>21 A. Yes.</p> <p>22 Q. And that's something -- a testimony, 23 something that you considered in preparing your 24 earlier report, correct?</p> <p>25 A. Yes.</p>	<p style="text-align: right;">Page 85</p> <p>1 MR. EWALD: Sure.</p> <p>2 DR. THOMPSON: -- so that he can -- 3 we can see the entire document.</p> <p>4 MR. EWALD: No problem. Just a 5 moment because it's a long document.</p> <p>6 THE WITNESS: No worries.</p> <p>7 BY MR. EWALD:</p> <p>8 Q. And while we're doing that, actually, as 9 a general matter, Doctor, do you have an 10 understanding as to what the purpose of that 11 February 4th, 2020, meeting with the FDA was?</p> <p>12 A. I cannot recall right now what that 13 purpose was.</p> <p>14 MR. EWALD: Okay. I'm getting an 15 error message when I try to attach it.</p> <p>16 THE WITNESS: I'm just going to 17 stand up for a moment.</p> <p>18 BY MR. EWALD:</p> <p>19 Q. Let's go ahead now. It's a document --</p> <p>20 MR. EWALD: Why don't we just take 21 a five-minute break? And then we can get 22 it sorted out by then.</p> <p>23 DR. THOMPSON: Excuse me. Can you 24 give me the Bates number or the name of 25 that document you're gonna put up?</p>

<p style="text-align: right;">Page 86</p> <p>1 MR. EWALD: It's -- there's not a</p> <p>2 Bates number. It's the direct link from</p> <p>3 his Materials Considered list --</p> <p>4 DR. THOMPSON: Okay.</p> <p>5 MR. EWALD: -- with the FDA</p> <p>6 website.</p> <p>7 DR. THOMPSON: FDA website?</p> <p>8 MR. EWALD: Yep.</p> <p>9 THE COURT REPORTER: All right.</p> <p>10 We're off the record at 11:21 here.</p> <p>11 (A recess was taken from 11:21 a.m. to</p> <p>12 11:26 a.m.)</p> <p>13 THE COURT REPORTER: We're back on</p> <p>14 the record at 11:26.</p> <p>15 BY MR. EWALD:</p> <p>16 Q. Okay. Thanks for the break. I was able</p> <p>17 to sort out the current issue. I uploaded in the</p> <p>18 Chat both the February 4th, 2020, transcript of</p> <p>19 the FDA meeting, also the -- just so you have</p> <p>20 it -- the FDA interagency white paper,</p> <p>21 December 2021.</p> <p>22 The -- going back do Exhibit 13 which</p> <p>23 is the transcript.</p> <p>24 A. You want me to click on these? Or will</p> <p>25 you show them to me?</p>	<p style="text-align: right;">Page 88</p> <p>1 MR. EWALD: And I'm relating it to</p> <p>2 something they concluded in the Zoom</p> <p>3 deposition -- in the new report.</p> <p>4 BY MR. EWALD:</p> <p>5 Q. Go ahead.</p> <p>6 A. I reviewed this in connection with the</p> <p>7 first report. I did not look at it again in</p> <p>8 connection with the second.</p> <p>9 BY MR. EWALD:</p> <p>10 Q. All right. And as you sit here today,</p> <p>11 you have no reliable understanding as to the</p> <p>12 purpose of this February 4th, 2020, meeting?</p> <p>13 DR. THOMPSON: Object to form.</p> <p>14 A. You just read me the statement in</p> <p>15 convening the meeting by the convenor. I have no</p> <p>16 reason to doubt that.</p> <p>17 BY MR. EWALD:</p> <p>18 Q. Okay.</p> <p>19 A. This meeting is, as you know, one step in</p> <p>20 a long chain that, among other things, resulted in</p> <p>21 a direct congressional instruction to FDA to</p> <p>22 develop a standardized testing method.</p> <p>23 Q. Understood. Okay. So -- and, of course,</p> <p>24 when I try to search it, it's crashing my Adobe.</p> <p>25 Hold on one second.</p>
<p style="text-align: right;">Page 87</p> <p>1 Q. I'm going to show it, and you're welcome</p> <p>2 to spend as much time as you want looking at it.</p> <p>3 I'm just going to -- I'm really going to ask you</p> <p>4 two questions about two parts. That doesn't mean</p> <p>5 that you can -- can't look at the other parts.</p> <p>6 But I first want to direct your</p> <p>7 attention to page 3, and we see comments from</p> <p>8 Ms. Kari Barrett, and she says, "The purpose of</p> <p>9 today's public meeting is to discuss and obtain</p> <p>10 scientific information on topics related to</p> <p>11 testing methods for asbestos in talc and cosmetic</p> <p>12 products containing talc. We expect this meeting</p> <p>13 to be an important step in our continued efforts</p> <p>14 to gather information on this topic, and we thank</p> <p>15 all thank of you in the room and online for</p> <p>16 joining us today."</p> <p>17 First, did I read that correctly?</p> <p>18 A. (Examined exhibit.) Yes.</p> <p>19 Q. All right. And is that generally</p> <p>20 consistent with your understanding of what the</p> <p>21 February 4th, 2020, meeting from the FDA was</p> <p>22 geared towards?</p> <p>23 DR. THOMPSON: Object to form. And</p> <p>24 this was included in his original report</p> <p>25 in deposition.</p>	<p style="text-align: right;">Page 89</p> <p>1 All right. Now, Doctor, we're on</p> <p>2 page 176 of the transcript, and do you see that</p> <p>3 Ms. Kari Barrett, the convenor, as you said, is</p> <p>4 introducing William Longo?</p> <p>5 Do you see that, sir?</p> <p>6 A. I do.</p> <p>7 Q. And he starts off his comments, after</p> <p>8 introducing himself, with the statement, "I would</p> <p>9 like to comment today on the research that we have</p> <p>10 done using heavy liquid separation for both</p> <p>11 amphibole asbestos, as well as our chrysotile</p> <p>12 asbestos that we have recently cracked the code,</p> <p>13 so to speak, where we can now do both."</p> <p>14 Did I read that correctly?</p> <p>15 A. Yes.</p> <p>16 Q. And with respect to his representation in</p> <p>17 February 2020 to the FDA in this public forum that</p> <p>18 they have "cracked the code" on heavy liquid</p> <p>19 separation for chrysotile asbestos, in your review</p> <p>20 of the December 2021 white paper from the</p> <p>21 interagency working group, did they adopt the</p> <p>22 heavy liquid separation chrysotile method</p> <p>23 discussed by Dr. Longo?</p> <p>24 DR. THOMPSON: Object to form.</p> <p>25 A. I do not know. I do not recall. Again,</p>

<p style="text-align: right;">Page 90</p> <p>1 you're pointing out steps in a process that led 2 from acceptance in the 1970s of an industry 3 proposed testing approach to a congressional 4 mandate in 2022 for FDA to finalize, by federal 5 regulation, a testing approach. I am shocked it 6 took that long to deal with something that 7 everyone understands causes cancer. But it did. 8 I am not quite understanding where 9 your questions are directed in terms of a 10 particular FDA meeting and interagency working 11 group. I will repeat, I have had no direct -- 12 I've had no contact of any sort with the officials 13 participating in this or personal contact with the 14 people testifying in this. 15 BY MR. EWALD: 16 Q. Okay. And I wasn't suggesting that you 17 had. 18 My question is: You've read -- and 19 you cite in your most recent report the 20 December 2021 interagency white paper, correct? 21 A. Yes. 22 Q. Okay. And my question is: In that 23 report where there are recommendations made, does 24 the interagency working group recommend the use of 25 heavy liquid separation for chrysotile asbestos,</p>	<p style="text-align: right;">Page 92</p> <p>1 A. Yes. 2 Q. And looking through these specific 3 opinions that are recommended by IWGACP, do you 4 see any reference to a adoption of a chrysotile 5 heavy liquid separation method? 6 A. Would you like to -- 7 DR. THOMPSON: Object to form. 8 A. Would you like to go through them one by 9 one as I read them? I have no other basis for 10 forming an opinion as to what's in the document 11 beyond using the document. 12 BY MR. EWALD: 13 Q. Sure. 14 A. Okay. So -- actually, would you scroll 15 up a little bit so I can see how they frame this 16 list -- 17 Q. (Complied.) Sure. 18 (Speaking simultaneously.) 19 DR. THOMPSON: And if you want to 20 go off the record and look at the entire 21 document, you're permitted to do that. 22 A. "opinions and related advice." Okay. 23 Now I see what they are trying to do. (Examined 24 exhibit.) Could there be something beyond 25 Number 5?</p>
<p style="text-align: right;">Page 91</p> <p>1 based on Dr. Longo's supposedly "crack the code" 2 method that he described in February 2020? 3 DR. THOMPSON: And object to form. 4 And if you're talking about the 5 interagency working group, we need to have 6 that document up. 7 MR. EWALD: We'll get there. 8 A. In answering your question, I do not 9 recall, but I imagine you will show me. 10 BY MR. EWALD: 11 Q. All right. So now I put the interagency 12 working group in the Box where it had previously 13 been marked as Exhibit 11. I'll also put it up on 14 the screen here. 15 Okay. So here we have the white 16 paper cited in your amended report and goes down 17 to, "Through its deliberations" -- we're on the 18 page, for the record, 5 -- "the IWGACP developed 19 the following scientific opinions and related 20 advice to help ensure reliable detection and 21 comprehensive reporting of asbestos and other 22 amphibole particles when testing cosmetic products 23 containing talc and talc intended for use in 24 cosmetics." 25 Did I read that correctly?</p>	<p style="text-align: right;">Page 93</p> <p>1 BY MR. EWALD: 2 Q. There is. 3 A. Thank you for showing it to me. 4 Q. I wasn't sure you were done. Just tell 5 me where to scroll. I'll scroll. 6 A. Okay. (Examined exhibit.) I do not see 7 any reference in this list of eight items to heavy 8 liquid separation. 9 Q. Okay. I do want to talk a little bit 10 about -- did you recommend -- you do recommend 11 here, am I correct, "Use both PLM and TEM methods 12 to identify/report, at minimum, the presence 13 asbestos, other amphibole minerals, and talc 14 particles exhibiting non-platy morphology," 15 correct? 16 A. Yes. 17 Q. And this is something that you talked 18 about in your amended report. If you go a little 19 bit up, it's talking about the J4-1 method, and 20 that's something that is discussed, correct? 21 A. The J4-1 method is discussed. 22 Q. All right. And this white paper talks 23 about how -- with a J4-1 method relies on 24 "screening techniques, [X-ray diffraction (XRD) or 25 infrared (IR) spectroscopy] and requires optical</p>

<p style="text-align: right;">Page 94</p> <p>1 microscopy [i.e. polarized light microscopy] only</p> <p>2 if the screening test is positive."</p> <p>3 That's what it reads, correct?</p> <p>4 A. (Examined exhibit.) Yes.</p> <p>5 Q. And it goes on to say that, "These two</p> <p>6 published protocols have long-recognized</p> <p>7 shortcomings and specificity and sensitivity to</p> <p>8 detect the presence of asbestos and similar</p> <p>9 mineral particles that may pose a health concern</p> <p>10 (see Appendix F)."</p> <p>11 And it goes on to say, "For example,</p> <p>12 recent testing in cosmetics by a private</p> <p>13 laboratory under contract with FDA using</p> <p>14 transmission electron microscopy (TEM) revealed</p> <p>15 the presence of asbestos in samples that had</p> <p>16 negative findings for the same products using PLM,</p> <p>17 highlighting the shortcomings of optical</p> <p>18 microscopy methods," correct?</p> <p>19 A. It says that.</p> <p>20 Q. And it goes on to say, "Thus, the</p> <p>21 Interagency Working Group on Asbestos in Consumer</p> <p>22 Products (IWGACP) advises that electron</p> <p>23 microscopy-based methods are preferred where the</p> <p>24 objective is to determine if asbestos is present,"</p> <p>25 correct?</p>	<p style="text-align: right;">Page 96</p> <p>1 paragraph that he's discussing this white</p> <p>2 paper. And I would appreciate you don't</p> <p>3 interrupt the witness mid answer.</p> <p>4 DR. THOMPSON: I apologize -- I</p> <p>5 apologize for interrupting the witness. I</p> <p>6 didn't realize I was doing it.</p> <p>7 BY MR. EWALD:</p> <p>8 Q. Doctor --</p> <p>9 DR. THOMPSON: You can go ahead and</p> <p>10 answer. My fault.</p> <p>11 A. What my expert impressions are -- my</p> <p>12 expert opinions are -- have to do with regulatory</p> <p>13 stasis. Has to do with a self-regulatory regime</p> <p>14 that was reliant on an industry process, an</p> <p>15 industry process that has been called into</p> <p>16 question in many ways.</p> <p>17 And then for whatever reasons,</p> <p>18 whether they be budgetary concerns, issues of</p> <p>19 institutional capacity at the time, or</p> <p>20 interventions by the regulated parties, there is</p> <p>21 essentially no progress in asbestos testing</p> <p>22 methods for talc during a long period when</p> <p>23 asbestos is known to be a carcinogen-including,</p> <p>24 with respect to ovarian cancer.</p> <p>25 And then breaking out from that</p>
<p style="text-align: right;">Page 95</p> <p>1 A. I'm sorry. The "determine is best," I'm</p> <p>2 not seeing it as a --</p> <p>3 (Speaking simultaneously.)</p> <p>4 Q. "determine if" --</p> <p>5 A. -- "is present." I'm sorry.</p> <p>6 Q. "asbestos." I was talking too fast.</p> <p>7 A. I'm sorry.</p> <p>8 Q. Yeah, that's not your fault.</p> <p>9 A. That's --</p> <p>10 Q. That's what it reads, right?</p> <p>11 A. That's -- yes. That's what it says.</p> <p>12 Q. All right. And -- and you talk about</p> <p>13 this in your amended report, right? That the J4-1</p> <p>14 method, the white paper states that it is</p> <p>15 inadequate and that it should use TEM in addition</p> <p>16 to PLM, correct?</p> <p>17 A. I don't believe I say anything that</p> <p>18 specific about testing methods in my report.</p> <p>19 Q. Okay.</p> <p>20 A. I do -- what I talk about --</p> <p>21 DR. THOMPSON: Did -- again, we're</p> <p>22 using his 2021 report. I just want to put</p> <p>23 that on the record.</p> <p>24 MR. EWALD: I'm talking about his</p> <p>25 amended 2023 report which is the same</p>	<p style="text-align: right;">Page 97</p> <p>1 recent stasis -- from that stasis in recent years,</p> <p>2 through a combination of things, which include the</p> <p>3 convening of the working group, the working group</p> <p>4 report, subsequent actions by other regulatory</p> <p>5 agencies, the cosmetics regulation Modernization</p> <p>6 Act, the congressional directive.</p> <p>7 And then we shall see what comes out</p> <p>8 of that directive, if and when -- I will say, when</p> <p>9 FDA actually publishes a proposed testing method.</p> <p>10 At which point, I would consider that regulation,</p> <p>11 though not incontestable -- and I am sure that</p> <p>12 your client as -- well as other parties -- will</p> <p>13 make plenty of public comments on whatever is</p> <p>14 proposed.</p> <p>15 But at that point, I think we can</p> <p>16 reengage this methodological question. I don't</p> <p>17 see what I can add to your -- your store of</p> <p>18 knowledge from this text that the -- you know, in</p> <p>19 the way it's being presented to me.</p> <p>20 BY MR. EWALD:</p> <p>21 Q. Well, and this is -- I'm not looking for</p> <p>22 you to add to my store of knowledge. I'm looking</p> <p>23 to have an understanding of what you understand</p> <p>24 and the basis for your expert opinions in this</p> <p>25 case.</p>

<p style="text-align: right;">Page 98</p> <p>1 And so you're citing to the white 2 paper, and I want to make sure that we're on the 3 same page, that what the white paper recommends is 4 that you don't just use PLM, you also use TEM, 5 correct?</p> <p>6 DR. THOMPSON: Object to form.</p> <p>7 A. That is what you have shown me. That is 8 a level of detail. I do know what a transmission 9 as opposed to a scanning electron microscope can 10 do. I know a little bit about, you know, geologic 11 crystal formation and plate structures for various 12 minerals -- not a lot -- might. I know much more 13 about the biomedical side of these things.</p> <p>14 But I'm here as an expert in 15 regulation, regulatory obligation, particularly 16 information in self-regulatory methods. We can 17 talk about this. I'm very happy to. I certainly 18 will renew the offer -- if there is something that 19 you think refutes my opinions regarding regulatory 20 stasis and emergence from regulatory stasis, I am 21 absolutely willing to look at it.</p> <p>22 BY MR. EWALD:</p> <p>23 Q. And we're getting there.</p> <p>24 So the -- you would agree with me 25 that the -- at least for the white paper, the</p>	<p style="text-align: right;">Page 100</p> <p>1 we're -- we marked as Exhibit 4. And this is the 2 paragraph that we were talking about. On 3 paragraph 123, that refers to the J4-1 method, and 4 the white paper -- or repealing noting -- 5 according to your paragraph of the "peculiarity of 6 retaining without considera- -- reconsideration 7 for nearly half a century a testing method clearly 8 at odds with current science."</p> <p>9 That's what you state, correct?</p> <p>10 A. Yes.</p> <p>11 Q. Okay. And you go on to state in 124, "At 12 no point has the FDA issued any regulation 13 dictating testing specifications for detecting 14 asbestos and talc and instead has relied on 15 industry substantiation of safety. Recognizing 16 the inadequacy of the situation given industry's 17 poor track record of incorporating established 18 science into testing talc-based cosmetic products 19 for potentially harmful components or contaminants 20 the Regulation Modernization Act requires FDA to 21 develop and issue regulations for asbestos 22 testing."</p> <p>23 That -- that's your opinion, and that 24 we've talked about earlier today, correct?</p> <p>25 A. Correct.</p>
<p style="text-align: right;">Page 99</p> <p>1 understanding -- the FDA's understanding of the 2 J4-1 method included XRD or infrared and PLM, 3 correct? That's what it states?</p> <p>4 DR. THOMPSON: Objection; form.</p> <p>5 A. I do not know the answer to that without 6 additional research. I will note that the 7 interagency working group does not say, "We 8 endorse the J4-1 method."</p> <p>9 BY MR. EWALD:</p> <p>10 Q. I didn't say that they did.</p> <p>11 I'm saying that what the white paper 12 that you cite in your report states, the testing 13 method used for the J4-1 method were XRD or IR and 14 PLM. That's what it states right here, right?</p> <p>15 DR. THOMPSON: Object to form.</p> <p>16 A. I would have to do additional review 17 specific to which testing methods come in which 18 report at which time.</p> <p>19 BY MR. EWALD:</p> <p>20 Q. Okay.</p> <p>21 A. If you'd like me to do that, I guess we 22 can set aside some time for doing it.</p> <p>23 Q. Not -- won't be necessary.</p> <p>24 I want to put back up your amended 25 report. Okay. Back to the amended report</p>	<p style="text-align: right;">Page 101</p> <p>1 Q. Okay. And then you conclude, on the 2 basis of the foregoing, that, "In sum, Johnson & 3 Johnson manipulated asbestos testing and 4 associated publicity so that 'none detectable' 5 would be interpreted as 'none,' distancing itself 6 from allegations of asbestos contamination but 7 never actually eliminating asbestos 8 contamination."</p> <p>9 That's your concluding sentence in 10 paragraph 125, correct?</p> <p>11 A. Correct.</p> <p>12 Q. All right. When you're preparing your 13 amended report and you're looking at the white 14 paper, did you conduct any research to understand 15 what testing methods Johnson & Johnson actually 16 used?</p> <p>17 DR. THOMPSON: Object to form.</p> <p>18 A. I conducted no additional review of those 19 matters, beyond what I might have done in 20 connection with the first report.</p> <p>21 BY MR. EWALD:</p> <p>22 Q. Right. And if we look at the first 23 report -- I'm sorry. If we look at the earlier 24 paragraph, which appears in the first report, you 25 have certain documents -- internal J&J documents</p>

<p style="text-align: right;">Page 102</p> <p>1 -- in the early '70s time frame, correct?</p> <p>2 A. Yes.</p> <p>3 Q. And those are all documents that are</p> <p>4 provided to you by plaintiffs' counsel, correct?</p> <p>5 A. Some may have been from publicly</p> <p>6 available sources, but the majority were likely</p> <p>7 from plaintiffs' counsel.</p> <p>8 Q. And that's fair.</p> <p>9 So here if we're seeing what -- I'm</p> <p>10 not sure if corporate attorneys -- I don't mean</p> <p>11 any disrespect. Do you know what a Bates number</p> <p>12 is?</p> <p>13 A. Only in passing, to be honest.</p> <p>14 Q. On these par- -- on these footnotes, you</p> <p>15 do have 33, the Hutt article, but which is a</p> <p>16 publicly available source, correct?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. But if we're talking about J&J</p> <p>19 Bates number documents in 30, 31, 32, those are</p> <p>20 the things that you would have received from</p> <p>21 plaintiffs' counsel, fair?</p> <p>22 A. I'll take your word for it.</p> <p>23 Q. Okay.</p> <p>24 DR. THOMPSON: Are we going to have</p> <p>25 something that's relevant to the amended</p>	<p style="text-align: right;">Page 104</p> <p>1 bottom, JNJMX68 and then 3591.</p> <p>2 (Exhibit 14 marked.)</p> <p>3 A. (Examined exhibit.)</p> <p>4 DR. THOMPSON: And I'm going to</p> <p>5 object to a 1978 document in this</p> <p>6 deposition --</p> <p>7 MR. EWALD: Okay.</p> <p>8 DR. THOMPSON: -- which is covered</p> <p>9 in his amended report and additional</p> <p>10 reliance.</p> <p>11 MR. EWALD: Okay. Objection noted.</p> <p>12 BY MR. EWALD:</p> <p>13 Q. Dr. Sage, have you seen this before?</p> <p>14 A. I don't recall.</p> <p>15 DR. THOMPSON: We'll see what</p> <p>16 that -- we'll see what the question is.</p> <p>17 A. I don't recall.</p> <p>18 BY MR. EWALD:</p> <p>19 Q. All right. Well, this is, you see, a --</p> <p>20 it has a Johnson & Johnson header -- letterhead,</p> <p>21 rather, dated February 23rd, 1978, and it's to</p> <p>22 R.N. Miller, president of Windsor Minerals.</p> <p>23 Do you know who Windsor Minerals are?</p> <p>24 A. I don't. But I see "Vermont," so let me</p> <p>25 assume it's somebody has to do with the mine.</p>
<p style="text-align: right;">Page 103</p> <p>1 report and reliance?</p> <p>2 MR. EWALD: Yes, we are. Yes.</p> <p>3 BY MR. EWALD:</p> <p>4 Q. So in connection with your amended report</p> <p>5 and looking at the white paper and talking</p> <p>6 about -- well, you -- you called it a "systematic</p> <p>7 thoughtful review," right?</p> <p>8 A. I'm sorry? Say again.</p> <p>9 Q. Earlier in the deposition, you called the</p> <p>10 white paper a "systematic thoughtful review" by</p> <p>11 the interagency working group, right?</p> <p>12 A. Using those terms in normal parlance,</p> <p>13 yes.</p> <p>14 Q. Sure. Okay. So -- I may have already</p> <p>15 asked this. I apologize. But I got distracted.</p> <p>16 The story that you give here, the</p> <p>17 chronology ends in 1976, right, with respect to</p> <p>18 the Johnson & Johnson and internal company</p> <p>19 documents and testing methods, correct?</p> <p>20 A. In the paragraph you showed me, it does,</p> <p>21 yes.</p> <p>22 Q. Okay. I just put a two-page document in</p> <p>23 Chat. And, Doctor, take as long as you want to</p> <p>24 review it. Is this something that you've seen</p> <p>25 before? There's a Bates number there at the</p>	<p style="text-align: right;">Page 105</p> <p>1 Q. And that assumption would be correct.</p> <p>2 And it says, "As you know, Windsor</p> <p>3 Minerals and the Baby Products Company have</p> <p>4 already authorized the documentation of a 'no</p> <p>5 detectable asbestos' requirement in the Windsor 66</p> <p>6 Talc Material Specification. In this regard, the</p> <p>7 testing requirement is solely for fibrous</p> <p>8 amphibole by the CTFA Method J4-1 and is intended</p> <p>9 to make the specification wholly consistent with</p> <p>10 the CTFA standard for cosmetic grade talc.</p> <p>11 "However, we need to recognize that</p> <p>12 Windsor Minerals and Johnson and Johnson have</p> <p>13 exercised more extensive controls and testing in</p> <p>14 the past than just meeting the J4-1 requirement.</p> <p>15 Furthermore, we intend continuing to surpass the</p> <p>16 industry standards -- testing as reflected by</p> <p>17 CTFA's J4-1. During the July 15th, 1977 meeting</p> <p>18 in your office, we had agreed to the need of</p> <p>19 documenting the entire audit protocol which has</p> <p>20 been your standard operating policy and procedure</p> <p>21 since August 1973 and will continue to be</p> <p>22 practised by Windsor Materials for Windsor 66</p> <p>23 Talc."</p> <p>24 Did I read that correctly?</p> <p>25 A. As best I can keep up with it, yes.</p>

<p style="text-align: right;">Page 106</p> <p>1 Q. Yeah.</p> <p>2 DR. THOMPSON: Are you marking this</p> <p>3 as an exhibit?</p> <p>4 MR. EWALD: Yes, I am. That's a</p> <p>5 good suggestion. We'll mark this as</p> <p>6 Exhibit 14.</p> <p>7 DR. THOMPSON: And I, as of yet,</p> <p>8 don't have the relevance of this document</p> <p>9 for his amended report.</p> <p>10 MR. EWALD: Okay. I will explain</p> <p>11 it after -- I think it's obvious, but</p> <p>12 we'll continue on.</p> <p>13 BY MR. EWALD:</p> <p>14 Q. Then it goes on to then state the testing</p> <p>15 methods. And do you see here test CTFA J4-1 for</p> <p>16 fibrous amphibole forms; and then serpentine</p> <p>17 forms, TM 7019; and asbestiform minerals, TM 7024?</p> <p>18 Do you see that there?</p> <p>19 A. Yes.</p> <p>20 DR. THOMPSON: Could you show the</p> <p>21 Bates number on that document?</p> <p>22 MR. EWALD: I did. Yeah, I read</p> <p>23 into the records there at the bottom.</p> <p>24 DR. THOMPSON: Okay. Yeah.</p> <p>25 This --</p>	<p style="text-align: right;">Page 108</p> <p>1 would like?</p> <p>2 BY MR. EWALD:</p> <p>3 Q. I would like you first to answer my</p> <p>4 question which is a straightforward "yes" or "no."</p> <p>5 Were you aware of any -- were you</p> <p>6 aware of anything about Johnson & Johnson's</p> <p>7 testing methods and whether or not they exceeded</p> <p>8 the industry J4-1 testing standard?</p> <p>9 A. I have been a- --</p> <p>10 DR. THOMPSON: Object to form.</p> <p>11 A. I have been aware, whether it was, I</p> <p>12 think, all for the first report, maybe, you know,</p> <p>13 referred to in passing in materials reviewed for</p> <p>14 the revised report. I have been aware of</p> <p>15 different moments in Johnson & Johnson's corporate</p> <p>16 history where it has been more or less attentive</p> <p>17 to the issue of asbestos in its product.</p> <p>18 BY MR. EWALD:</p> <p>19 Q. Okay. Are you aware of -- at any</p> <p>20 point -- well, are you aware of how often</p> <p>21 Johnson & Johnson conducted TEM testing of its</p> <p>22 talc with presence of asbestos?</p> <p>23 A. No.</p> <p>24 DR. THOMPSON: Objection.</p> <p>25 BY MR. EWALD:</p>
<p style="text-align: right;">Page 107</p> <p>1 MR. EWALD: JNJMX68_3592.</p> <p>2 BY MR. EWALD:</p> <p>3 Q. Going back up to this first paragraph</p> <p>4 where they're talking about surpassing industry</p> <p>5 testing as reflected in in J4-1, do you know</p> <p>6 anything about that?</p> <p>7 A. I do not know how to answer this</p> <p>8 question. If you want to ask me a question such</p> <p>9 as how do I interpret in light of my report this</p> <p>10 assertion and internal correspondence of Johnson &</p> <p>11 Johnson's desire to comply with a higher standard</p> <p>12 than J4-1, please ask me that question.</p> <p>13 I don't know how to respond to a</p> <p>14 question about this document otherwise.</p> <p>15 Q. Well --</p> <p>16 A. It's like -- to my knowledge, I'm seeing</p> <p>17 it for the first time. I may have seen it before.</p> <p>18 Q. Well, and, you know, my question to you</p> <p>19 is: As you sit here today, do you have any</p> <p>20 knowledge about Johnson & Johnson's testing</p> <p>21 methods and whether or not they did, in fact,</p> <p>22 exceed industry testing reflected in J4-1?</p> <p>23 DR. THOMPSON: Object to form.</p> <p>24 A. You've shown me a document that I'm happy</p> <p>25 to engage with on its face. Is that what you</p>	<p style="text-align: right;">Page 109</p> <p>1 Q. Okay. And do you see here on -- the</p> <p>2 "Material will be tested for conformance on audit</p> <p>3 basis, frequencies noted according to sample types</p> <p>4 described and tests required"?</p> <p>5 Ground ore. TM 7024 tests. Biweekly</p> <p>6 composite samples by Windsor.</p> <p>7 Do you see that?</p> <p>8 A. Yes.</p> <p>9 Q. Okay. And flash dried talc, test CTFA</p> <p>10 J4-1, TM 7019, weekly composite samples by J&J,</p> <p>11 correct?</p> <p>12 A. Yes.</p> <p>13 DR. THOMPSON: Objection. And</p> <p>14 objection to all the questions regarding</p> <p>15 this document. He's not seen the '78.</p> <p>16 MR. EWALD: Okay.</p> <p>17 THE COURT REPORTER: Margaret,</p> <p>18 you're getting very garbled, just so you</p> <p>19 know.</p> <p>20 DR. THOMPSON: Okay. I will try</p> <p>21 not to garble. I don't know --</p> <p>22 (Speaking simultaneously.)</p> <p>23 MR. EWALD: That's better.</p> <p>24 DR. THOMPSON: -- garbley.</p> <p>25 Do I need to repeat anything for</p>

<p style="text-align: right;">Page 110</p> <p>1 you?</p> <p>2 THE COURT REPORTER: Yeah. Go</p> <p>3 ahead and repeat your objection.</p> <p>4 DR. THOMPSON: The objection was to</p> <p>5 all the questions regarding this document</p> <p>6 that Dr. Sage testified that he had not</p> <p>7 seen before, and it's dated 1978.</p> <p>8 THE COURT REPORTER: Thank you.</p> <p>9 DR. THOMPSON: And having relevance</p> <p>10 to his amended report or additional</p> <p>11 opinions contained in that report.</p> <p>12 MR. EWALD: All right.</p> <p>13 BY MR. EWALD:</p> <p>14 Q. Back to the --</p> <p>15 (Speaking simultaneously.)</p> <p>16 MR. EWALD: I'm sorry. What?</p> <p>17 DR. THOMPSON: I was just asking</p> <p>18 the court reporter if that was any better.</p> <p>19 MR. EWALD: Oh.</p> <p>20 THE COURT REPORTER: Yes.</p> <p>21 MR. EWALD: Yes.</p> <p>22 DR. THOMPSON: Okay. Thank you.</p> <p>23 BY MR. EWALD:</p> <p>24 Q. And then just returning to your amended</p> <p>25 expert report, I want you to assume, for purposes</p>	<p style="text-align: right;">Page 112</p> <p>1 Q. Answer the question, please.</p> <p>2 DR. THOMPSON: I think --</p> <p>3 (Speaking simultaneously.)</p> <p>4 MR. GOLOMB: Well, except that --</p> <p>5 Wait. Wait. Wait. Wait. Wait. Wait.</p> <p>6 Except that this question was</p> <p>7 available to him in 2021 when he testified</p> <p>8 previously. It's not anything that's</p> <p>9 updated in the new report.</p> <p>10 We've given you a lot of leeway</p> <p>11 here today. So I'll explain the time</p> <p>12 frame that you're referring to. If you're</p> <p>13 referring to a time period before November</p> <p>14 of 2021 when this deposition was taken</p> <p>15 previously, then we're gonna object.</p> <p>16 MR. EWALD: Okay. And your</p> <p>17 objection's noted.</p> <p>18 BY MR. EWALD:</p> <p>19 Q. Answer the question.</p> <p>20 DR. THOMPSON: If you know -- have</p> <p>21 knowledge based on your report.</p> <p>22 A. I stand -- I stand by my statement in</p> <p>23 light of the totality of the information that I</p> <p>24 have been presented with and reviewed in the</p> <p>25 course of reviewing the original -- preparing the</p>
<p style="text-align: right;">Page 111</p> <p>1 of my question, that in addition to J4-1,</p> <p>2 Johnson & Johnson tested its talc for presence of</p> <p>3 asbestos using TEM.</p> <p>4 You with me so far?</p> <p>5 A. I will assume that it used TEM at some</p> <p>6 point. I don't have knowledge, unless you want me</p> <p>7 to review a lot more information about when it</p> <p>8 used transmission microscopy and when it didn't.</p> <p>9 Q. That's fair enough. That's why it's a</p> <p>10 hypothetical. I'm asking you to assume a</p> <p>11 hypothetical.</p> <p>12 Assuming that Johnson & Johnson used</p> <p>13 TEM to test its talc for the presence of asbestos</p> <p>14 in addition to the J4-1 method, is it your opinion</p> <p>15 that Johnson & Johnson manipulated asbestos</p> <p>16 testing in associated publicities, but "none</p> <p>17 detectable" would be interpreted as "none"?</p> <p>18 DR. THOMPSON: Object to form.</p> <p>19 MR. GOLOMB: Objection. Can I --</p> <p>20 what is the time frame you're limiting</p> <p>21 your question to?</p> <p>22 MR. EWALD: His paragraph is not</p> <p>23 limited to a time frame. So my question</p> <p>24 is unlimited time frame.</p> <p>25 BY MR. EWALD:</p>	<p style="text-align: right;">Page 113</p> <p>1 original on the amended reports.</p> <p>2 It is in my expert experience in</p> <p>3 regulatory matters, not unusual for corporations,</p> <p>4 to take different positions and different</p> <p>5 practices over time with respect to risks to the</p> <p>6 public.</p> <p>7 General Motors had one of the early</p> <p>8 patents on airbags and was a supporter of airbag</p> <p>9 technology for many years when other auto makers</p> <p>10 were resistant.</p> <p>11 I notice that J&J in the 1950s had a</p> <p>12 patent on corn starch for use in talcum powder --</p> <p>13 powder products and seemed to be very open to a</p> <p>14 reformulation at that time. Subsequently, it</p> <p>15 wasn't.</p> <p>16 In the 1970s, as we all know, public</p> <p>17 attention on asbestos was extreme in many forms,</p> <p>18 and corporations of many types appeared to have</p> <p>19 made efforts to reassure their consuming public</p> <p>20 regarding asbestos.</p> <p>21 Now, that does not mean that that was</p> <p>22 the position throughout Johnson & Johnson</p> <p>23 corporate history, and I've certainly reviewed</p> <p>24 plenty of information to the contrary.</p> <p>25 And, frankly, I was offended in</p>

<p style="text-align: right;">Page 114</p> <p>1 preparing the first report by the conclusory 2 nature by which Johnson & Johnson, on its website, 3 which constitutes part of its product labeling, 4 was reassuring its mothers and children about the 5 purity and asbestos-free nature of their talcum 6 powder products. 7 So I can assume that at some point in 8 Johnson & Johnson's corporate history, it 9 attempted to behave responsibly with respect to 10 both testing and the use of testing. But I have 11 seen nothing to indicate that that was a 12 consistent practice, and I stand by my opinion. 13 BY MR. EWALD: 14 Q. Well, so you are assuming that it behaved 15 responsibly at some point in time, but you 16 haven't -- you don't know how much. That's 17 because you have not asked for documentation from 18 plaintiffs' counsel as to how frequently Johnson & 19 Johnson tested its talc and in what manner, 20 correct? 21 DR. THOMPSON: Object to form. 22 A. As I've said before, anything you would 23 like to show me I will be happy to review. 24 BY MR. EWALD: 25 Q. Okay. I've shown you some stuff, and I</p>	<p style="text-align: right;">Page 116</p> <p>1 Q. Better? 2 DR. THOMPSON: Sorry, guys. 3 Richard walked out for a minute, and I -- 4 he had it unmuted, but I turned down the 5 volume. That should help. 6 MR. EWALD: All right. That sounds 7 better. Sorry about that. 8 DR. THOMPSON: Sorry. 9 MR. EWALD: No. 10 BY MR. EWALD: 11 Q. So the white paper, we went over it, and 12 I understand -- well, the testimony will speak for 13 itself. 14 I want you to assume that -- for 15 purposes of my question -- that the white paper 16 from December of 2021 is recommending that in 17 order to test for the presence of asbestos in 18 cosmetic talc, that companies use both TEM and 19 PLM. 20 Do you have that hypothetical in your 21 head? 22 DR. THOMPSON: Object to form. 23 A. To some extent, yes, but I'm not 24 following the purpose of the question. 25 BY MR. EWALD:</p>
<p style="text-align: right;">Page 115</p> <p>1 have limited time. 2 I want to know, based on what you 3 have reviewed for your deposition today and for 4 the expert opinions that you are offering, to a 5 reasonable degree of scientific certainty, am I 6 correct that you have not reviewed and not 7 received from plaintiffs' counsel documents that 8 indicate how often and in what manner Johnson & 9 Johnson tested its talc with the presence of 10 asbestos? 11 DR. THOMPSON: Object to form and 12 beyond the scope of his amended report. 13 A. I have not received documents for my 14 amended report. I received many documents from my 15 original report. The details of them I do not 16 recall. 17 BY MR. EWALD: 18 Q. Okay. We talked about the white paper 19 that you cite in your amended report the first 20 time, and if -- you know, if you assume, 21 hypothetically, if -- 22 A. One moment. Dealing with an unattended 23 computer and an echo. 24 Q. Oh, I'm sorry. 25 A. Try again.</p>	<p style="text-align: right;">Page 117</p> <p>1 Q. Well, that's coming. 2 So with that hypothetical, is it your 3 opinion that the interagency working group, by 4 recommending testing for the presence of asbestos 5 in cosmetic talc by using TEM and PLM, is 6 manipulating asbestos testing and associating 7 publicities that "none detectable" would be 8 interpreted as "none"? 9 DR. THOMPSON: Object to form as to 10 the assumption and as to the relevance to 11 the amended report. 12 A. You were quoting a paragraph in my 13 original report that was unaltered in the 14 amendment. 15 BY MR. EWALD: 16 Q. Yes. 17 A. That is explicitly and, by location, a 18 summary of material that preceded it, not limited 19 to a single paragraph, and I stand by it. 20 Q. But I didn't ask you about Johnson & 21 Johnson. 22 I said, if FDA is recommending the 23 use of TEM and PLM for testing the presence of 24 cosmetic talc -- presence of asbestos in cosmetic 25 talc, is it your opinion that the FDA is</p>

<p style="text-align: right;">Page 118</p> <p>1 manipulating asbestos testing?</p> <p>2 DR. THOMPSON: Same objection.</p> <p>3 A. That would be a peculiar inference, and I</p> <p>4 don't have a better answer to the question. I</p> <p>5 don't believe there is a question here as to the</p> <p>6 good faith of the post-2019 FDA.</p> <p>7 BY MR. EWALD:</p> <p>8 Q. Is there a question about the good faith</p> <p>9 of post- -- pre- -- 2019 FDA?</p> <p>10 A. You're asking me about a 2020 interagency</p> <p>11 working group.</p> <p>12 Q. I know. I'm asking you --</p> <p>13 A. I -- I have seen -- as I said, a long</p> <p>14 period of regulatory stasis poses questions to an</p> <p>15 expert on regulatory processes, regulation, and</p> <p>16 legislation. So yes, there are questions, as I</p> <p>17 said before. The more -- the inferences one draws</p> <p>18 are arranged from budgetary considerations to</p> <p>19 industry involvement to several other things.</p> <p>20 And I have certainly seen enough</p> <p>21 material with public and nonpublic in preparing</p> <p>22 the original report as well as the amendment that</p> <p>23 make me be inter- -- make me quite interested in</p> <p>24 the knowing as much as possible about that</p> <p>25 history.</p>	<p style="text-align: right;">Page 120</p> <p>1 (Exhibit 15 marked.)</p> <p>2 A. Date?</p> <p>3 BY MR. EWALD:</p> <p>4 Q. 2023 [sic-2022].</p> <p>5 A. Okay.</p> <p>6 Q. Doctor, is this something you've seen</p> <p>7 before?</p> <p>8 A. (Examined exhibit.) No.</p> <p>9 Q. Okay. All right.</p> <p>10 Now I want to go to the GAO report.</p> <p>11 (Short pause.) Give me just a moment.</p> <p>12 Okay. My .pdf -- Acrobat crashed</p> <p>13 earlier, so I had to recover some things.</p> <p>14 Okay. The GAO report, which we've</p> <p>15 marked as Exhibit 8 --</p> <p>16 MR. GOLOMB: What is the date of</p> <p>17 the report?</p> <p>18 MR. EWALD: The date of the report</p> <p>19 is December 2023. And --</p> <p>20 DR. THOMPSON: What?</p> <p>21 MR. EWALD: I'm sorry? What?</p> <p>22 DR. THOMPSON: Are we still talking</p> <p>23 about Sanchez?</p> <p>24 MR. EWALD: No.</p> <p>25 DR. THOMPSON: Okay. I don't see</p>
<p style="text-align: right;">Page 119</p> <p>1 I really struggle with your client's</p> <p>2 approach to being forthcoming about the risks it</p> <p>3 just created with its hazardous products.</p> <p>4 Q. All right. Whoops. I can't share my</p> <p>5 screen yet. You'll see all my secrets.</p> <p>6 A. No worries on that.</p> <p>7 Q. All right. I'm putting in the Chat --</p> <p>8 all right. Okay, I put in the Chat a scientific</p> <p>9 article -- although I didn't give you the -- the</p> <p>10 way, you know, the lead -- I basically just want</p> <p>11 to know whether you've seen this before. And if</p> <p>12 you haven't, maybe it'll be good reading for</p> <p>13 later --</p> <p>14 A. Was this Sanchez that -- in this one?</p> <p>15 Q. Yes.</p> <p>16 A. Okay.</p> <p>17 Q. Okay. First, we mark it. Let's go</p> <p>18 through the normal process.</p> <p>19 I'm marking as Exhibit 15 an article,</p> <p>20 "Environmental Research," from Matthew Sanchez,</p> <p>21 amongst others. "Characterization of elongate</p> <p>22 mineral particles including talc, amphiboles, and</p> <p>23 biopyriboles observed in mineral derived powders:</p> <p>24 Comparisons of analysis of the same talcum powders</p> <p>25 sampled by two laboratories."</p>	<p style="text-align: right;">Page 121</p> <p>1 anything else in yet.</p> <p>2 THE WITNESS: We had it as an</p> <p>3 exhibit already. We went back to the GAO</p> <p>4 report.</p> <p>5 DR. THOMPSON: Oh, I'm sorry.</p> <p>6 (Speaking simultaneously.)</p> <p>7 MR. EWALD: It's Exhibit -- yes,</p> <p>8 yes, so this is the GAO report.</p> <p>9 DR. THOMPSON: Oh, the GAO. Okay.</p> <p>10 I'm sorry.</p> <p>11 MR. EWALD: No worries.</p> <p>12 BY MR. EWALD:</p> <p>13 Q. If we go --</p> <p>14 MS. PARFITT: Is it Exhibit 8?</p> <p>15 MR. EWALD: Yes.</p> <p>16 BY MR. EWALD:</p> <p>17 Q. If you will go to page 19 -- actually,</p> <p>18 .pdf page 23, but the actual page on the paper</p> <p>19 version is 19. Let me blow it up here a little</p> <p>20 bit.</p> <p>21 In this discussion, it talks about,</p> <p>22 you see, Doctor, "In addition, some studies</p> <p>23 suggest associations between asbestos</p> <p>24 contamination of talc and negative health</p> <p>25 effects."</p>

<p style="text-align: right;">Page 122</p> <p>1 You see where I'm talking about?</p> <p>2 A. Yes.</p> <p>3 Q. And it says, "Specifically, one study we</p> <p>4 reviewed suggested the talc used in cosmetics -</p> <p>5 also known as talcum powder - may sometimes be</p> <p>6 contaminated with asbestos," and it has a footnote</p> <p>7 cite to -- 47.</p> <p>8 Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. If we go down, is -- the cite is to</p> <p>11 "Jacqueline Moline, Keshia Patel, and Arthur L.</p> <p>12 Frank, 'Exposure to cosmetic talc and</p> <p>13 mesothelioma,' Journal of Occupational Medicine</p> <p>14 and Toxicology,'" in 2023.</p> <p>15 Do you see that?</p> <p>16 A. Yes.</p> <p>17 Q. Have you -- are you familiar with that</p> <p>18 article from Dr. Moline?</p> <p>19 A. No.</p> <p>20 Q. Are you familiar with an article that she</p> <p>21 published on cosmetic talc and mesothelioma in</p> <p>22 2020?</p> <p>23 A. If it had been -- I read several</p> <p>24 scientific articles on various aspects of health</p> <p>25 risks from talcum powder, asbestos, and other</p>	<p style="text-align: right;">Page 124</p> <p>1 to this study, including potential biases inherent</p> <p>2 inherent in studies of cases for which data were</p> <p>3 collected as part of litigation. Patients'</p> <p>4 exposure history was collected in sworn testimony</p> <p>5 from patients and patients' families as part of</p> <p>6 the litigation's and medical-legal review."</p> <p>7 And goes on and -- I'm sorry. I</p> <p>8 guess it should be one more sentence from the</p> <p>9 text. "This case study in patients with a</p> <p>10 mesothelioma diagnosis found that in 122 of 166</p> <p>11 cases, the only known exposure to asbestos was</p> <p>12 from cosmetic talc."</p> <p>13 That's what it reads in the text,</p> <p>14 right?</p> <p>15 A. It does.</p> <p>16 Q. All right. And do -- in this section of</p> <p>17 the GAO report that you put on your Materials</p> <p>18 Considered list, does -- does it list any article,</p> <p>19 other than Moline in 2023, in talking about</p> <p>20 potential studies suggesting associations between</p> <p>21 asbestos contamination and talc and negative</p> <p>22 health effects?</p> <p>23 A. I would have to reread the report to see.</p> <p>24 But in my expert opinion, it does not matter</p> <p>25 because my expert review of the GAO report showed</p>
<p style="text-align: right;">Page 123</p> <p>1 things in connection with my first report. I, in</p> <p>2 fact, requested them of counsel and went</p> <p>3 through -- I don't know -- 10 or 15 peer-reviewed</p> <p>4 articles at the time. I would have to look at a</p> <p>5 list to know if that was among them.</p> <p>6 Q. And I'm not trying to tread that ground.</p> <p>7 But would -- if you had reviewed it,</p> <p>8 would it be on your Materials Considered list from</p> <p>9 your first report?</p> <p>10 A. It should have been. Those were all my</p> <p>11 articles that were provided on my request by</p> <p>12 counsel.</p> <p>13 Q. Okay. And the GAO report goes on a</p> <p>14 little bit further in that last paragraph. Starts</p> <p>15 there in the middle, "However, one study reviewed</p> <p>16 suggested that the inhalation of talc contaminated</p> <p>17 with asbestos may be associated with mesothelioma,</p> <p>18 a type of cancer that develops on the thin layer</p> <p>19 of tissue that lines the lungs, chest wall, and</p> <p>20 many internal organs," and it cites to</p> <p>21 Footnote 48, right?</p> <p>22 A. Yes.</p> <p>23 Q. Okay. And then Footnote 48 is "Moline,</p> <p>24 Patel, and Frank." The same article. Goes on to</p> <p>25 state that, "The authors noted several limitations</p>	<p style="text-align: right;">Page 125</p> <p>1 that the GAO report's strength was the expertise</p> <p>2 brought to bear on compliance with government</p> <p>3 processes. Its handling of the context and</p> <p>4 science is abbreviated and not particularly</p> <p>5 compelling.</p> <p>6 Q. Correct. At least from what we've looked</p> <p>7 at in Footnotes 47, 48, 49, the only scientific</p> <p>8 article that's included there is the Moline</p> <p>9 article, correct?</p> <p>10 A. I will take your word for it. What you</p> <p>11 read me, that's the only scientific article. But</p> <p>12 as I said before, I don't think anyone would rely</p> <p>13 on this report for the analysis of the underlying</p> <p>14 science. The utility of this report, for my</p> <p>15 amendment and the revision, was the FDA's ongoing</p> <p>16 efforts to comply with the Modernization Act, and</p> <p>17 it's really the second half of the report that</p> <p>18 goes to that. The first part of the report is</p> <p>19 something I did read, but I did not rely on. It</p> <p>20 is not that type of expertise.</p> <p>21 Q. After -- at any point in time after your</p> <p>22 deposition in September of 2021, did you</p> <p>23 communicate with Dr. Longo?</p> <p>24 A. No.</p> <p>25 Q. At any point in time after your</p>


<p style="text-align: right;">Page 126</p> <p>1 deposition in September of 2021 -- 2021, did you</p> <p>2 communicate in any way with Dr. Mark Rigler?</p> <p>3 A. No. I'm not sure I remember who that is.</p> <p>4 Is that the other author on the report?</p> <p>5 Q. He is the author on the Longo report that</p> <p>6 you had earlier, yes.</p> <p>7 In preparing for today's deposition,</p> <p>8 did you -- well, let me rephrase the question.</p> <p>9 In preparing your opinions contained</p> <p>10 in your amended expert report, did you communicate</p> <p>11 with any individuals, apart from plaintiffs'</p> <p>12 counsel, about those opinions?</p> <p>13 A. No.</p> <p>14 Q. Approximately how much time did you spend</p> <p>15 preparing for today's deposition?</p> <p>16 A. Preparing for today's deposition? And</p> <p>17 I'm not hesitating to answer. I'm trying to think</p> <p>18 about it in my mind.</p> <p>19 Q. That's fine.</p> <p>20 A. I mean, that required looking at what I</p> <p>21 had done before, reading my report, you know,</p> <p>22 several times to -- and then rereading the</p> <p>23 Modernization Act and the cited materials from CRS</p> <p>24 and making sure I had it all in my head. So</p> <p>25 probably the answer to that is between 10 and 15</p>	<p style="text-align: right;">Page 128</p> <p>1 DR. THOMPSON: -- and come back? I</p> <p>2 don't expect to have much, but --</p> <p>3 MR. EWALD: Sure.</p> <p>4 DR. THOMPSON: -- I want to</p> <p>5 converse with co-counsel. Thanks.</p> <p>6 MR. EWALD: Sure.</p> <p>7 DR. THOMPSON: I got it.</p> <p>8 THE COURT REPORTER: All right.</p> <p>9 We're off the record at 12:22.</p> <p>10 (A recess was taken from 12:22 p.m. to</p> <p>11 12:25 p.m.)</p> <p>12 THE COURT REPORTER: Back on the</p> <p>13 record at 12:25 p.m.</p> <p>14 EXAMINATION</p> <p>15 BY DR. THOMPSON:</p> <p>16 Q. Dr. Sage, was there anything that you</p> <p>17 heard in this morning's deposition from counsel,</p> <p>18 that changes the opinions that you have in your</p> <p>19 previous testimony?</p> <p>20 A. No.</p> <p>21 Q. And you stand by the opinions that you've</p> <p>22 provided in your initial expert report, your</p> <p>23 amended expert report, and these two depositions?</p> <p>24 A. Yes.</p> <p>25 DR. THOMPSON: No further</p>
<p style="text-align: right;">Page 127</p> <p>1 hours.</p> <p>2 Q. And did you meet with counsel in</p> <p>3 preparation for today's deposition?</p> <p>4 A. Yes.</p> <p>5 Q. And I don't want to know anything about</p> <p>6 the content of those communications. I just want</p> <p>7 to know approximately how long those meetings</p> <p>8 were.</p> <p>9 A. We probably had an hour to an hour and a</p> <p>10 half of calls and two hours of face-to-face.</p> <p>11 Q. Okay. And who participated -- which</p> <p>12 counsel participated in those preparation</p> <p>13 sections?</p> <p>14 A. Dr. Thompson, Mr. Golomb. And that's</p> <p>15 really it. Ms. O'Dell very, very briefly. But it</p> <p>16 wasn't really a part of the preparation.</p> <p>17 MR. EWALD: Doctor, subject to any</p> <p>18 questions that your counsel -- or</p> <p>19 plaintiffs' counsel may have, I don't have</p> <p>20 any further questions at this time. Thank</p> <p>21 you for your time.</p> <p>22 THE WITNESS: Thank you so much.</p> <p>23 DR. THOMPSON: Could we just take a</p> <p>24 five-minute break --</p> <p>25 MR. EWALD: Sure.</p>	<p style="text-align: right;">Page 129</p> <p>1 questions.</p> <p>2 MR. EWALD: I have nothing further.</p> <p>3 MR. GOLOMB: No further questions.</p> <p>4</p> <p>5 (Following discussion had for</p> <p>6 administrative purposes.)</p> <p>7</p> <p>8 THE COURT REPORTER: I have a</p> <p>9 couple admin questions for y'all.</p> <p>10 Mr. Ewald, would you like a rough</p> <p>11 draft with your transcript?</p> <p>12 MR. EWALD: Yes, I would. And I</p> <p>13 believe we can follow the standing order.</p> <p>14 THE COURT REPORTER: Yes, sir, I</p> <p>15 would, but the entire standing order is</p> <p>16 struck-through.</p> <p>17 MR. EWALD: Well, you can go with</p> <p>18 it not being struck-through, and I would</p> <p>19 like the standing order.</p> <p>20 THE COURT REPORTER: Yes, sir.</p> <p>21 That would be a rough draft and regular</p> <p>22 delivery of the final transcript.</p> <p>23 MR. EWALD: Yes, ma'am. Correct.</p> <p>24 THE COURT REPORTER: Dr. Thompson,</p> <p>25 I have your standing order down for a</p>

<p style="text-align: right;">Page 130</p> <p>1 rough draft and regular delivery.</p> <p>2 DR. THOMPSON: Yes, ma'am. That is</p> <p>3 correct. Thank you.</p> <p>4 THE COURT REPORTER: And may I send</p> <p>5 you signature for the witness?</p> <p>6 DR. THOMPSON: Yes, you can. And</p> <p>7 I'll take care of it with the witness.</p> <p>8 THE COURT REPORTER: Yes, ma'am.</p> <p>9 Mr. Golomb, would you like a copy</p> <p>10 of the transcript?</p> <p>11 MR. GOLOMB: No thank you. I don't</p> <p>12 need a copy.</p> <p>13 THE COURT REPORTER: Yes, sir.</p> <p>14 Thank you.</p> <p>15 With that, that concludes our</p> <p>16 deposition today.</p> <p>17</p> <p>18 (Remote deposition concluded at</p> <p>19 12:27 p.m., April 1, 2024.)</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p style="text-align: right;">Page 132</p> <p>1 I, WILLIAM SAGE, M.D., J.D., have read the</p> <p>2 foregoing deposition and hereby affix my signature</p> <p>3 that same is true and correct, except as noted</p> <p>4 above.</p> <p>5 _____</p> <p>6 WILLIAM SAGE, M.D., J.D.</p> <p>7</p> <p>8 THE STATE OF _____)</p> <p>9</p> <p>10 COUNTY OF _____)</p> <p>11 Before me, _____, on</p> <p>12 this day personally appeared WILLIAM SAGE, M.D.,</p> <p>13 J.D., known to me (or proved to me under oath or</p> <p>14 through _____) (description</p> <p>15 of identity card or other document) to be the</p> <p>16 person whose name is subscribed to the foregoing</p> <p>17 instrument and acknowledged to me that they</p> <p>18 executed the same for the purposes and</p> <p>19 consideration therein expressed.</p> <p>20 Given under my hand and seal of office this</p> <p>21 _____ day of _____, 2024.</p> <p>22</p> <p>23 _____</p> <p>24 NOTARY PUBLIC IN AND FOR</p> <p>25 THE STATE OF _____</p>
<p style="text-align: right;">Page 131</p> <p>1 CHANGES AND SIGNATURE</p> <p>2 WITNESS NAME: WILLIAM SAGE, M.D.</p> <p>3 DATE: APRIL 1, 2024</p> <p>4 PAGE/LINE CHANGE REASON</p> <p>5 _____</p> <p>6 _____</p> <p>7 _____</p> <p>8 _____</p> <p>9 _____</p> <p>10 _____</p> <p>11 _____</p> <p>12 _____</p> <p>13 _____</p> <p>14 _____</p> <p>15 _____</p> <p>16 _____</p> <p>17 _____</p> <p>18 _____</p> <p>19 _____</p> <p>20 _____</p> <p>21 _____</p> <p>22 _____</p> <p>23 _____</p> <p>24 _____</p> <p>25 _____</p>	<p style="text-align: right;">Page 133</p> <p>1 IN THE UNITED STATES DISTRICT COURT</p> <p>2 FOR THE DISTRICT OF NEW JERSEY</p> <p>3</p> <p>4 IN RE JOHNSON & JOHNSON §</p> <p>5 TALCUM POWDER PRODUCTS § MDL NO.:</p> <p>6 MARKETING, SALES §</p> <p>7 PRACTICES, AND PRODUCTS § 16-2738(MAS)(RLS)</p> <p>8 LIABILITY LITIGATION §</p> <p>9</p> <p>10 *****</p> <p>11 REMOTE VIDEOCONFERENCED DEPOSITION OF</p> <p>12 WILLIAM SAGE, M.D.</p> <p>13 APRIL 1, 2024</p> <p>14 *****</p> <p>15</p> <p>16 CERTIFIED STENOGRAPHIC</p> <p>17 COURT REPORTER'S CERTIFICATE</p> <p>18</p> <p>19 I, Karen L. D. Schoeve, RDR, CRR, RSA,</p> <p>20 residing in the State of Texas, do hereby certify</p> <p>21 that the foregoing proceedings were reported</p> <p>22 remotely by me and that the foregoing transcript</p> <p>23 constitutes a full, true, and correct transcription</p> <p>24 of my stenographic notes, to the best of my ability</p> <p>25 and hereby certify to the following:</p> <p>By agreement of all attending attorneys, the</p> <p>witness, WILLIAM SAGE, M.D., was remotely duly</p> <p>sworn by the officer and that the transcript of the</p>

Page 134

1 oral deposition is a true record of the testimony
2 given by the witness;
3 That the original deposition was delivered to
4 John Ewald, custodial attorney;
5 That a copy of this certificate was served on
6 all parties and/or the witness shown herein on
7 _____.
8 I further certify that the signature of the
9 witness was requested by the witness or a party
10 before the completion of the deposition and the
11 signature is to be returned within 30 days from
12 date of receipt of the transcript.
13 If returned, the attached Changes and
14 Signature Page contains any changes and the reasons
15 therefor.
16 That pursuant to information given to the
17 deposition officer at the time said testimony was
18 taken, the following includes counsel for all
19 parties of record:
20
21 FOR THE MDL PLAINTIFFS:
22 MARGARET M. THOMPSON, ESQUIRE
23 BEASLEY ALLEN, P.C.
24
25 FOR THE PLAINTIFF STEERING COMMITTEE:
MICHELLE A. PARFITT, ESQUIRE
ASHCRAFT & GEREL

Page 135

1 FOR PLAINTIFF NEW JERSEY STATE COURT:
2 RICHARD GOLOMB, ESQUIRE
3 GOLOMB LEGAL
4
5 FOR DEFENDANT JOHNSON & JOHNSON:
6 JOHN EWALD, ESQUIRE
7 KING & SPALDING LLP
8
9 I further certify that I am neither counsel
10 for, related to, nor employed by any of the parties
11 in the action in which this proceeding was taken,
12 and further that I am not financially or otherwise
13 interested in the outcome of the action.
14
15 Subscribed and sworn to on this the 11th day
16 of April, 2024.
17
18
19 
Karen L.D. Schoeve, RDR, CRR, RSA
20 NCRA Exp. Date: 09-30-24
21 Litigation Services
22 Firm Registration No. 726
23 3960 Howard Hughes Parkway, Suite 700
24 Las Vegas, Nevada 89169
25 T: 877.370.3777
F: 917.591.5672
Job No. 6485334

35 (Pages 134 - 135)

[& - 2021]

Page 1

&	1	12:25 128:11,13	1976 103:17
& 1:2 3:10,18 3:19 6:22 20:18 23:8 26:14,22 37:18 40:10,21 40:24 41:5,19 41:25 42:2,7 43:15,20 48:22 49:4,8,9,18 50:2,11,25 51:10 58:18 65:13 66:7,14 70:10 71:16 72:7 73:12 101:2,15 103:18 104:20 107:10,20 108:6,15,21 111:2,12,15 113:22 114:2,8 114:18 115:8 117:20 133:2 134:25 135:4,5	1 1:10 2:5 5:3,7 5:9 9:8,11 80:10 130:19 131:3 133:10 10 6:9 36:17,20 123:3 126:25 10/01/21 5:7 10036 3:20 104 6:22 109 40:24 10:29 53:8,9 10:36 53:10,12 11 6:12 20:13 45:5,11 91:13 11/15/23 5:11 6:10 11/17/23 6:18 1185 3:20 11:21 86:10,11 11:26 86:12,14 11th 135:14 12 6:15 53:14 53:18,25 56:18 58:9 60:12	12:27 2:6 130:19 13 6:19 84:16 84:17 86:22 130 3:16 131 4:11 133 4:14 14 6:22 104:2 106:6 15 5:6 7:1 119:19 120:1 123:3 126:25 15th 16:24 17:1 18:1 19:7 36:19 54:15 105:17 16 5:8 16-2738 1:4 133:4 166 124:10 16th 3:16 17 7:3 176 89:2 17th 53:25 54:12,16 18th 3:16 19 5:10 121:17 121:19 19103 3:16 1950s 113:11 1970's 77:20 1970s 77:17 82:23 90:2 113:16 1973 81:13,21 105:21	1976 103:17 1977 105:17 1978 104:5,21 110:7 1l 14:13 1st 15:22 17:1 17:11 18:1
0			2
000003591 6:23 01/15/24 5:9 02/04/20 6:20 02/23/1978 6:23 03/27/24 5:15 5:18 03/31/24 5:22 09-30-24 135:20	120 7:1 122 124:10 123 45:22,25 100:3 124 100:11 125 101:10 12597 135:18 128 4:8 12:22 128:9,10		2 5:6 15:21,23 19:15 75:5 20 6:18 45:22 72:12 2000s 58:20 2019 55:6,22 64:7 66:20 67:3 118:6,9 2020 63:18 83:19 84:7,19 85:11 86:18 87:21 88:12 89:17 91:2 118:10 122:22 2021 12:17 14:6 14:8 15:22 16:4 16:8 17:9 25:15 26:16 27:8 30:21,23 45:3 45:10 46:6 47:17 66:22 67:21 80:11 86:21 89:20 90:20 95:22 112:7,14 116:16 125:22 126:1,1

[2022 - a&m]

Page 2

2022 6:8 25:23 25:24 26:10 34:25 90:4 120:4 2023 17:2,11 19:7 24:19 25:21 28:16 32:13 36:19 53:25 54:12 55:22 56:3 58:1 61:12,13,19 65:24 68:12 78:4,15 79:8 95:25 120:4,19 122:14 124:19 2024 1:10 2:5 16:25 31:13,19 31:25 55:4,21 130:19 131:3 132:20 133:10 135:15 212.556.2100 3:21 212.790.5341 3:21 215.278.4449 3:17 218 3:6 23 33:21 121:18 23rd 104:21 24 5:15,19,22 25 6:8 26 5:11,13,17 5:20 27 55:21	27th 16:4,8 31:13,19 55:4 28 5:5 29403 3:11	48 123:21,23 125:7 49 125:7 4th 83:18 84:7 84:19 85:11 86:18 87:21 88:12	74 16:9 77 6:4 78 109:15
	3		8
	3 4:3 5:8 16:19 16:21 87:7		8 4:7 6:1 32:14 32:15 35:15 120:15 121:14
	30 81:17 102:19 134:11	5	800 3:7 16:9
	30th 16:4,8	5 5:13 9:20 31:11,14 55:3 91:18 92:25	83 6:11
	31 5:13,16 6:14 102:19	53 6:15	84 6:19
	31st 31:25	59,200 16:10	843.699.8280 3:12
	32 5:20 6:1 39:16 102:19	6	850.435.7000 3:12
	33 39:20 102:15	6 5:16 31:17,20 55:20 81:17	877.370.3777 135:22
	34th 3:20	6485334 1:25 135:24	888.212.9702 3:7
212.556.2100 3:21 212.790.5341 3:21 215.278.4449 3:17 218 3:6 23 33:21 121:18 23rd 104:21 24 5:15,19,22 25 6:8 26 5:11,13,17 5:20 27 55:21	35 6:5	66 105:5,22	89169 135:22
	3591 104:1	68 73:4,18 74:10,23	898.2034 3:7
	3592 6:23 107:1	7	9
	36 6:9	7 5:20 11:13 32:1,5 33:18 83:14	9 5:3 6:5 35:2 35:17,21
	36104 3:6	700 135:21	90 73:5
	382 6:21	701 3:11	900 15:17
	3960 135:21	7019 106:17 109:10	917.591.5672 135:23
	3rd 53:21	7024 106:17 109:5	93 74:9,10,23
	4	70s 102:1	99 5:12
	4 5:10 19:6,8 40:3 100:1	726 135:21	9:25 2:6
212.556.2100 3:21 212.790.5341 3:21 215.278.4449 3:17 218 3:6 23 33:21 121:18 23rd 104:21 24 5:15,19,22 25 6:8 26 5:11,13,17 5:20 27 55:21	40 74:17		a
	411 3:11		a&m 13:9,11 13:21 14:4,12 15:3,10 54:22
	43 74:17		
	45 6:12		
	46 16:16		
	47 122:7 125:7		

[a.m. - amendment]

Page 3

a.m. 2:6 53:9 53:10 86:11,12 abbreviated 125:4 ability 133:21 able 15:6 26:11 34:17 56:1 86:16 above 2:5 41:1 73:24 132:4 absent 28:11 54:19 65:16 absolutely 12:18 40:8 98:21 academic 10:15 13:11,14 17:15 17:23 22:8 23:6 29:20 30:14 64:25 65:19 76:17 acceptance 90:2 accepted 11:23 accepting 59:17 60:11 access 13:14 accomplished 42:10 accountability 6:2 25:25 32:10 34:1 accounting 34:2 accurate 36:15	accurately 74:15 acknowledged 132:16 acrobat 120:12 act 6:8 25:9 26:4,6,9 27:23 27:24 28:15 29:16 34:25 97:6 100:20 125:16 126:23 action 135:10 135:12 actions 97:4 activities 37:21 37:22,23 actual 121:18 actually 24:21 65:7 70:3 73:2 85:8 92:14 97:9 101:7,15 121:17 add 97:17,22 addition 95:15 111:1,14 121:22 additional 42:21,22 47:25 99:6,16 101:18 104:9 110:10 address 20:14 admin 129:9 administration 83:16 administrative 28:18 129:6	admitted 20:9 adobe 88:24 adopt 89:21 adopted 51:13 adoption 92:4 adulteration 58:22 71:23 73:15 advanced 46:18 adverse 71:6 advice 91:20 92:22 advises 94:22 affect 74:24 affix 132:2 agencies 97:5 agency 49:16 ago 28:14 56:6 56:10 78:7,19 agree 52:10 54:18,19 67:23 68:4 81:7 98:24 agreed 105:18 agreement 2:4 81:6 133:23 ahead 9:7 19:5 21:9 27:16 31:7 32:13 61:9 62:6 62:19,21,23 85:19 88:5 96:9 110:3 airbag 113:8 airbags 113:8 alabama 3:6 allegations 101:6	allen 3:5 8:7 134:22 allocations 10:21 allow 38:6 ama's 11:20 ambiguity 71:5 amended 5:11 5:13,14,17,17 5:20,21 16:25 18:4 19:6,14 21:10 22:23 23:20,23,25 24:20,24 25:4 27:3 29:5 30:3 31:10,11,18,23 32:5 34:22 36:25 37:25 38:14,14 40:2 43:13 44:10,15 45:2,19 48:1 54:9,13,14 55:4 55:19 78:3 83:14 84:2 91:16 93:18 95:13,25 99:24 99:25 101:13 102:25 103:4 104:9 106:9 110:10,24 113:1 115:12 115:14,19 117:11 126:10 128:23 amendment 117:14 118:22
--	--	---	--

[amendment - asking]

Page 4

125:15 americas 3:20 amphibole 62:13 64:9 74:19 77:22 89:11 91:22 93:13 105:8 106:16 amphiboles 7:2 119:22 analyses 76:12 analysis 6:16 53:22 74:8,13 75:11,12 77:19 119:24 125:13 analyzing 75:7 answer 20:10 21:12 22:1 27:14 29:23 36:2 38:7 39:13 39:14 43:18 58:5 62:7 69:24 71:3 76:5 78:9 79:25 80:1,3,18 80:19,21 81:19 83:3 96:3,10 99:5 107:7 108:3 112:1,19 118:4 126:17 126:25 answered 60:15 80:25 answering 91:8 anticipating 65:8	apart 27:1 126:11 apologies 78:17 apologize 52:5 96:4,5 103:15 app 26:8 appear 9:17 appearances 4:3 appeared 3:2 113:18 132:11 appears 13:4 101:24 appendix 94:10 applicable 21:14 applies 52:11 apply 34:10 60:12 appointment 13:11 appreciate 69:12 96:2 approach 49:10 65:18 90:3,5 119:2 appropriate 80:20 appropriations 26:8 approval 14:21 approvals 15:11 approximately 23:15 37:9 55:1 56:10 126:14	127:7 april 1:10 2:5 130:19 131:3 133:10 135:15 area 23:4,5 27:7 areas 36:1 46:17 arranged 118:18 art 40:11 arthur 122:11 article 7:1 35:21 36:4 65:1 102:15 119:9 119:19 122:18 122:20 123:24 124:18 125:8,9 125:11 article's 11:19 articles 11:13 122:24 123:4 123:11 asbestiform 65:12 73:7 106:17 asbestos 6:13 23:1 28:1,10 29:2 45:7,9 46:7 47:22 49:18 50:18,24 51:12 58:13 64:7,9,10,14 65:11 66:10,25 71:16,24 72:14 72:17,24 73:7	77:22 81:21 83:17 87:11 89:11,12,19 90:25 91:21 93:13 94:8,15 94:21,24 95:6 96:21,23 100:14,21 101:3,6,7 105:5 108:17,22 111:3,13,15 113:17,20 114:5 115:10 116:17 117:4,6 117:24 118:1 121:23 122:6 122:25 123:17 124:11,21 ashcraft 3:10 134:25 ashcraftlaw.c... 3:13 aside 43:24 99:22 asked 14:21 17:19 18:10 19:11 20:14,21 22:1 23:3,11 24:7 29:7 54:25 60:15 79:12 80:25 103:15 114:17 asking 22:10,19 39:24 40:6 43:21 61:22 63:14 67:9,11
--	---	---	--

[asking - better]

Page 5

68:18,22 79:5 110:17 111:10 118:10,12 aspect 22:19 aspects 14:17 122:24 assay 60:19 assertion 107:10 assertions 50:17 assessing 41:22 assessment 60:5 74:12 77:4 assessor's 34:8 assist 27:1 associated 22:8 22:15 29:13 46:15 49:15 101:4 111:16 123:17 associating 117:6 associations 121:23 124:20 assume 39:17 104:25 110:25 111:5,10 114:7 115:20 116:14 assuming 111:12 114:14 assumption 105:1 117:10 attach 85:15 attached 2:10 28:15 134:13	attaching 24:10 attempt 28:11 attempted 114:9 attending 133:23 attention 29:19 87:7 113:17 attentive 29:15 108:16 attorney 134:4 attorneys 8:3 102:10 133:23 audio 2:15 18:8 37:5 audit 105:19 109:2 august 105:21 author 10:8 25:8 126:4,5 authorized 105:4 authors 123:25 auto 113:9 available 22:13 28:12 63:9,17 68:11 79:11 102:6,16 112:7 avenue 3:20 aware 36:5 44:6 45:13 61:1 61:22 63:22 108:5,6,11,14 108:19,20	b b 5:14,18,21 20:12 31:11,18 31:23 55:4 81:17 baby 105:3 back 11:6 12:11 12:16 19:24 23:17 24:18 25:1 34:18,21 38:13 47:7 52:20,24 53:12 54:22 55:3 64:24 81:14 83:12 86:13,22 99:24,25 107:3 110:14 121:3 128:1,12 background 76:8 bad 39:7 ballpark 74:5 bankruptcy 17:14 barely 13:1 30:7 barrett 87:8 89:3 based 52:8 77:19 91:1 94:23 100:18 112:21 115:2 basic 25:12 basically 22:1 33:16 119:10	basics 25:2 47:12 basis 59:9 71:18 92:9 97:24 101:2 109:3 bates 6:23 85:24 86:2 102:11,19 103:25 106:21 bay 3:11 bear 60:22 73:9 125:2 bears 83:10 beasley 3:5 8:7 134:22 begins 40:23 behave 114:9 behaved 114:14 belief 42:1 believe 18:13 20:13 24:15 45:22 50:13 56:7,19 58:21 59:25 65:16 67:2 72:6 73:3 73:19 76:9 77:10 95:17 118:5 129:13 bell 23:20 best 45:15 95:1 105:25 133:21 better 6:3 32:11 109:23 110:18 116:1,7 118:4
--	---	--	--

[beyond - child]

Page 6

<p>beyond 28:12 38:10 41:1 48:12 78:2 79:7 92:11,24 101:19 115:12 biases 124:1 billed 16:8 bills 26:5 binder 18:12 biomedical 98:13 biopyrboles 7:3 119:23 bit 25:1 47:11 51:18 54:25 56:17 75:4 92:15 93:9,19 98:10 121:20 123:14 biweekly 109:5 blow 121:19 bond 42:2 book 10:7,14,15 10:18 11:9 born 13:25 bottom 104:1 106:23 box 91:12 break 43:19 50:20 51:18 85:21 86:16 127:24 breaking 96:25 briefly 10:13 127:15</p>	<p>bringing 19:12 brings 59:13 broad 29:23 30:14 broader 40:15 brought 60:22 125:2 bucket 23:14 budgetary 10:20 96:18 118:18 built 25:23 business 42:5 72:7 73:12 buttons 57:11</p> <tr> <td>c</td><td></td></tr> <tr> <td> <p>c 3:1 8:1 call 12:3 13:13 called 34:1 96:15 103:6,9 calls 127:10 cancer 20:23 90:7 96:24 123:18 capacity 96:19 captured 28:15 carcinogen 96:23 card 132:14 care 6:7 11:16 11:17 34:24 130:7 career 13:16 64:25</p> </td><td></td></tr>	c		<p>c 3:1 8:1 call 12:3 13:13 called 34:1 96:15 103:6,9 calls 127:10 cancer 20:23 90:7 96:24 123:18 capacity 96:19 captured 28:15 carcinogen 96:23 card 132:14 care 6:7 11:16 11:17 34:24 130:7 career 13:16 64:25</p>	
c					
<p>c 3:1 8:1 call 12:3 13:13 called 34:1 96:15 103:6,9 calls 127:10 cancer 20:23 90:7 96:24 123:18 capacity 96:19 captured 28:15 carcinogen 96:23 card 132:14 care 6:7 11:16 11:17 34:24 130:7 career 13:16 64:25</p>					

<p>careful 22:12 carefully 22:9 carolina 3:11 case 12:16 15:8 17:8,12,18 18:2 29:6 30:1 32:21 33:18 35:6,22 36:6 37:16 38:1 38:15 41:17 43:11,14 48:15 58:11 59:10 60:13 68:13 97:25 124:9 cases 21:12 124:2,11 casually 15:7 categories 43:19 cause 2:5,15 20:23 caused 29:7 30:2 causes 90:7 caveat 79:16 centered 72:20 central 14:18 century 46:3 100:7 certain 41:14 101:25 certainly 11:20 30:9 47:4 48:17 66:10 81:13 98:17 113:23 118:20</p>	<p>certainty 66:8 71:4 115:5 certificate 4:14 133:14 134:5 certified 3:23 4:13 133:13 certify 133:17 133:22 134:8 135:8 cetera 81:17 chain 88:20 chancellor's 13:12 change 13:4,16 13:16 36:16 46:15,16 49:15 83:9 131:4 changes 4:11 36:8 128:18 131:1 134:13 134:14 chapter 10:14 10:18 11:2,8 chapters 10:7 11:10 characterizati... 7:2 119:21 charleston 3:11 chat 32:23 56:23 57:7,18 84:25 86:18 103:23 119:7,8 check 9:20 chest 123:19 child 42:2</p>
--	---

[children - concludes]

Page 7

children 114:4 china 58:20 73:13 chinese 6:17 53:24 58:16 72:5,10,12,25 74:4,7,18 chronology 103:17 chrysotile 61:3 61:24 62:10 63:6,8,10,16,25 64:9,14 67:7,16 67:20 68:7,20 69:19 71:13 72:17 74:8,13 74:19,20 75:8 75:11,14 77:19 77:21 80:12 84:5 89:11,19 89:22 90:25 92:4 circle 25:1 cite 45:2 54:11 90:19 99:12 115:19 122:7 122:10 cited 91:16 126:23 cites 123:20 citing 45:18 98:1 civil 2:9 claims 40:24 clarity 2:19	class 14:13 clear 47:20 51:10 52:7 65:21,22 79:21 80:6 clearer 39:15 clearly 46:4 100:7 click 86:24 client 17:13 97:12 client's 119:1 coauthor 11:15 code 89:12,18 91:1 coffee 51:19 collaboration 11:25 collected 124:3 124:4 collectively 9:4 college 13:25 colloquies 70:4 colloquy 69:10 82:4 colombia 78:22 colorado 75:10 75:15 76:23 77:8,14 82:10 82:22 columbia 14:16 combination 51:6 97:2 come 22:24 52:20 99:17 128:1	comes 97:7 comfort 51:10 coming 117:1 comment 28:19 89:9 commenting 79:17 comments 87:7 89:7 97:13 commerce 3:6 committee 3:9 8:10 134:23 communicate 125:23 126:2 126:10 communicati... 40:21 42:8 50:16,16 127:6 communities 12:2 companies 116:18 company 71:6 103:18 105:3 comparison 15:7 comparisons 119:24 compelling 125:5 compilation 68:9 complete 64:13 completely 42:10 65:18	completion 134:10 compliance 40:25 125:2 complied 10:2 12:13 34:9 45:24 50:11 65:14 92:17 comply 20:18 107:11 125:16 component 13:11 14:4 components 100:19 composite 109:6,10 comprehensive 91:21 comprise 10:24 computer 57:10 115:23 computerized 2:8 concern 94:9 concerned 43:2 50:10 concerning 74:23 concerns 96:18 conclude 65:15 101:1 concluded 88:2 130:18 concludes 130:15
--	---	--	--

[concluding - correct]

Page 8

concluding 101:9	123:1	contact 90:12 90:13	controls 105:13
conclusion 70:23	consider 64:21 97:10	contained 34:6 34:7 38:24	convening 88:15 97:3
conclusory 114:1	considera 100:6	39:19 61:17	convenor 88:15 89:3
conduct 30:2 42:8 101:14	consideration 132:18	110:11 126:9	conversations 58:5
conducted 101:18 108:21	considerations 118:18	containers 6:17 53:23 58:14	converse 128:5
confidence 71:23	considered 5:14,18,21 31:8 31:12,18,24	containing 6:14 18:13 45:8	cool 21:4
confident 36:14 68:12,14	32:6 83:8,13,23 86:3 123:8	83:18 87:12 91:23	coordination 52:9
confirmatory 58:12	124:18	contains 134:14	copies 59:25
confirmed 41:23 61:2 63:6	consistent 18:6 65:18 87:20 105:9 114:12	contaminants 100:19	copy 18:23 33:1 37:10 45:16
conformance 109:2	consolidated 26:8	contaminated 122:6 123:16	130:9,12 134:5
congressional 6:2,6 25:20 32:10 33:23 34:4 49:19 51:7 88:21 90:3 97:6	consolidation 26:8	contamination 101:6,8 121:24 124:21	core 49:13 77:9
connected 76:19	constituent 26:5	content 127:6	corn 113:12
connection 15:13 16:2 17:7 22:22 23:24 25:4 27:2 31:10 32:20 35:6 36:24 44:9 46:13 60:13 84:2 88:6,8 101:20 103:4	constitutes 114:3 133:20	context 48:11 48:12 59:15 64:25 125:3	corporate 18:15 26:15,22 40:12,13 41:20 42:1,3 65:14 102:10 108:15 113:23 114:8
	consulting 14:23 15:3,13	continue 55:17 67:11 81:2,4 105:21 106:12	corporation 42:4
	consumer 6:17 45:9 46:7 53:23 64:14 94:21	continued 71:22 87:13	corporations 113:3,18
	consumers 40:14	continuing 105:15	correct 10:11 13:5 15:16 16:10,11,16 17:2 22:3 27:8 27:9 30:18,22 39:20,22 44:3,4 44:20,21 45:3,4 53:4 54:9,11,13 56:20,21 68:17
	consuming 113:19	contract 94:13 contrary 64:19 66:16 113:24	
		contribute 11:8	

[correct - dated]

Page 9

83:24 90:20 93:11,15,20 94:3,18,25 95:16 98:5 99:3 100:9,24,25 101:10,11 102:1,4,16 103:19 105:1 109:11 114:20 115:6 125:6,9 129:23 130:3 132:3 133:20 correctly 16:5 21:25 46:9 58:17 75:17 87:17 89:14 91:25 105:24 correspondence 107:10 cosmetic 6:3,13 27:7 32:11 45:7 47:23 49:20,23 71:6 75:7,14 77:16 83:18 87:11 91:22 100:18 105:10 116:18 117:5 117:24,24 122:12,21 124:12 cosmetics 6:7,7 20:17 22:14 34:24,25 36:10 50:13 91:24 94:12 97:5 122:4	counsel 2:4 9:16 15:21 16:12 22:11,20 23:23 24:3,7 27:2 31:9 32:7 42:20 43:6,14 44:5,17 56:20 57:24 58:2 65:25 69:10 80:4,4 102:4,7 102:21 114:18 115:7 123:2,12 126:12 127:2 127:12,18,19 128:5,17 134:18 135:8 county 132:8 couple 15:20 24:11 25:20 32:6 44:24 56:10 78:7 84:21 129:9 course 11:23 14:14,15 18:21 26:3 30:16 33:13 35:18 59:16 88:23 112:25 court 1:1 3:14 3:23 4:14 8:2 8:16 17:14 19:16 20:1,3,8 21:16,20 51:21 51:25 52:4,12 53:7,11 65:10 76:3 81:25 82:5	82:8,17 86:9,13 109:17 110:2,8 110:18,20 128:8,12 129:8 129:14,20,24 130:4,8,13 133:1,14 135:1 covered 66:22 67:21 81:15 104:8 covers 11:2 16:25 crack 91:1 cracked 89:12 89:18 crashed 120:12 crashing 88:24 created 37:19 54:22 119:3 criticisms 48:8 48:10 65:4,9 criticizes 66:1 critique 59:5,8 68:25 critiques 44:7 critiquing 44:19 crr 2:7 3:24 133:16 135:19 crs 126:23 crystal 98:11 crystallography 60:19 csm 75:10 csmpp 77:20	ctfa 105:8,10 106:15 109:9 ctfa's 105:17 current 9:10,18 10:5 15:16 46:4 48:23 50:3 51:6 86:17 100:8 currently 8:13 9:5,6 28:8 curriculum 5:4 custodial 134:4 cv 9:8,18 10:5 11:13 12:12
d			
d 2:6 3:21,24 4:1 8:1 133:16 d.c. 14:11 data 2:15 124:2 date 9:17 12:15 17:8 24:22 31:19 33:21 38:10 39:5 68:11,16 120:2 120:16,18 131:3 134:12 135:20 dated 5:7,9,11 5:14,18,22 6:10 6:18,20,23 15:22 16:24 19:7 31:12 36:18 39:4 45:9 54:15,15 55:4 55:20 104:21 110:7			

[david - discuss]

Page 10

david 43:11 day 23:18 56:1 80:10 132:11 132:20 135:14 days 26:7 54:17 134:11 deadline 28:16 33:23 deal 12:2 90:6 dealing 115:22 debate 29:15 decade 14:15 december 32:13 33:21 45:10 47:17 86:21 89:20 90:20 116:16 120:19 dedication 50:3 deep 42:6 defendant 135:4 defendant's 43:15 defendants 2:3 3:18 defined 23:5 degree 115:5 delay 21:11 deliberations 91:17 delighted 14:12 delivered 134:3 delivery 129:22 130:1	delta 74:9 delve 14:2 demonstrating 13:23 dependent 74:1 74:5 deposed 12:15 13:3 deposition 1:8 2:1 12:24,25 14:6,10,20 16:2 16:3,3,16 17:8 17:17 26:15,23 27:8 29:7,11 30:1,7,19,20 36:2 38:8,10 60:2 64:3,18 66:23 67:22 79:12 80:11 81:22 87:25 88:3 103:9 104:6 112:14 115:3 125:22 126:1,7,15,16 127:3 128:17 130:16,18 132:2 133:8 134:1,3,10,17 depositions 128:23 derived 119:23 describe 10:14 11:18 13:7 49:10 described 91:2 109:4	description 5:2 132:13 desire 107:11 detail 98:8 detailed 59:3 details 69:13 115:15 detect 94:8 detectable 72:24 101:4 105:5 111:17 117:7 detected 72:14 detecting 100:13 detection 75:14 77:21 91:20 determine 94:24 95:1,4 determining 22:5 develop 48:4 88:22 100:21 developed 14:15 48:20 75:15 76:17 77:8 91:18 developing 27:25 75:13 development 20:19 25:12 28:8 34:10 49:14 developments 21:13,14	develops 123:18 diagnosis 124:10 dictating 100:13 differ 14:5,7 15:4 difference 73:17 74:24 83:7 different 23:23 31:8 60:18 108:15 113:4,4 diffraction 93:24 direct 2:20 10:21 30:8 47:8 48:4 57:22 86:2 87:6 88:21 90:11 directed 90:9 directing 28:4 direction 48:11 directive 97:6,8 directly 15:14 26:12 37:23 48:25 50:19,24 disagreement 68:6 disclosure 66:13 discovered 34:7 discuss 46:1 87:9
---	--	---	---

[discussed - draws]

Page 11

discussed 9:3 11:4 30:1 48:13 89:23 93:20,21 discussing 96:1 discussion 121:21 129:5 dispositive 72:19 disrespect 102:11 disrupts 2:16 distancing 101:5 distorted 18:8 37:5 distortion 2:15 distracted 103:15 district 1:1,1 133:1,1 disturbed 29:11 disturbing 42:7 42:13 doctor 8:24 9:13 15:19 19:11 20:10 21:25 32:4,18 33:15 35:7 36:24 46:23 54:1 57:20 61:22 62:7,16 67:13 70:2 82:21 83:13,20 84:22 85:9 89:1 96:8 103:23 120:6 121:22	127:17 document 6:6 6:24 19:20 21:18 33:25 34:19,22 39:3 45:19 46:24 47:6 81:13,14 81:21 85:3,5,19 85:25 91:6 92:10,11,21 103:22 104:5 106:8,21 107:14,24 109:15 110:5 132:14 documentation 105:4 114:17 documenting 105:19 documents 18:10,13 22:10 22:20,21,24 24:8 25:13,20 26:15,17,19,22 28:5 32:7 33:20 42:21,22 44:13 77:17 101:25 101:25 102:3 102:19 103:19 115:7,13,14 doing 22:12 27:22 51:4 85:8 96:6 99:22 domestic 58:16 doubt 88:16	downtown 9:2 dr 4:8 8:6,12 19:6,22 21:2 27:13 29:10 30:5 32:22,25 33:3,5,12 35:9 35:12,16 37:11 37:15 38:3,25 39:18,21 40:5,7 41:16 42:16,19 43:2,5,7,11,17 44:2,7,16 46:23 47:18 48:16 50:6 51:2 52:17 52:19 53:1,5,16 54:8 56:3,17,22 57:3,16 58:10 58:15,25 59:1,8 59:11,13,22,23 60:1,6,14 61:4 61:11,15,24 62:1,9,10,14,18 62:23 63:4,5,8 63:15,22,24 64:1 65:6,24 66:2,5,20 67:8 67:14,16,18,22 68:1,5,10,21,23 68:23 69:1,4,15 69:15,16,23 70:11,14 71:8 71:13,17 74:12 74:14 75:4,20 75:22,24 76:5,6 76:25 77:6 78:1 78:16 79:9,11	79:15 80:10,12 80:12,14,14,15 80:18 81:11 84:5,8,24 85:2 85:23 86:4,7 87:23 88:13 89:23,24 91:1,3 92:7,19 95:21 96:4,9 98:6 99:4,15 101:17 102:24 104:4,8 104:13,15 106:2,7,20,24 107:23 108:10 108:24 109:13 109:20,24 110:4,6,9,17,22 111:18 112:2 112:20 114:21 115:11 116:2,8 116:22 117:9 118:2 120:20 120:22,25 121:5,9 122:18 125:23 126:2 127:14,23 128:1,4,7,15,16 128:25 129:24 130:2,6 draft 11:6 129:11,21 130:1 drafting 37:25 65:1 draws 118:17
---	---	---	--

[drew - ewald]

Page 12

drew 36:11 73:6 76:19 dried 109:9 driven 10:17 drug 25:7 83:16 due 2:13 duly 2:3 8:19 133:24	either 57:22 74:19 electron 94:14 94:22 98:9 eliminating 101:7 elongate 7:2 119:21 em 13:22,25 emergence 98:20 empirical 36:11 employed 135:9 employment 12:5 encompass 62:2 endorse 59:4,7 99:8 ends 103:17 enforced 49:21 engage 22:7 107:25 enhance 6:3 32:12 ensure 91:20 entering 52:5 entire 85:3 92:20 105:19 129:15 entities 29:3 entity 42:3 environment 37:18	environmental 119:20 epa's 64:11 error 85:15 especially 47:25 esquire 3:5,10 3:15,19 134:22 134:24 135:2,5 ess 26:3 essential 42:3 essentially 19:12 96:21 established 100:17 et 81:17 ethical 41:20 65:14 ethics 11:21 40:25 event 71:7 ewald 3:19 4:7 8:11,11,23 9:12 15:25 16:23 19:10,21 20:2,6 20:24 21:4,6,19 21:23 27:17 29:22 30:17 31:5,6,16,22 32:3,17,24 33:9 33:13,14 35:4 35:11,14,18,19 36:22 38:22 39:23 41:11 42:14 43:22 45:12 47:3 48:7	49:2 50:8 51:15 52:14,16,22 53:3,13,19 55:10,15,18 57:6,19 59:6,20 60:8,25 61:6,8 61:15,21 62:5,8 62:15,17,20,25 63:13,21 64:22 65:20 66:18 67:2,12,23 68:4 69:2,6,22,25 70:1,16 71:10 71:25 75:1 76:2 76:4,21 77:2,12 78:5,11,19,25 79:3,14,20 80:2 80:22 81:24 82:7,16,19 84:10,18 85:1,4 85:7,14,18,20 86:1,5,8,15 88:1,4,9,17 90:15 91:7,10 92:12 93:1 95:24 96:7 97:20 98:22 99:9,19 101:21 103:2,3 104:7 104:11,12,18 106:4,10,13,22 107:1,2 108:2 108:18,25 109:16,23 110:12,13,16 110:19,21,23
e			
e 3:1,1 4:1 6:10 8:1,1 24:10,14 earlier 26:24 30:6 44:22 54:7 54:25 56:19 83:8,24 100:24 101:23 103:9 120:13 126:6 early 58:20 77:20 102:1 113:7 east 3:11 easy 9:20 58:5 echo 115:23 editing 11:22 editor 65:5 education 12:5 effects 121:25 124:22 efficient 75:13 efforts 6:3 32:12 34:15 44:23 87:13 113:19 125:16 eight 93:7			

[ewald - fault]

Page 13

111:22,25 112:16,18 114:13,24 115:17 116:6,9 116:10,25 117:15 118:7 120:3,18,21,24 121:7,11,12,15 121:16 127:17 127:25 128:3,6 129:2,10,12,17 129:23 134:4 135:5 exact 28:17 exactly 43:18 50:7 examination 4:7,8 8:22 69:9 128:14 examined 9:14 15:24 16:22 19:9 31:15,21 32:2,16 35:3 36:21 45:15 54:3 87:18 92:23 93:6 94:4 104:3 120:8 example 42:23 43:20 44:1 46:20 94:11 exceed 107:22 exceeded 108:7 except 112:4,6 132:3 excuse 19:16,17 42:5 62:17,18	78:5 85:23 executed 132:17 exercised 105:13 exhibit 5:1,3,6 5:8,10,13,14,16 5:18,20,21 6:1 6:5,9,12,15,19 6:22 7:1 9:8,11 9:14 15:21,23 15:24 16:19,21 16:22 19:6,8,9 31:11,11,14,15 31:17,18,20,21 31:23 32:1,2,5 32:14,15,16 33:18 35:2,3,15 35:17,21 36:17 36:20,21 40:3 45:5,11,15 53:14,18,25 54:3 55:3,4,20 56:18 58:9 60:12 83:14 84:16,17 86:22 87:18 91:13 92:24 93:6 94:4 100:1 104:2,3 106:3,6 119:19 120:1,8,15 121:3,7,14 exhibiting 93:14 exhibits 35:13	existed 34:16 exists 22:16 exp 135:20 expect 87:12 128:2 experience 28:3 38:6 52:23 113:2 expert 5:11,13 5:17,20 6:10 16:25 19:6 29:5 30:24 36:18 37:10,25 38:23 40:2,2 50:10 54:9,13 60:23 68:9 71:12 72:13 78:16 81:16 96:11,12 97:24 98:14 110:25 113:2 115:4 118:15 124:24,25 126:10 128:22 128:23 expertise 14:17 49:13 59:13,22 60:3,7,24 125:1 125:20 explain 81:7 106:10 112:11 explicit 11:16 explicitly 117:17 exposure 64:15 122:12 124:4 124:11	expressed 30:11 132:18 extensive 105:13 extent 11:2 22:15 59:19 116:23 extreme 113:17 extremely 36:7 41:13 f f 3:7,12 94:10 135:23 face 107:25 127:10,10 fact 42:7 48:23 107:21 123:2 fail 39:15 fair 12:11 22:2 26:20 43:2,3,23 50:4 71:7,9 102:8,21 111:9 faith 118:6,8 fall 12:4 14:10 familial 12:8 familiar 122:17 122:20 families 124:5 family 12:8 far 9:22 51:4 69:6 111:4 fashion 49:25 fast 95:6 fault 95:8 96:10
---	---	---	---

[fda - frame]

Page 14

fda 6:3,6,20 25:13,16,17 27:6,21 28:2,21 29:1 34:23 48:4 48:8,13 49:17 64:5 66:21 67:4 85:11 86:5,7,19 86:20 87:21 88:21 89:17 90:4,10 94:13 97:9 100:12,20 117:22,25 118:6,9 fda's 28:8 34:8 35:25 99:1 125:15 february 83:18 84:7,19 85:11 86:18 87:21 88:12 89:17 91:2 104:21 federal 2:9 21:15 26:6 46:6 50:12 51:3 76:3 90:4 feedback 20:25 55:11,13,16 feel 30:10 feeling 36:14 fees 15:12 fibers 65:12 fibrous 73:7 105:7 106:16 figure 26:4 39:8 47:11 54:24	final 26:13 129:22 finalize 90:4 finalized 27:23 finally 11:23 financially 135:11 find 23:18 28:12,21 47:6 60:20 82:3 finding 48:23 49:17 64:7 67:16,20 71:16 72:18,19 findings 44:14 61:3,24 63:6,8 63:10,24 66:21 67:4,7,18,19 68:19 69:19 70:10,12 71:13 73:25 74:11 84:6 94:16 fine 38:12 57:24 126:19 finish 50:22 62:19,22,24 78:8 firm 135:21 first 8:19 9:8 12:16 14:6,20 17:17 20:13 22:2 23:5 29:7 29:11 30:1 32:8 34:21 39:17 41:12 47:7 63:15 64:18	66:21 67:9 72:3 84:23 87:6,17 88:7 101:20,22 101:24 107:3 107:17 108:3 108:12 114:1 115:19 119:17 123:1,9 125:18 five 51:17 52:18 52:20,24 53:3 85:21 127:24 fix 19:23 fixing 21:3 flash 109:9 floor 3:16,20 focus 13:2 focused 10:23 11:10 64:8 folks 51:19 follow 82:20 129:13 followed 17:18 following 91:19 116:24 129:5 133:22 134:18 follows 8:21 food 25:6 83:16 footnote 122:6 123:21,23 footnotes 102:14 125:7 foregoing 101:2 132:2,15 133:18,19 form 27:13 28:18 29:10	39:21 40:7 41:16 43:17 47:18 48:16 50:6 51:2 59:1 59:11,23 60:14 62:1 64:1 65:6 66:5 70:14 71:8 71:17 72:24 74:14 76:25 77:6 80:25 84:8 87:23 88:13 89:24 91:3 92:7 98:6 99:4,15 101:17 107:23 108:10 111:18 114:21 115:11 116:22 117:9 formation 98:11 forming 92:10 forms 106:16 106:17 113:17 fort 9:2 forthcoming 10:10 41:20 119:2 forum 89:17 found 23:14 24:8 25:10,20 25:24 27:11,12 27:21 42:6,13 59:18 124:10 frame 24:19 61:5 92:15 102:1 111:20 111:23,24
--	--	---	--

[frame - government]

Page 15

112:12 frames 46:15 frank 122:12 123:24 frankly 113:25 free 50:18,24 71:5 114:5 frequencies 109:3 frequently 114:18 front 18:11,12 18:21 19:1,2 38:16,21 45:16 57:4,10 64:23 full 75:5 133:20 fully 36:14 fundamentals 30:15 funding 13:12 further 16:1 29:9 30:2 39:19 77:14 123:14 127:20 128:25 129:2,3 134:8 135:8,11 furthermore 105:15	121:3,8,9 123:13 124:17 124:25 125:1 garble 109:21 garbled 109:18 garbley 109:24 gather 87:14 geared 87:22 general 20:19 34:2 40:12 52:23 71:9 85:9 113:7 generally 11:19 14:23 18:20 25:5 87:19 gentlemen 19:17 genuinely 81:25 geologic 98:10 geological 77:9 george 6:10 14:9 36:18 gerel 3:10 134:25 getting 17:5 46:12 83:2 85:14 98:23 109:18 give 11:3 20:21 42:23 61:4 65:25 70:5 71:22 78:12 81:1 85:24 103:16 119:9 120:11	given 21:13,14 23:6 44:2,16 72:11 100:16 112:10 132:19 134:2,16 gives 44:6 giving 79:18 globalized 49:22 gmail.com 3:8 go 9:7 11:5 12:11 15:13 18:19 19:5 21:9 21:22 23:17 24:25 27:15 31:5,7 32:13 34:21 38:13,18 38:19 40:11,11 46:1 52:3 55:2 60:2 61:9 62:6 62:18,21,23 66:24 77:13 81:14 85:19 88:5 92:8,20 93:18 96:9 100:11 110:2 120:10 121:13 121:17 122:10 129:17 god 8:21 goes 40:18,20 40:23 41:1,1,3 48:25 49:24,24 50:19,24 91:16 94:5,11,20 106:14 119:17	123:13,24 124:7 125:18 going 12:22 13:21 18:9,24 31:2,3 38:3 46:25 49:4 50:21 51:16 56:1 67:10 71:1 78:2 81:2,3 83:12 84:12 85:16 86:22 87:1,3,3 102:24 104:4 107:3 golomb 3:15,15 8:13,14 52:2,4 52:15 55:12 79:24 80:17 81:9 111:19 112:4 120:16 127:14 129:3 130:9,11 135:2 135:2 gonna 31:7 54:18,19 56:23 56:24 85:25 112:15 good 8:24 9:1 9:22 13:18 28:3 34:10 53:6 106:5 118:6,8 119:12 government 6:1 10:22 25:19 25:25 32:9 33:20 34:1,10 125:2
g			
g 8:1 ga 32:19 gained 41:9 gao 32:19 33:17 33:25 35:14 120:10,14			

[government's - identify]

Page 16

government's 46:6 governmental 29:3 grab 31:2 51:19 grade 105:10 graduate 13:20 grateful 34:16 great 13:17 18:17 19:4 23:6 37:9 greater 71:23 grossman 25:7 ground 62:2 66:15 109:5 123:6 grounded 59:18 grounds 14:16 group 28:13 44:23 45:8 46:7 47:17,19 51:4 89:21 90:11,24 91:5,12 94:21 97:3,3 99:7 103:11 117:3 118:11 guess 22:25 23:10 32:13 48:2 50:2 99:21 124:8 guidance 64:12 guidances 28:5 guidelines 15:3 guys 20:4 78:7 80:23,24 116:2	h half 14:13 46:3 100:7 125:17 127:10 hand 132:19 handling 125:3 happened 56:5 66:24 happening 17:21 29:15 happy 18:9 39:12 41:8 64:21 66:16 70:19 71:20 80:5,23 98:17 107:24 114:23 hard 20:7 harm 47:23 harmful 100:19 harming 12:3 hazardous 119:3 he'll 57:14 head 116:21 126:24 header 104:20 health 10:8,9 10:16 11:17 12:3 13:12 17:15 30:13 94:9 121:24 122:24 124:22 healthcare 10:24 13:14	hear 52:17 heard 57:25 58:3,6 128:17 hearings 49:19 heavily 34:13 36:11 41:3 heavy 75:8 77:15 82:11 84:6 89:10,18 89:22 90:25 92:5 93:7 hegarty 80:10 help 8:20 12:1 91:20 116:5 helpful 18:25 41:13 70:19 hereto 2:10 hesitating 126:17 hi 8:6 high 72:25 higher 73:2 107:11 highlighted 32:7 highlighting 94:17 historical 6:16 6:17 53:22,24 history 37:21 66:25 72:12 108:16 113:23 114:8 118:25 124:4 hit 55:6	hls 75:11 76:11 77:15 hold 13:20 88:25 honest 102:13 honorific 78:23 honoring 41:19 hook 13:22,25 hope 24:14 hopkins 81:16 hospitals 10:25 hotel 9:1 hour 15:17 16:10 50:21 51:16 127:9,9 hourly 15:16 hours 16:9,16 18:2 127:1,10 housing 12:5 howard 135:21 hsl 82:11 hughes 135:21 hum 25:6 hutt 25:7 102:15 hypothetical 111:10,11 116:20 117:2 hypothetically 115:21 i i.e. 94:1 identified 53:21 identify 39:24 53:16 93:12
--	--	---	--

[identity - interesting]

Page 17

identity 132:14	includes 134:18	118:17	institutional
imagine 83:9	including 7:2	influence 73:14	96:19
91:9	38:4 96:23	inform 37:15	instruction
immediately	119:22 124:1	48:13 58:10	48:4 88:21
71:15	income 12:4	information	instrument
immigration	incontestable	21:13 28:21	132:16
12:6	97:11	34:5 36:5 40:22	insufficiency
impact 74:11	incorporate	43:6,15 44:18	48:19
impacted 49:8	29:20	50:15 54:20	insurance 12:4
implement 6:3	incorporating	66:9,17 79:10	intend 105:15
32:12	100:17	87:10,14 98:16	intended 42:9
implementation	incredibly	111:7 112:23	91:23 105:8
34:15	42:13	113:24 134:16	intensively
implies 63:7	index 5:1	informational	17:16
import 11:7	indicate 114:11	37:18 40:10	intent 40:13
66:4	115:8	informs 48:17	inter 118:23
important	indicated 60:10	71:21	interagency
22:12 66:6	indication	infrared 93:25	28:13 44:23
70:24 87:13	47:20	99:2	45:8 46:7 47:16
impression	indirectly	inhalation	47:19 51:4
34:14 76:16	10:22	123:16	86:20 89:21
impressions	individuals	inherent 124:1	90:10,20,24
96:11	126:11	124:2	91:5,11 94:21
improvements	industrialized	initial 17:10	99:7 103:11
47:21	49:22	18:2 128:22	117:3 118:10
inadequacy	industry 48:20	insights 35:24	interest 23:6
100:16	90:2 96:14,15	41:9,14	48:23
inadequate	100:15 105:16	insignificant	interested
95:15	107:4,22 108:8	74:5	17:16 30:12,16
inclined 77:10	118:19	instance 2:2	33:19 34:6
include 54:8	industry's	65:10	118:23 135:12
73:20 97:2	100:16	institute 13:13	interesting
included 44:12	inference 73:6	13:13	34:12 56:14
48:3 80:13	118:3	institution	60:20 72:18,21
87:24 99:2	inferences	76:18	72:22
125:8	48:22 49:5,8		

[internal - july]

Page 18

internal 26:15 26:19,22 101:25 103:18 107:10 123:20 interpret 107:9 interpreted 101:5 111:17 117:8 interpreting 65:8 interrupt 20:9 21:17 62:24 78:11 96:3 interrupting 80:5 96:5 interventions 96:20 intricacies 69:13 introduce 8:3 introducing 89:4,8 introduction 83:4 introductory 11:8 intuitive 27:19 investigation 30:2 investigations 51:7 investment 11:15 invigorated 49:17	invited 10:15 11:8,20 invoice 5:7,9 15:22 16:13,17 16:20,24 17:6 invoices 15:20 involvement 25:15 29:18 60:16 118:19 involves 30:15 ir 93:25 99:13 irony 42:7 issue 19:23 28:14 86:17 100:21 108:17 issued 46:6 75:6 100:12 issues 10:20 20:25 58:22 96:18 issuing 33:23 it'll 18:25 119:12 italy 73:20 items 93:7 iwgacp 6:12 45:6 91:18 92:3 94:22	j&j's 6:16 53:22 j.d. 4:6 132:1,6 132:12 j4-1 46:1,13 93:19,21,23 95:13 99:2,8,13 100:3 105:8,14 105:17 106:15 107:5,12,22 108:8 109:10 111:1,14 jacqueline 122:11 january 16:24 jd 5:4,11,14,17 5:21 jersey 1:1 3:14 8:15 133:1 135:1 jewald 3:22 jnjmx68 6:23 104:1 107:1 job 1:25 135:24 john 3:19 8:11 66:20 67:24 134:4 135:5 johnson 1:2,2 3:18,18 6:22,22 20:18,18 23:8 26:14,14,22,22 37:18,19 40:10 40:21,24,24 41:5,6,19,19,25 42:2,3,7 43:15 43:16,20,21	48:22 49:4,8,8 49:9,18,18 50:2 50:11,11,25,25 51:10,10 58:18 58:18 65:13,13 66:7,14,14 70:10,10 71:16 71:16 72:7 73:12 101:2,3 101:15,15 103:18,18 104:20,20 105:12,12 107:10,20 108:6,15,21,21 111:2,2,12,12 111:15,15 113:22,22 114:2,2,8,18,19 115:8,9 117:20 117:21 133:2,2 135:4,4 johnson's 23:8 40:10,21 41:25 42:8 48:22 49:4 49:9 50:2 66:7 72:7 73:12 107:11,20 108:6,15 114:8 joining 8:14 87:16 journal 11:21 122:13 july 16:4,8 105:17
	j		
	j&j 6:17 8:11 53:23 77:22 81:16 101:25 102:18 109:10 113:11		

[justified - list]

Page 19

justified 51:11	109:21 112:20	language 26:12	legislation
k	113:16 114:16	26:13 28:15	14:14 26:7
karen 2:6 3:24	115:2,20	largely 17:22	30:15 48:3,3
133:16 135:19	118:12 119:10	34:8	49:14 118:16
kari 87:8 89:3	119:11 123:3,5	las 135:22	letter 6:22 65:4
keep 51:14	126:21 127:5,7	late 46:6 48:2	letterhead
105:25	knowing	52:6	104:20
keeps 80:4	118:24	laughing 54:23	level 40:15 98:8
kesha 122:11	knowledge 29:4	launch 13:12	levels 44:14
kessler 43:11	29:13 47:25	law 6:4 10:8,8,9	48:18
kind 18:22 34:3	76:18 77:1	10:10,16,19	liability 1:4
34:10 47:12	97:18,22	13:19 14:16,22	10:19 11:3,11
72:20	107:16,20	17:14 21:15	11:11 12:10,10
king 3:19 135:5	111:6 112:21	28:18 32:12	133:4
knew 34:2	known 96:23	35:24 36:8	light 76:9 94:1
know 9:9 17:20	122:5 124:11	50:13 51:8	107:9 112:23
24:2 26:3 30:13	132:12	78:22	likely 102:6
33:22 37:13	kslaw.com 3:22	lawyer 18:15	limitations
38:10,16 39:16	l	layer 123:18	123:25
39:16 40:18	l 2:6 3:24	lead 119:10	limited 63:19
41:17,18,23	122:11 133:16	leadership	111:23 115:1
43:24 45:16,23	l.d. 135:19	34:11	117:18
47:6,8 49:12	lab 61:1,1,23	leading 25:6	limiting 61:20
51:20 54:17,21	64:17 68:19	learned 40:22	111:20
56:11 59:14,21	72:16	leave 31:3	limits 63:12
60:4 69:2,8	labeling 40:11	43:24	line 50:22 131:4
71:18 72:13,18	50:15 114:3	led 51:7 62:13	lines 123:19
73:8,23 76:7,11	laboratories	90:1	link 86:2
78:1 79:1 88:19	119:25	leeway 112:10	links 25:17
89:25 97:18	laboratory	left 19:23	liquid 75:8
98:8,10,10,12	63:23 72:14	legal 3:15 11:16	76:12 77:15
99:5 102:11	94:13	11:25 12:3,5	82:11 84:6
104:23 105:2	lack 48:22 50:2	36:16 41:1,19	89:10,18,22
107:5,7,13,18	71:4,5 78:23	43:21,24 58:22	90:25 92:5 93:8
108:12 109:19		65:14 66:7,13	list 5:14,18,21
		124:6 135:2	24:5,11,13

[list - margaret]

Page 20

26:24 31:12,18 31:24 32:6 60:2 62:12 63:3 83:13 86:3 92:16 93:7 123:5,8 124:18 124:18 lists 23:24,24 31:9 litigation 1:4 8:15 11:3 18:17 25:16 29:17 30:20 38:6 63:17 76:19 124:3 133:4 135:20 litigation's 124:6 litigations 61:18 litigator 18:15 little 10:17 25:1 30:8 39:15 47:11 51:18 54:25 55:11 56:16 58:3 75:3 77:13 92:15 93:9,18 98:10 121:19 123:14 llp 3:19 135:5 located 8:25 location 117:17 long 29:12 42:5 48:24 51:13 78:12 81:1 85:5 88:20 90:6 94:6	96:22 103:23 118:13 127:7 longer 51:19 52:1 longo 22:25 23:15 24:17,17 44:16 53:16 54:1,8 56:3,14 56:17 58:1,10 58:25 59:8,13 61:15,24 62:10 63:15 65:24 66:2 67:16 68:10,21 70:11 70:21 71:13 72:4 75:4,20 76:6 79:10 80:14 84:5 89:4 89:23 125:23 126:5 longo's 44:2,7 58:15 59:22 60:1,6 63:5,8 63:24 66:21 67:3,18 69:1 74:12 75:24 80:12 91:1 look 11:6 18:5 25:23 28:6 29:8 45:21 55:9,19 57:17,21,23 66:16 87:5 88:7 92:20 98:21 101:22,23 123:4	looked 17:20 25:8,19,21 28:20 54:4,14 84:1 125:6 looking 10:16 25:22 87:2 92:2 97:21,22 101:13 103:5 126:20 looks 10:5 lose 70:4 lot 25:12 27:22 27:22 59:15,16 65:7 69:9,10 72:20 98:12 111:7 112:10 love 18:5 lungs 123:19 m m 3:5 5:4 134:22 m.d. 1:9 2:2 4:6 8:18 131:2 132:1,6,11 133:9,24 m.thompson... 3:8 ma'am 20:1 129:23 130:2,8 mac 22:14 57:11 machine 2:8 madam 81:25 made 10:21 13:4 30:9 36:9	40:14 41:6,23 49:3 63:16 90:23 113:19 mail 24:10,14 maintained 37:19 major 13:16 majority 102:6 make 13:22 15:6 21:12 39:15 52:6,8 74:3 79:2 80:6 80:20,24 97:13 98:2 105:9 118:23,23 makers 113:9 makes 52:11 58:21 making 126:24 mandate 90:4 manipulated 101:3 111:15 manipulating 117:6 118:1 manner 114:19 115:8 manufacture 20:19 manufacturers 20:17 march 31:13,19 31:25 55:4,21 margaret 3:5 8:7 9:6 109:17 134:22
---	---	---	---

[mark - mineral]

Page 21

mark 9:8 15:21 16:19 19:5 31:8 31:10 32:14 45:5 53:14 84:15 106:5 119:17 126:2	31:18,24 32:6,8 48:21 83:13,15 86:3 105:22 108:13 123:8 124:17 126:23	medicine 122:13	methodological 97:16
marked 9:11 15:23 16:21 19:8 31:14,20 32:1,15 33:17 35:2,13,21 36:20 40:3 45:11 53:18,25 55:3,20 56:18 58:9 84:17 91:13 100:1 104:2 120:1,15	maternal 42:2 matter 18:19 29:18 30:13,20 30:24 42:1 43:16 60:17 61:6 65:19 71:9 77:3 80:8 85:9 124:24	medicolegal 11:24 meet 127:2 meeting 6:20 83:17 84:7,13 84:20 85:11 86:19 87:9,12 87:21 88:12,15 88:19 90:10 105:14,17	methodology 20:12 75:25 79:17 methods 6:13 45:7 47:15,22 59:2,8 60:18,19 69:1,17 83:17 87:11 93:11 94:18,23 95:18 96:22 98:16 99:17 101:15 103:19 106:15 107:21 108:7
marketing 1:3 20:19 23:3,8 37:20,21,23 41:6 133:3	matters 10:9 12:7,8 49:15 101:19 113:3	meetings 17:10 18:2 127:7	michelle 3:10 8:9 134:24
marking 36:17 106:2 119:19	matthew 119:20	mentioned 44:22 67:3 72:3 73:17 82:21	microphone 19:23
marks 2:19	md 5:4,11,14 5:17,21	merit 81:5	microscope 98:9
mas 1:4 6:16 61:2,23 63:23 74:8 75:6,12 77:19 133:4	mdl 1:3 3:4 8:8 53:22 54:8 75:6 133:3 134:21	mesothelioma 122:13,21 123:17 124:10	microscopy 60:19 76:9 94:1 94:1,14,18,23 111:8
material 17:23 31:11 40:19 41:7 65:16 70:25 84:13 105:6 109:2 117:18 118:21	mean 23:10 42:11,23 43:20 48:17 51:1,3 54:16 59:16 62:24 71:5 87:4 102:10 113:21 126:20	message 85:15 method 28:1,9 28:19 46:1,4,13 48:5 58:24 60:21 66:2 75:9 75:12,16,20 76:17,23 77:5,9 82:22 83:5,7 88:22 89:22 91:2 92:5 93:19 93:21,23 95:14 97:9 99:2,8,13 99:13 100:3,7 105:8 111:14	mind 9:19 22:24 41:14 48:10 50:3 71:15 82:2 126:18
materials 5:14 5:18,21 31:8,12	means 10:9 27:15 59:17 meant 22:9 medical 11:25 124:6		mine 104:25 mineral 7:2 73:7 94:9

[mineral - november]

Page 22

119:22,23 minerals 6:23 93:13 98:12 104:22,23 105:3,12 106:17 mines 58:16,16 75:10,15 76:23 77:8,15 82:11 82:22 minimal 52:13 minimum 93:12 minor 25:11 minute 51:18 67:15 82:6 85:21 116:3 127:24 misbranding 40:20 misrepresent... 41:5 mlp 11:16 mocra 6:8 35:1 models 49:20 modern 49:22 modernization 6:7 22:14 27:23 27:24 28:14 34:25 51:8 97:5 100:20 125:16 126:23 modernizatio... 25:9 modification 74:22	moline 122:11 122:18 123:23 124:19 125:8 moment 70:5 85:5,17 115:22 120:11 moments 108:15 montgomery 3:6 months 56:6 morning 8:24 9:1 morning's 128:17 morphology 93:14 mothers 114:4 motions 43:21 43:25 motors 113:7 mouth 49:6 move 13:8 moved 11:12 mparfitt 3:13 multiple 13:11 n n 3:1 4:1 8:1 name 85:24 131:2 132:15 narrow 29:24 nature 10:14 114:2,5 ncra 135:20	nearly 46:3 100:7 necessarily 2:20 54:16 necessary 47:21 99:23 need 14:24 18:18 19:18 21:17 46:24 51:19,24 56:23 57:18 65:3 71:14 91:5 105:11,18 109:25 130:12 needed 22:5 needs 12:3 38:19 negative 70:23 94:16 121:24 124:21 neither 135:8 nevada 135:22 never 101:7 new 1:1 3:14,20 3:20 6:4 8:15 32:7,12 35:24 36:4 53:15 88:3 112:9 133:1 135:1 newest 53:15 newly 49:16 76:17 newman 6:10 23:7 26:18 36:18 37:11,15 41:9,15,24,25	42:12,15,16 56:4,8,14 newman's 38:3 38:25 39:18 40:5 42:19 43:2 43:5,7 news 17:20 night 34:20 non 6:16 53:22 93:14 nonpublic 118:21 nonsample 74:5 nora 34:23 36:4 normal 103:12 119:18 north 3:16 notably 27:25 notary 132:24 note 2:13,13 46:14,17 99:6 noted 46:5 64:11 104:11 109:3 112:17 123:25 132:3 notedly 22:14 notes 133:21 notice 113:11 noticed 24:12 noting 100:4 november 17:1 18:1 19:7 36:19 53:25 54:12,15 54:16 55:22 56:3 58:1 61:12
---	---	--	--

[november - opinion]

Page 23

61:19 68:12 78:15 112:13 number 28:6 56:6 60:17 68:9 73:24 85:24 86:2 92:25 102:11,19 103:25 106:21 numbered 2:5 numbers 74:23	104:11 108:24 109:13,14 110:3,4 111:19 118:2 objection's 112:17 objections 52:8 52:10,12 69:7 69:11 80:24 81:2,3,5,7 82:14 objective 94:24 obligation 58:23 66:13 70:10 98:15 obligations 40:10 41:20 49:15 50:12,14 65:15 66:7 70:8 observed 119:23 obtain 87:9 obvious 106:11 obviously 17:18 39:3 occasional 17:19 occasionally 17:23 34:4 occupational 64:15 122:13 october 15:22 17:1,11 18:1 odds 46:4 100:8 offended 113:25	offer 37:17 98:18 offered 13:10 offering 37:16 48:14 58:11 68:24 115:4 office 6:2 25:25 32:10 34:1,3 105:18 132:19 officer 133:25 134:17 officials 90:12 oh 17:12 19:21 19:21 26:3 33:5 62:25 69:2 70:7 75:2 110:19 115:24 121:5,9 okay 8:16 9:7 9:13,21 10:4 15:2,19 16:15 19:5,5,11 20:3 21:4,16,20,22 23:9 27:20 28:24 31:7 32:4 32:25 33:6 37:4 37:14 44:15 45:1,18,25 46:22 50:9 52:1 55:9,25 57:6,25 58:8 59:21 63:13 67:13 68:1 69:15,16 69:25 71:1,11 72:1 73:17 76:22 77:3,13 78:18 79:20	80:22 81:24 82:17 83:11,12 84:4,11 85:14 86:4,16 88:18 88:23 90:16,22 91:15 92:14,22 93:6,9 95:19 99:20,25 100:11 101:1 102:18,23 103:14,22 104:7,11 106:10,24 108:19 109:1,9 109:16,20 110:22 112:16 114:25 115:18 119:8,16,17 120:5,9,12,14 120:25 121:9 123:13,23 127:11 old 38:20 62:2 once 20:4 ongoing 125:15 online 87:15 open 113:13 operate 20:17 operating 105:20 opinion 20:22 39:19 41:6 74:25 83:10 92:10 100:23 111:14 114:12 117:3,25
o			
o 8:1 o'dell 127:15 oath 132:12 object 27:13 39:21 40:7 41:16 43:17 47:18 48:16 50:6 59:1,11,23 60:14 62:1 64:1 65:6 66:5 70:14 71:8,17 74:14 76:25 77:6 78:2 84:8 87:23 88:13 89:24 91:3 92:7 98:6 99:15 101:17 104:5 107:23 108:10 111:18 112:15 114:21 115:11 116:22 117:9 objection 29:10 30:5 51:2 75:22 80:20 99:4			

[opinion - passed]

Page 24

124:24 opinions 6:13 30:3,11 32:20 33:18 34:8 35:6 35:22 37:15,17 38:4,9,24 39:2 44:19 45:6 47:15,24 48:14 48:17,25 58:11 59:9 60:13 66:16 68:25 75:24 79:18 80:13 91:19 92:3,22 96:12 97:24 98:19 110:11 115:4 126:9,12 128:18,21 opportunities 34:3 opportunity 13:10,17,19 opposed 72:5 98:9 optical 93:25 94:17 oral 134:1 order 6:24 49:21 52:9 116:17 129:13 129:15,19,25 ore 109:5 organs 123:20 origin 26:11 original 20:15 24:13 33:22	44:12 59:25 87:24 112:25 113:1 115:15 117:13 118:22 134:3 outcome 135:12 outside 36:11 61:2,23 63:23 ovarian 96:24 overall 58:21 72:23 overspeaking 2:15 overtalk 18:8 37:4 overview 11:7 41:13 own 23:14 24:8 25:3 27:6 35:24 57:23 65:8 p p 3:1,1 8:1 p.c. 3:5 134:22 p.m. 2:6 128:10 128:11,13 130:19 page 4:2 5:2,7,9 9:19 11:13 19:15 32:5 34:20 39:16 45:22 53:17 57:22 75:5 87:7 89:2 91:18 98:3 103:22 121:17	121:18,18 131:4 134:14 pages 5:5,12,15 5:19,22 6:4,8 6:11,14,18,21 7:3 39:20 82:3 paid 16:12 17:12 painful 83:10 paper 6:12 45:2 45:6,13 46:5 47:14,17,20 48:9,13 50:23 86:20 89:20 90:20 91:16 93:22 95:14 96:2 98:2,3,25 99:11 100:4 101:14 103:5 103:10 115:18 116:11,15 121:18 par 102:14 paragraph 20:12 39:25 40:24 45:22,25 75:5 76:14,20 82:12 96:1 100:2,3,5 101:10,24 103:20 107:3 111:22 117:12 117:19 123:14 parfitt 3:10 8:9 8:9 121:14 134:24	parkway 135:21 parlance 103:12 part 39:7 48:5 49:7 77:19 83:5 83:6 114:3 124:3,5 125:18 127:16 participated 127:11,12 participating 90:13 particles 7:2 91:22 93:14 94:9 119:22 particular 41:24 43:7,16 64:4 68:15 70:22 90:10 particularly 21:14 46:16 50:14 98:15 125:4 parties 3:2 10:17,23,24 11:1 96:20 97:12 134:6,19 135:9 partnership 11:24 parts 87:4,5 party 134:9 passage 27:24 passed 26:9
---	--	---	---

[passing - powders]

Page 25

passing 102:13 108:13	period 16:7 17:14 18:1	126:11 127:19 134:21	policy 13:13 17:15 30:13
past 16:9 44:24 105:14	48:24 96:22 112:13 118:14	planning 6:3 32:11 47:5	105:20
patel 122:11 123:24	permitted 92:21	plate 98:11	poor 100:17
patent 113:12	person 132:15	platy 93:14	pose 94:9
patents 113:8	personal 6:7	play 24:4	poses 118:14
patients 12:2 124:3,5,5,9	12:7,8 22:13 34:24 90:13	played 24:6	position 43:16 65:2 79:21 80:7
pause 120:11	personally 132:11	please 2:13 8:3 19:20 41:13	80:9,16 81:20 113:22
pay 29:19	perspective 71:12	62:22 78:9 107:12 112:1	positions 113:4
pdf 120:12 121:18	ph.d. 6:10 36:18	plenty 97:13 113:24	positive 74:9,18 94:2
peculiar 118:3	philadelphia 3:16	plm 61:2,24 62:9 63:16,24	positives 73:18
peculiarity 46:2 100:5	physicians 10:25	67:7 68:7,20 71:14 74:8,12	possible 77:21 118:24
peer 65:2 76:24 123:3	pick 18:9	75:12 84:5 93:11 94:16	possibly 60:2 79:6
pending 82:1,9	pickups 18:22	95:16 98:4 99:2 99:14 116:19	post 118:6,9
pennsylvania 3:16	pinpoint 56:1	117:5,23	potential 65:3 124:1,20
people 19:17 52:23 57:7	place 51:13	point 17:9 42:17 43:4 49:3	potentially 100:19
90:14	plaintiff 3:9,14 8:10 134:23	57:20 60:16 65:23 70:18	powder 1:3 6:16 20:20,22
peoples 60:24	135:1	97:10,15 100:12 108:20	29:14 37:20 40:17 41:21
perceive 64:24	plaintiffs 3:4 8:8 9:16 15:21	111:6 114:7,15 125:21,25	49:18 50:18,24 53:23 58:13,19
percent 73:4,5 73:18 74:9,10	22:11,19 27:2 42:20 43:6,14	pointed 24:14	65:12 71:24 73:15 74:17
percentage 72:23 73:18	44:5,17 52:5 56:20 65:25	pointing 90:1	77:23 113:12 113:13 114:6
percolated 29:14	80:7,9,15 102:4 102:7,21	points 61:18	122:5,25 133:3
perfect 42:1	114:18 115:7	polarized 76:9 94:1	powders 119:23,24

[practice - proved]

Page 26

practice 18:16 114:12	presence 23:1 28:9 29:2 58:12	probably 34:18 52:20 126:25	65:13 71:24
practices 1:4 20:16 23:3	65:11 66:10	127:9	73:15 83:18
51:12 72:7	93:12 94:8,15	problem 63:20	87:12 91:22
73:12 113:5	108:22 111:2	70:4 82:7 85:4	94:16,22
133:4	111:13 115:9	procedure 2:9	100:18 105:3
practised	116:17 117:4	105:20	113:13 114:6
105:22	117:23,24	proceed 69:8	119:3 133:3,4
pre 118:9	present 64:8	79:18 80:6,23	professionals
preceded 72:6	94:24 95:5	proceeding	12:1
117:18	presented 84:5	135:10	professor 14:9
preferred	97:19 112:24	proceedings	17:15 23:7 79:2
94:23	preserve 42:9	133:18	program 40:25
preliminary	president	process 2:16	progress 96:21
28:22 30:11	104:22	22:5,7 34:9	progression
33:23	press 7:1	90:1 96:14,15	21:11
premoderniza...	pretty 28:3	119:18	prohibition
36:9	34:5,16 51:9	processes 28:4	64:13
preparation	prevalence	118:15 125:3	prompted 13:8
12:24 13:2 16:3	72:23	produce 38:19	proper 29:3,19
16:15,25 17:17	prevalent 73:8	produced 2:2	properly 49:23
24:10 27:3 30:3	previous 62:8	61:17	proposal 28:17
36:24 44:9 47:8	66:22 79:10,11	producing	28:18,22
59:24 64:2,16	128:19	47:23	proposed 29:1
75:9,12 77:16	previously 36:5	product 6:17	90:3 97:9,14
77:18 127:3,12	39:4 54:7 62:4	10:18 11:3,11	proposing
127:16	67:21 68:10	12:10 20:22	64:13
preparing 2:16	91:12 112:8,15	42:5 53:23	prospects 42:5
17:22 22:22	primarily 40:4	108:17 114:3	protected 6:24
24:19 29:5	prior 22:6 37:2	products 1:3,4	protective 6:24
43:13 48:1	62:12 63:11	6:7,13 20:20,23	protocol 75:10
56:15 83:23	71:3 74:10 83:3	29:14 34:24	75:13 105:19
101:12 112:25	private 10:8,10	37:20 40:17	protocols 94:6
114:1 118:21	10:17,23,24	45:7,9 46:8	protracted
126:7,9,15,16	11:1 94:12	48:24 50:18	41:18
		58:19 64:14	proved 132:12

[provide - reading]

Page 27

provide 24:7 64:19 66:17 provided 9:15 22:22 24:7,15 25:17 30:18,20 36:4 56:20 78:15 102:4 123:11 128:22 provisionally 11:22 provisions 2:9 public 6:20 11:15 25:13 28:19 40:15 41:21 83:16 84:12 87:9 89:17 97:13 113:6,16,19 118:21 132:24 publication 11:14 28:16 65:2 publicities 111:16 117:7 publicity 101:4 publicly 22:13 28:12 102:5,16 published 76:24 94:6 122:21 publishes 97:9 pull 9:9 81:14 83:12 pulled 26:3 pulling 57:7	purity 114:5 purpose 85:10 85:13 87:8 88:12 116:24 purposes 74:6 110:25 116:15 129:6 132:17 pursuant 2:8 134:16 push 57:12 put 18:24 19:3 19:20 21:17 24:13 32:22 49:5 51:9 56:23 57:8,14 64:24 84:24 85:25 91:11,13 95:22 99:24 103:22 119:8 124:17 puts 76:6 putting 24:5 119:7	63:22 68:2,3,15 69:21 71:20 74:20,23 79:25 80:1,3,19 81:10 81:12 82:1,9,20 83:2 90:18,22 91:8 96:16 97:16 104:16 107:8,8,12,14 107:18 108:4 111:1,21,23 112:1,6,19 116:15,24 118:4,5,8 126:8 questionable 51:12 questioned 14:25 62:3,3 65:10 80:11 questioning 50:22 questions 14:21 14:24 17:19 18:7 20:14 21:25 46:25 47:10 56:25 67:10,11 69:14 72:20 79:5 80:18,19 84:21 87:4 90:9 109:14 110:5 118:14,16 127:18,20 129:1,3,9 quite 27:21,22 48:25 90:8	118:23 quotation 2:19 quote 2:20 quotes 47:6 quoting 117:12 r r 3:1 8:1 r.n. 104:22 raised 28:14 43:7 rate 15:17 16:9 rather 57:18 58:16 104:21 ray 93:24 rdr 2:7 3:24 133:16 135:19 read 16:1,5 25:14,25 33:25 34:17 41:24 43:1,20 46:2,9 47:7 48:10,11 60:17,21 64:4,5 66:15 75:17 76:15 82:12 83:4 87:17 88:14 89:14 90:18 91:25 92:9 105:24 106:22 122:23 125:11,19 132:1 reading 22:9 35:24 42:15 65:23 74:15 76:15 82:10
---	--	--	--

[reading - regulation]

Page 28

119:12 126:21 reads 94:3 95:10 124:13 ready 52:21 realize 96:6 really 66:23 69:6 71:5,19 73:11 87:3 119:1 125:17 127:15,16 reask 33:15 reason 60:6 64:16 88:16 131:4 reasonable 115:5 reasons 96:17 134:14 reassure 113:19 reassuring 73:24 114:4 recall 11:10 12:14,15 14:25 17:13 23:17 24:21 25:8 26:18,21,25 30:8 36:3 45:18 58:17 59:24 64:18 76:15 84:4,9 85:12 89:25 91:9 104:14,17 115:16 receipt 134:12	receive 15:12 23:15 37:10 55:1 received 15:10 15:20 23:20,23 24:2,18 31:9,24 34:20 37:1 39:5 44:20 54:2,7 56:2 58:8 80:15 102:20 115:7 115:13,14 receiving 26:21 58:2 65:23 recent 11:6 37:22 64:11 82:22 83:5,7 90:19 94:12 97:1,1 recently 54:5 60:22 89:12 recess 53:9 86:11 128:10 recognize 105:11 recognized 94:6 recognizing 49:19 100:15 recollection 59:3 recommend 90:24 93:10,10 recommendat... 90:23 recommended 47:16 92:3	recommending 116:16 117:4 117:22 recommends 98:3 reconsideration 46:3 100:6 record 2:10 8:4 9:3 13:24 52:3 53:8,12 63:14 86:10,14 91:18 92:20 95:23 100:17 128:9 128:13 134:1 134:19 record's 52:7 records 106:23 recover 120:13 reengage 97:16 reference 23:24 24:5 92:4 93:7 referenced 26:17 referred 108:13 referring 49:11 54:2 63:1 76:9 84:20 112:12 112:13 refers 100:3 reflect 2:20 13:24 48:20 63:15 reflected 17:5 17:10 26:23 44:7 61:3 62:12 63:25 66:2 67:7	68:8 79:4,8 105:16 107:5 107:22 reflecting 59:12 78:14 reflection 36:16 reflects 16:15 38:9 39:1,2 61:16 reform 29:16 48:11 51:8 reformulation 113:14 refutes 98:19 regard 105:6 regarding 23:3 48:19 50:14 58:12 65:10 98:19 109:14 110:5 113:20 regardless 29:17 33:11 70:11 regime 96:13 registration 135:21 regular 129:21 130:1 regulated 96:20 regulation 6:6 6:8 14:14 22:15 25:7 27:7 29:2 30:16 34:23,25 36:10 49:14,20 64:13 90:5 97:5 97:10 98:15
--	---	---	---

[regulation - report]

Page 29

100:12,20	reliable 70:12	repeat 90:11	59:25 60:1 61:3
118:15	77:4 88:11	109:25 110:3	61:14,25 62:11
regulations	91:20	repeatedly 46:5	63:25 64:2,3,9
100:21	reliance 23:24	rephrase 126:8	64:17 65:24
regulatory	26:24 62:12	report 5:11,13	66:3,21,22 67:4
14:17,18 17:22	103:1 104:10	5:17,20 6:2,10	67:8,22 68:8,11
20:16 28:15	reliant 96:14	6:16 14:19 17:1	68:21 70:20,21
29:14 46:15,16	relied 35:23	18:4,6,7,24	70:25 71:12,21
46:19,19 48:6	36:13 100:14	19:6,14 20:14	72:4,5 73:20,23
49:20 50:12	relies 93:23	20:15 21:10	74:4 75:4,6,21
51:8 70:8 96:12	rely 33:17	22:2,2,6,23,25	76:7 77:14 78:3
96:13 97:4	34:13 35:20	23:2,5,7,16,25	78:6,8,14 79:4
98:15,16,19,20	38:3 39:3 40:1	24:5,9,17,20,24	79:7 80:14 83:6
113:3 118:14	59:2,12,14	25:4,25 26:18	83:10,11,24
118:15	60:23,23	27:3 29:5 30:4	84:2 87:24 88:3
related 87:10	125:12,19	30:11 31:10	88:7 90:19,23
91:19 92:22	relying 32:19	32:10,19,20	91:16 93:12,18
135:9	36:6 38:24	33:17,19 34:14	95:13,18,22,25
relating 88:1	39:18 40:5 59:9	36:15,18,25	97:4 99:12,18
relationship	59:16,17 60:10	37:2,10,15,25	99:25,25
42:9,11	62:9,11 67:8	38:3,5,9,14,14	101:13,20,23
relative 24:9	remain 13:14	38:18,23,25	101:24 103:1,4
released 28:23	remained 21:12	39:1,17,18,25	104:9 106:9
28:24 45:3	remember	40:2,3,5,8 41:9	107:9 108:12
relevance 23:4	14:24 24:22,22	41:24,25 42:12	108:14 110:10
106:8 110:9	24:23 28:17	42:15,19 43:2,5	110:11,25
117:10	64:12 66:6	43:8,10,13 44:3	112:9,21 114:1
relevant 25:10	76:11,13 81:25	44:8,10,12,16	115:12,14,15
37:23 40:9	84:12,13 126:3	44:19 45:2,19	115:19 117:11
56:15 58:21	remote 1:8 2:1	47:8 48:1 49:1	117:13 118:22
59:18 60:4,22	130:18 133:8	50:11,19 53:15	120:10,14,17
72:13 73:11	remotely 2:3,7	53:15,22 54:1,4	120:18 121:4,8
102:25	3:2 133:19,24	54:8,9,13,14	123:1,9,13
reliability	renew 98:18	55:6,22 56:4,5	124:17,23,25
74:12	repealing 100:4	56:8,17 58:1,9	125:13,14,17
		58:10,25 59:2	125:18 126:4,5

[report - right]

Page 30

126:10,21 128:22,23 report's 125:1 reported 2:7 71:15 133:18 reporter 3:23 8:2,16 19:16 20:1,3,8 21:16 21:20 51:21,25 53:7,11 82:1,5 82:8,17 86:9,13 109:17 110:2,8 110:18,20 128:8,12 129:8 129:14,20,24 130:4,8,13 reporter's 2:13 4:14 133:14 reporting 70:9 71:6,19 73:10 91:21 reports 25:21 56:14 60:17 64:6 68:9 71:13 79:10 113:1 represent 23:22 representation 89:16 representations 40:13 50:25 representing 8:15 reputable 76:17 reputation 40:12	request 123:11 requested 123:2 134:9 requesters 6:2 32:11 34:4 requesting 26:21 require 66:8,8 required 14:13 15:10 109:4 126:20 requirement 105:5,7,14 requirements 14:22 15:9 41:1 requires 93:25 100:20 reread 47:7 124:23 rereading 126:22 research 6:6 13:15 16:2 25:3 25:13,21 27:6 89:9 99:6 101:14 119:20 reserve 52:8 residing 133:17 resistance 41:2 41:18 resistant 113:10 respect 19:13 44:15 47:14 70:20 78:24 89:16 96:24	103:17 113:5 114:9 respond 62:6 107:13 responding 44:18 65:9 response 30:6 responsibly 114:9,15 resulted 88:20 results 54:12 63:16 retain 6:17 53:24 retained 30:24 retaining 46:2 100:6 returned 134:11,13 returning 110:24 revealed 94:14 review 18:2 22:11,13,21 29:3 36:8 37:6 37:7 42:20,22 44:12 46:24 51:5 56:24 57:1 65:16 89:19 99:16 101:18 103:7,10,24 111:7 114:23 124:6,25 reviewed 12:23 15:9 24:11 26:14,18 32:8	35:5 36:23 43:10 65:2 76:24 88:6 108:13 112:24 113:23 115:3,6 122:4 123:3,7 123:15 reviewing 35:25 42:19 43:5 60:12 75:9 112:25 revised 20:15 37:2 108:14 revising 64:3 revision 125:15 rhythms 18:16 18:17 richard 3:15 8:12,14 19:22 21:2 52:3 55:11 116:3 135:2 right 10:6 12:17,19 13:3,7 14:20 15:19 16:18 17:25 20:2,8 21:7,24 22:4,17 24:1,4 29:24 31:1 33:10 34:18 36:17 37:7,24 44:22,24 46:11 47:12 51:15 52:8,22 53:5,14 53:20 54:6,24 55:15,16 56:9 56:12,16 58:8
--	---	--	---

[right - sections]

Page 31

65:21 70:7 72:9 73:21 75:3 76:10 78:25 79:14 82:25 83:1 84:15 85:12 86:9 87:19 88:10 89:1 91:11 93:22 95:10,12 95:13 99:14,14 101:12,22 103:7,11,17 104:19 110:12 116:6 119:4,7,8 120:9 123:21 124:14,16 128:8 rigler 126:2 ring 23:19 risk 48:18,19 66:9,11,12 71:4 73:14 risks 29:13 40:16 41:21,22 48:21 49:22 113:5 119:2 122:25 rls 1:4 133:4 robust 40:25 role 24:4,6,6 room 9:1,4 19:18 87:15 rough 129:10 129:21 130:1 roughly 56:9 72:12	rsa 2:7 3:24 133:16 135:19 rule 5:11,13,17 5:20 rules 2:9 s s 3:1 8:1 safe 49:23 safety 6:3 12:9 32:11 100:15 sage 1:9 2:2 4:6 5:4,11,14,17,21 8:18 19:6 62:9 63:22 67:8 68:23 69:15 76:5 78:16,16 80:12,15,18 104:13 110:6 128:16 131:2 132:1,6,11 133:9,24 sage's 67:22 79:11 sale 20:20 sales 1:3 133:3 sample 49:19 66:10 74:1 75:9 75:11 77:16,18 109:3 sampled 119:25 samples 6:18 53:24 58:13,15 72:24 73:4,5,8 74:17 75:7,14 94:15 109:6,10	sampling 76:12 sanchez 119:14 119:20 120:23 saw 54:17 saying 50:5 57:4 67:15 76:16 82:23 99:11 says 16:17 20:21 83:6 87:8 94:19 95:11 105:2 122:3 sayta's 80:10 scanning 98:9 schoeve 2:7 3:24 133:16 135:19 scholarly 36:12 school 13:19 14:16,22 75:10 75:15 76:23 77:8,15 78:22 82:10,22 science 46:5,18 51:6,14 59:15 77:10 100:8,18 125:4,14 scientific 6:12 29:12 40:22 45:6 46:16 48:18,18,23 59:13,22 60:5 70:12 76:7 87:10 91:19 115:5 119:8 122:24 125:7	125:11 scientifically 59:18 scope 78:3 79:7 81:22 115:12 screen 18:24 19:3,19 31:4 32:23 33:10 34:23 53:20 55:5 57:8,15 72:11 74:17 91:14 119:5 screening 93:24 94:2 scroll 32:4 92:14 93:5,5 scroller 57:22 scrolling 9:19 9:21,23,25 72:8 75:3 seal 132:19 search 33:20 60:2 88:24 searches 28:20 searching 55:5 second 5:17 22:2 23:14 31:17 55:19 75:5 88:8,25 125:17 secrets 119:5 section 25:9 40:4,23 41:2 82:10 124:16 sections 38:23 40:9,20 41:4
--	---	---	--

[sections - sorry]

Page 32

127:13 sector 49:23 see 9:13 25:8 49:16 55:7,21 55:23 69:20 71:12 72:10 74:7 75:5 77:18 77:24 81:14 82:13 83:15,20 85:3 87:7 89:2 89:5 92:4,15,23 93:6 94:10 97:7 97:17 104:15 104:16,19,24 106:15,18 109:1,7 119:5 120:25 121:22 122:1,8,15 124:23 seeing 17:19 95:2 102:9 107:16 seem 46:20 72:20 74:1 seemed 24:12 60:21 72:13 73:2 113:13 seen 23:2 103:24 104:13 107:17 109:15 110:7 114:11 118:13,20 119:11 120:6 self 46:19 49:20 50:12 70:8 96:13 98:16	send 130:4 sense 11:4 38:2 40:1 56:2 58:4 70:8 71:2 sensitivity 94:7 sent 18:14 24:10 29:1 sentence 46:12 101:9 124:8 separately 22:18 25:24 separation 75:8 77:15 82:12 84:6 89:10,19 89:22 90:25 92:5 93:8 september 12:17,21 16:4,8 17:9 24:19 26:16 27:8 30:21,23 61:13 78:4 79:8 125:22 126:1 seriously 30:12 serpentine 72:17 106:16 served 134:5 service 6:6 12:1 25:21 services 135:20 set 99:22 several 17:13 118:19 122:23 123:25 126:22 share 119:4	shared 53:20 shift 73:12 shocked 90:5 shoot 53:3 short 36:2 120:11 shortcomings 94:7,17 shorthand 2:8 shortly 56:7 show 15:19 55:2,2,5 65:17 86:25 87:1 91:9 106:20 114:23 showed 78:7 103:20 124:25 showing 93:3 shown 83:5 98:7 107:24 114:25 134:6 shows 34:22 sic 120:4 side 18:22 62:16 98:13 sign 13:25 signature 4:11 130:5 131:1 132:2 134:8,11 134:14 135:18 significant 73:25 significantly 73:2 similar 44:13 44:14 47:22 94:8	simply 70:23 simultaneously 39:11 52:25 57:13 61:10 69:5 78:10,20 79:23 92:18 95:3 109:22 110:15 112:3 121:6 single 39:19,25 117:19 sip 31:3 sir 8:14 45:14 82:5 89:5 129:14,20 130:13 sit 26:20 39:2 88:10 107:19 situation 100:16 skimmed 13:1 30:7 skipping 55:13 slightly 29:24 social 12:1 solely 105:7 somebody 65:4 104:25 soon 52:21 sophisticated 60:21 sorry 14:2 20:3 20:9 21:16 23:9 27:19 39:10 49:5 77:7 95:1 95:5,7 101:23
---	--	--	--

[sorry - studies]

Page 33

103:8 110:16 115:24 116:2,7 116:8 120:21 121:5,10 124:7 sort 12:4 28:6 43:24 73:25 74:5 86:17 90:12 sorted 85:22 sorts 81:15 sound 12:17 13:18 23:25 sounds 53:6 55:14 116:6 source 36:12 73:3 102:16 sourced 72:5,6 72:12,15,25 73:1 74:4,18 77:22 sources 22:13 59:16 63:11 102:6 sourcing 58:18 73:13 south 3:11 spalding 3:19 135:5 speak 89:13 116:12 speaking 39:11 52:25 57:13 61:10 69:5,7,11 76:3 78:10,20 79:23 81:1,3,4 81:6 92:18 95:3	109:22 110:15 112:3 121:6 specific 12:14 14:24 27:25 34:14 38:4 41:9 41:14 47:6,24 56:1,24 92:2 95:18 99:17 specifically 37:13 40:14 45:25 50:1 67:6 77:17,21 122:3 specification 105:6,9 specifications 100:13 specificity 94:7 specify 25:11 spectroscopy 93:25 speech 78:12 spend 65:7 87:2 126:14 spent 17:6 26:4 spoken 42:16 spot 77:9 staffing 34:11 stages 11:22 stamped 6:23 stand 51:11 66:14 85:17 112:22,22 114:12 117:19 128:21 standard 28:22 33:24 105:10	105:20 107:11 108:8 standardized 27:25 28:9,19 29:1 48:5 88:22 standards 20:16,18 34:9 46:19 48:20 105:16 standing 129:13,15,19 129:25 stands 76:11 starch 113:12 start 9:7 started 58:18 82:15 starting 55:10 starts 89:7 123:14 stasis 96:13 97:1,1 98:20,20 118:14 state 3:14 8:15 14:18 46:2 51:6 52:4,12 64:20 100:9,11 106:14 123:25 132:7,25 133:17 135:1 stated 2:10 18:5 18:7 40:13 59:3 statement 60:3 66:14 74:16 76:6 79:16 88:14 89:8	112:22 statements 36:15 59:15 64:6 states 1:1 6:1 32:9 95:14 99:3 99:12,14 133:1 station 14:1 status 12:5,6 28:8 statutory 26:11 steering 3:9 8:10 134:23 stenographic 3:23 4:13 133:13,21 step 87:13 88:19 steps 90:1 stop 9:24 10:1,7 store 97:17,22 story 48:6 103:16 straightforward 108:4 street 3:6,11,16 strength 125:1 strike 70:24 strong 46:20 struck 129:16 129:18 structures 98:11 struggle 119:1 studies 121:22 124:2,20
--	--	--	---

[study - talcum]

Page 34

study 122:3 123:15 124:1,9 stuff 114:25 styled 2:5 subject 6:24 60:17 127:17 subjective 66:13 submission 24:24 37:2 submitted 11:14 38:1 61:14 78:3 subscribed 132:15 135:14 subsequent 25:15 36:1 37:1 97:4 subsequently 29:18 39:5 113:14 substances 47:22 substantiation 100:15 successfully 54:22 sufficient 38:7 66:15 sufficiently 49:21 suggest 83:4 121:23 suggested 122:4 123:16	suggesting 70:9 90:16 124:20 suggestion 71:4 106:5 suggestive 66:9 66:11 suite 3:11 135:21 sum 101:2 summary 117:18 supplement 18:20 supplemental 53:21 support 39:19 40:5 supported 48:21 supporter 113:8 suppose 79:19 supposed 38:11 58:4 supposedly 91:1 sure 9:16 18:9 19:21 21:12,19 32:24,24 34:17 35:11 42:25 43:18 47:10 52:6,14 54:21 57:2 70:6 71:19 74:3 84:15 85:1 92:13,17 93:4 97:11 98:2	102:10 103:14 126:3,24 127:25 128:3,6 surpass 105:15 surpassing 107:4 surrounding 66:12 survey 64:17 suspect 11:5 swear 8:5 sweet 77:9 sworn 2:3 8:19 124:4 133:25 135:14 system 10:20 10:25 systematic 51:5 103:6,10 t t 3:7,12,17,21 135:22 table 79:25 take 22:17 46:14,17 47:9 50:20 51:17,18 81:20 82:6 85:20 102:22 103:23 113:4 125:10 127:23 130:7 taken 2:4 14:10 53:9 86:11 112:14 128:10 134:18 135:10	talc 6:14,17 7:2 28:1,10 29:2 45:8 47:23 53:24 58:19 65:12 71:16 72:5,6,12,15,25 73:1,3,7 74:4,7 74:18 75:7,14 77:16 83:17,18 87:11,12 91:23 91:23 93:13 96:22 100:14 100:18 105:6 105:10,23 108:22 109:9 111:2,13 114:19 115:9 116:18 117:5 117:24,25 119:22 121:24 122:4,12,21 123:16 124:12 124:21 talcum 1:3 6:16 20:20,22 23:1 29:13 37:20 40:17 41:21 49:18 50:18,24 53:23 58:13,19 58:19 65:12 71:23 73:15 74:17 77:23 113:12 114:5 119:24 122:5 122:25 133:3
--	--	--	--

[talk - things]

Page 35

<p>talk 17:4 34:19 41:8 56:16 70:22 93:9 95:12,20 98:17 talked 27:5 43:1 49:7 71:3 93:17 100:24 115:18 talking 14:3 50:1 56:9 61:12 67:5,6,17,19 69:17,18 70:3,7 81:12 91:4 93:19 95:6,24 100:2 102:18 103:5 107:4 120:22 122:1 124:19 talks 10:6 41:25 77:14,17 93:22 121:21 task 18:3 19:13 tasks 27:25 59:14 taught 14:15 78:21,22 teach 14:13 teaching 13:15 14:4,5,8 17:23 18:16 29:20 30:14 techniques 93:24 technologies 50:4</p>	<p>technology 46:18 113:9 tell 8:19 18:18 22:4 27:10 32:18 45:15 51:5 58:4 70:19 71:20 72:1 77:7 93:4 tem 93:11 94:14 95:15 98:4 108:21 111:3,5,13 116:18 117:5 117:23 ten 52:18 53:2 53:4 term 40:11 42:5 terms 10:20 13:14 18:7 34:11 72:14,23 90:9 103:12 test 54:12 75:20 94:2 106:15 109:9 111:13 116:17 tested 72:16 73:4,5 109:2 111:2 114:19 115:9 testified 8:21 56:19 68:24 75:23 110:6 112:7 testifying 90:14</p>	<p>testimony 16:2 30:19 70:13,15 70:17,18 71:21 83:22 116:12 124:4 128:19 134:1,17 testing 6:13 23:1 28:1,9,19 29:1 41:2 44:2 44:7,16 45:6 46:4 47:15,21 49:9 50:3 51:11 58:15,25 59:8 60:18 61:1,16 61:23 62:10,13 63:15 64:4,7,17 65:10 66:1,25 68:7,18,20 69:1 75:24 77:8 78:6 83:17 87:11 88:22 90:3,5 91:22 94:12 95:18 96:21 97:9 99:12,17 100:7,13,18,22 101:3,15 103:19 105:7 105:13,16 106:14 107:5 107:20,22 108:7,8,21 111:16 114:10 114:10 117:4,6 117:23 118:1 tests 109:4,5</p>	<p>texas 9:2 13:8,9 13:20 14:4,22 15:3,5,10 133:17 text 25:6 26:4 35:24 97:18 124:9,13 thank 8:16 11:12 24:16 33:12 35:17 38:19 41:12 52:15 57:9 72:9 76:2 82:17 87:14,15 93:3 110:8,22 127:20,22 130:3,11,14 thanks 20:11 38:20 53:4 82:16 86:16 128:5 theory 14:17 therefor 134:15 thin 123:18 thing 57:17 69:18,20 83:3 things 11:24 23:11 26:10 27:5 28:6 33:22 34:12 42:12 43:1 45:1 54:17 60:20 70:21,24 71:3 73:10 76:12 88:20 97:2 98:13 102:20 118:19</p>
---	--	--	---

[things - transcription]

Page 36

120:13 123:1	74:14 75:22	time 11:16	89:9 100:24
think 11:9	76:25 77:6 78:1	12:16 14:6 15:4	107:19 112:11
12:20,20 18:25	79:9,15 81:11	16:7 17:5,9,25	115:3 130:16
26:2 52:22	84:8,24 85:2,23	21:21 23:5	today's 12:24
55:12,15 58:4	86:4,7 87:23	24:19 26:4	87:9 126:7,15
63:4,12 66:23	88:13 89:24	29:17 30:9	126:16 127:3
68:5 74:15	91:3 92:7,19	40:17 42:17	together 24:5
81:18 97:15	95:21 96:4,9	43:4 46:14 47:9	51:9
98:19 106:11	98:6 99:4,15	48:24 54:22	told 29:16
108:12 112:2	101:17 102:24	56:4 57:20 60:4	took 51:10
125:12 126:17	104:4,8,15	61:5,18,20	80:10 90:6
thinking 51:17	106:2,7,20,24	63:19 65:7,23	top 12:11
third 5:21	107:23 108:10	66:11 67:9	topic 17:16
31:23 32:5	108:24 109:13	81:18 84:13	43:7 60:22
34:21 83:14	109:20,24	87:2 96:19	87:14
thompson 3:5	110:4,9,17,22	99:18,22 102:1	topics 11:9
4:8 8:6,7,12 9:6	111:18 112:2	107:17 111:20	87:10
19:22 21:2	112:20 114:21	111:23,24	tort 10:19
27:13 29:10	115:11 116:2,8	112:11,13	11:11 12:10
30:5 32:22,25	116:22 117:9	113:5,14	total 16:9,10
33:3,5,12 35:9	118:2 120:20	114:15 115:1	totality 112:23
35:12,16 39:21	120:22,25	115:20 123:4	touch 51:25
40:7 41:16	121:5,9 127:14	125:21,25	towards 87:22
43:17 46:23	127:23 128:1,4	126:14 127:20	toxicology
47:18 48:16	128:7,15,25	127:21 134:17	122:14
50:6 51:2 52:11	129:24 130:2,6	times 126:22	trace 26:11
52:17,19 53:1,5	134:22	tissue 123:19	track 100:17
56:22 57:3,16	thought 22:11	titled 6:2,6,12	train 70:5
59:1,11,23	29:19 42:4	6:16 7:1 11:15	transcript 2:17
60:14 61:4,11	59:17 60:11,11	tm 106:17,17	6:20 12:24 30:8
62:1,14,18,23	62:25 70:5,20	109:5,10	84:20 86:18,23
63:4 64:1 65:6	82:21 83:1	today 8:25 13:2	89:2 129:11,22
66:5,20 67:14	thoughtful 51:5	26:20 37:3 39:4	130:10 133:19
68:1,5,23 69:4	103:7,10	56:15,19 67:1	133:25 134:12
69:15,16,23	three 23:23	71:22 81:23	transcription
70:14 71:8,17	31:8	87:16 88:10	133:20

[transferred - version]

Page 37

transferred 42:2	u	understanding 21:24 28:7,11	117:23
transmission 2:14 94:14 98:8 111:8	u.s. 10:16 58:16 83:16	28:25 38:8 39:12 40:16 50:4 55:25 58:14,17,24 72:4,15 75:19 76:22 82:24 85:10 87:20 88:11 90:8 97:23 99:1,1	used 2:19 24:9 36:13 99:13 101:16 111:5,8 111:12 122:4
transparency 34:11 40:15	ubiquitous 73:9	understands 90:7	user 57:10
travel 54:22	um 25:6	understood 59:19 88:23	using 58:25 68:20 71:14 75:8,11,20 89:10 92:11 94:13,16 95:22 103:12 111:3 117:5
tread 123:6	unaltered 117:13	undoubtedly 46:17	usual 11:23
trial 30:19	unattended 115:22	united 1:1 6:1 32:9 133:1	usually 12:1,7
true 132:3 133:20 134:1	uncertainties 29:12 40:16 41:22	university 13:8 13:17,20 14:9 14:22 15:5,10	utility 125:14
trust 42:1,9,11	uncertainty 48:19 66:12 73:14	unlimited 111:24	v
truth 8:19,20 8:20	unchanged 20:13	unmuted 116:4	vague 58:3
try 39:15 85:15 88:24 109:20 115:25	uncomfortable 30:10	unusual 113:3	validated 61:24 63:24
trying 26:4 38:1,13 39:7 40:1 42:25 47:11 54:24 56:2 71:2,11 82:2 92:23 123:6 126:17	under 6:7 11:13 20:12,16 34:24 50:12 94:13 132:12,19	update 22:25 23:2 32:12	validation 67:15,17 68:18
turned 116:4	undergraduate 13:19	updated 22:5 23:15 24:17 44:2 112:9	various 40:22 48:22 60:20 61:17,18 64:5 98:11 122:24
two 18:2 22:24 37:12 78:19 87:4,4 94:5 103:22 119:25 127:10 128:23	underlying 48:21 125:13	uploaded 86:17	vegas 135:22
type 28:17 123:18 125:20	understand 18:3 19:13 38:13 39:6 47:13 54:6 68:13 69:12 76:8 97:23 101:14 116:12	use 90:24 91:23 93:11 95:15 98:4,4 113:12 114:10 116:18	verification 35:23
types 40:22 109:3 113:18			vermont 72:6 72:10,15 73:1,3 73:13,20 77:22 104:24
			version 9:10,18 36:9 54:7 55:22

[version - working]

Page 38

121:19 versions 37:22 versus 64:9 veteran 12:6 videoconfere... 2:14,17 videoconfere... 1:8 2:1 133:8 view 36:8 47:19 violating 42:10 violation 58:22 visiting 14:8 visits 17:13 vitae 5:4 volume 116:5 vulnerable 12:2	99:24 103:23 107:8 110:25 111:6 115:2 116:14 119:10 120:10 127:5,6 128:4 wanted 74:3 warning 50:15 washington 14:9,11 water 31:3 way 26:10 36:14 51:9 59:4 59:7,14 71:21 72:19 77:1 78:2 82:24 83:9 97:19 119:10 126:2 ways 10:16 96:16 we've 9:3 11:12 15:20 33:17 35:21 40:3 50:20 51:16 55:3,20 56:17 58:9 100:24 112:10 120:14 125:6 website 25:14 25:16,17 28:3 28:21 35:25 86:6,7 114:2 week 12:21 weekly 109:10 weeks 37:12 56:10 78:7,19	welcome 87:1 wells 34:23 35:21 36:4 went 15:8,9 25:13 116:11 121:3 123:2 whatsoever 74:11 where'd 38:18 white 6:12 45:2 45:5,13 46:5 47:14,17,20 48:9,13 50:23 86:20 89:20 90:20 91:15 93:22 95:14 96:1 98:1,3,25 99:11 100:4 101:13 103:5 103:10 115:18 116:11,15 wholly 105:9 whoops 119:4 wife 13:25 william 1:9 2:1 4:6 5:4,11,14 5:17,21 8:18 89:4 131:2 132:1,6,11 133:9,24 willing 98:21 windows 57:10 windsor 6:22 104:22,23 105:2,5,12,22 105:22 109:6	withdraw 23:21 witness 2:2 8:5 20:11 21:1 27:15 31:2 33:2 33:4,7 38:18 51:23 57:2,5,9 57:14 62:21 67:24 78:18,21 79:1 85:6,16 96:3,5 121:2 127:22 130:5,7 131:2 133:24 134:2,6,9,9 witnesses 81:17 word 55:5 102:22 125:10 words 49:6 wordy 70:4 work 13:4 14:23 15:3,8,13 17:7,12,18 18:21 22:8 29:21 30:14 36:11,12 46:14 65:8,9 77:20 worked 26:12 75:12 working 28:13 44:23 45:8 46:7 47:16,19 51:4 89:21 90:10,24 91:5,12 94:21 97:3,3 99:7 103:11 117:3 118:11
w			
wait 67:14 68:1 79:24,24 112:5 112:5,5,5,5,5 waiting 19:18 walk 25:4 walked 116:3 wall 123:19 want 14:2 15:19 17:4 19:3 25:1 29:8 49:5 50:21 52:6,18 53:14 57:17,21 57:23 72:1 78:13 79:20 80:6,24 82:15 86:24 87:2,6 92:19 93:9 95:22 98:2			

[world - zoom]

Page 39

world 17:22 68:19	113:9
worries 21:5 85:6 119:6 121:11	yep 10:3 33:4 86:8
worry 65:3	yesterday 24:12 31:25
worrying 57:12	york 3:20,20
worse 41:23	z
worth 9:2 81:18	zero 73:24
writes 65:4	zoom 2:14 3:2 18:16,17 88:2
writing 17:24 22:8	
written 22:9 39:3	
wrong 81:8	
x	
x 4:1 93:24	
xrd 93:24 99:2 99:13	
y	
y'all 20:24 129:9	
yeah 12:20 19:21 39:10,14 45:22 51:21 53:1 57:16,20 57:21 61:11 62:23 75:2 95:8 106:1,22,24 110:2	
year 10:10 26:9 48:1,2 72:12	
years 28:14 44:24 97:1	

Federal Rules of Civil Procedure

Rule 30

(e) Review By the Witness; Changes.

(1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:

(A) to review the transcript or recording; and

(B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.

(2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1, 2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS

COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted

fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.